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Abstract 
Hypoxia in cystic fibrosis (CF) may occur during sleep, and also during exercise, chest 
exacerbations and air travel. No standardised definition of nocturnal hypoxia in CF exists. 
Theoretical evidence suggests hypoxia may have a deleterious impact on clinical status in 
CF, due to effects on upregulation of pro-inflammatory cytokines, changes in Pseudomonas 
aeruginosa growth patterns, and causation of pulmonary hypertension. It was hypothesised 
that hypoxia, and resultant inflammation would adversely affect clinical phenotype in CF. 
 
Forty-one children with CF were studied, each undergoing home oximetry before attending 
for a day of clinical testing (exercise testing, lung function, respiratory and skeletal muscle 
testing, echocardiography, and quality of life assessment).  In vitro work was undertaken to 
assess the effects of hypoxia on cell growth and interleukin-8 (IL-8) secretion in wild-type 
and CF airway epithelial cells. The effects of hypoxia were compared to a known pro-
inflammatory stimulus - lipopolysaccharide (LPS) from Pseudomonas aeruginosa.  
 
ROC  statistics  were  used  to  derive  the  most  sensitive  and  specific  definition  of  sleep 
hypoxia in the detection of elevated levels of inflammation (WBC, CRP, neutrophil counts 
and IL-8 levels). This definition (SpO2 <93% for>10% sleep) was used to dichotomise the 
study population. Hypoxic CF subjects (n=9) had, when compared to normoxic controls 
(n=32): lower exercise capacity, lower BMI, lower FEV1 and FVC, elevated RV/TLC ratio, 
and higher Chrispin-Norman scores. Hypoxic subjects also had reduced quality of life, bone 
density,  and  increased  RV  thickness  on  echocardiogram.  Hypoxic  cell  culture  was 
suggested  to  be  pro-inflammatory,  with  increased  IL-8  production,  and  synergistically 
increased IL-8 secretion when cells were co-incubated with LPS under hypoxic conditions. 
 
Hypoxia  is  associated  with  reduced  clinical  well-being  and  increased  inflammation  in 
childhood CF. The paradigm exists of whether hypoxia is merely an endpoint of severe CF 
lung disease; or whether hypoxia may be a causative factor (as suggested by the in vitro 
work), as well as an effect of CF lung inflammation. A trial of restoration of normoxia in 
children with CF, with careful re-evaluation of clinically-relevant outcomes is suggested 
from this preliminary work.  
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Definitions used in this study 
 
•  Nocturnal hypoxia in CF – SpO2 <93% for>10% study 
 
 
•  Normal ranges for lung function and plethysmography data – z scores constructed 
from: 
 
Rosenthal M, Bain SH, Cramer D, Helms P, Denison D, Bush A, Warner JO. Lung 
function in white children aged 4 to 19 years: – Spirometry. Thorax 1993; 48: 794-802. 
 
   
•  Normal ranges for respiratory muscle pressure data – z scores constructed from: 
 
Stefanutti D, Fitting JW. Sniff inspiratory muscle pressure. Reference values in Caucasian 
children. Am J Respir Crit Care Med 1999; 159: 107-111. 
 
 
•  Normal ranges for skeletal muscle pressure data – z scores constructed from: 
QUADRICEPS – 
Backman E, Odenrick P, Henriksson KG, Ledin T. Isometric muscle force and anthropometric 
values in normal children aged between 3.5 and 15 years. Scand J Rehab Med 1989; 21: 105-
114. 
 
HANDGRIP STRENGTH –  
Mathiowetz V, Wierner DM, Federman SM. Grip and pinch strength: Norms for 6- 19 year 
olds. Am J Occup Ther 1986; 40: 705-11. 
 
 
•  Pulmonary hypertension 
Defined as sPAP>30mmHg where sPAP is measured from Bernoulli equation (section 
2.2.2.7) and added to right atrial pressure.   28 
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CHAPTER 1: Introduction 
 
1.1 Research Question 
The aim of this thesis was to define a hypoxic phenotype amongst children with cystic 
fibrosis.  The  principal  hypothesis  of  the  study  is  that,  hypoxia  via  up-regulation  of 
inflammation, may exert a deleterious effect on clinical status in children with CF. The 
potential  mechanisms  by  which  hypoxia  may  stimulate  inflammation  are  presented 
throughout Chapter 1, along with discussion of the potential impact of inflammation driven 
by hypoxia on the CF lung. 
 
Using direct measures of inflammation, the work sets out to establish an optimal definition 
of hypoxia to apply to the group (Chapter 3); and then to dichotomise the group on the 
basis of hypoxia to examine the association with clinical (Chapters 4 and 5) variables.  
 
Chapter 6 tests the hypothesis that hypoxia may directly upregulate inflammation in CF. 
The effects of hypoxia on inflammation in both CF and non-CF cell lines are explored, and 
compared and contrasted to a known stimulus of inflammation, namely lipopolysaccharide 
(LPS) from Pseudomonas aeruginosa. 
 
The  study  hypothesises  that  hypoxia  may  directly  and  also  indirectly  propagate  lung 
inflammation,  which,  in  turn  may  potentiate  a  downward  pathophysiological  spiral  of 
worsening disease in CF. The hypothesis is that those children defined as having significant 
hypoxia will be associated with adverse measures of clinical status. 
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1.2 Cystic Fibrosis 
Cystic Fibrosis (CF) is the UK’s commonest life-threatening inherited disease, affecting 
over  7500  children  and  young  adults.  Average  life  expectancy  is  quoted  as  35  years 
(www.cftrust.org.uk)  but  predicted  median  age  of  survival  for  a  baby  born  in  the  21
st 
century exceeds 50 years (Dodge et al. 2007). CF is a multisystem disorder that affects the 
upper and lower airways, pancreas, bowel and reproductive tracts (Davies et al. 2007), as 
well as having later endocrine (Lanng 2001) and bone effects (Aris et al. 2005, UK CF 
Trust 2007).  
 
1.2.1 CF genetics  
CF  is  an  autosomal  recessive  condition,  caused  by  mutations  in  the  cystic  fibrosis 
transmembrane conductance regulator (CFTR) gene on chromosome 7. This gene codes for 
CFTR protein, a chloride channel at the epithelial cell surface which allows co-transport of 
sodium and chloride along with water across the cell membrane (Figure 1.1).  
 
Figure 1.1 
Normal CFTR function  
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1.3 Hypoxia  
 
1.3.1 Hypoxia and cellular respiration 
Aerobic cellular respiration is dependent upon the efficient supply of oxygen substrate to 
the  mitochondria.  The  efficiency  of  oxygen  delivery  is  dependent  upon  the  interaction 
between cardiac output, ventilatory responses and metabolic factors. Cellular respiration 
leads to energy production (in the form of ATP). This is at its most efficient under aerobic 
conditions, whereby 38 molecules of ATP are generated for every molecule of glucose. 
Adequate  cardiorespiratory  response  is  relied  upon  to  supply  oxygen  for  aerobic  ATP 
regeneration (Wasserman et al. 2004). Under anaerobic conditions, only 2 ATP molecules 
per molecule of glucose are produced.  
 
Air, with 21% inspired oxygen concentration is moved by convection through the airways 
to reach the alveoli, whence oxygen diffuses out of the alveoli and into the pulmonary 
capillaries. It binds to haemoglobin to form oxyhaemoglobin and is then transported to the 
tissues,  where  it  diffuses  out  of  the  microcirculation,  across  the  interstitium  and  cell 
membranes and into the cell, where it finally enters the mitochondria (Nathan and Singer 
1999). The impact of hypoxaemia therefore is that less oxygen is available at cellular level 
for aerobic metabolism leading to a shift to anaerobic energy production, which utilises 
glycolysis – the catabolism of glucose.  
 
1.3.2 Defining hypoxia  
The state of hypoxia can be described on the basis of arterial oxygen tensions below 8kPa 
(Mallory et al. 2005), or on the basis of oxyhaemoglobin desaturation such that arterial 
oxygen saturation (SaO2) are below 90% (Mallory  et al. 2005).  Others have suggested 
higher cut off values for SaO2 and hypoxia, for example SaO2 of 93% is the point on the 
oxygen dissociation curve at which small changes in pO2 result in exponential decreases in 
SaO2. Extrapolation from the following graph (Figure 1.2) suggests that a SaO2 value of 
93% equates to a pO2 of around 70mmHg (9kPa). 
  
Figure 1.2 
The oxygen-haemoglobin dissociation curve
[Source: Ganong WF, Review of Medical Physiology (14
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.4.2.1  Limitations in assessment and definition of hypoxia in children
 
Pulse oximetry provides the main assessment tool for oxygenation in children. 
light originates from the oximeter probe at two wavelengths (665nm 
infrared).  The  light  is  partly  absorbed  by  haemoglobin  (Hb),  by  amounts  which  differ 
depending  on  whether  it  is  saturated  or  desaturated  with  oxygen.  By  calcula
absorption at the two wavelengths the processor can compute the proportion of Hb which is 
oxygenated.  Although  freely  available,  and  a  non
oxygenation, correlation between 
(SpO2) and arterial PaO
+/-2% (Soubani 2001). 
 
 
SaO2 93% 
haemoglobin dissociation curve 
[Source: Ganong WF, Review of Medical Physiology (14
th Edition), 19
1.4.2.1  Limitations in assessment and definition of hypoxia in children
Pulse oximetry provides the main assessment tool for oxygenation in children. 
light originates from the oximeter probe at two wavelengths (665nm 
infrared).  The  light  is  partly  absorbed  by  haemoglobin  (Hb),  by  amounts  which  differ 
depending  on  whether  it  is  saturated  or  desaturated  with  oxygen.  By  calcula
absorption at the two wavelengths the processor can compute the proportion of Hb which is 
oxygenated.  Although  freely  available,  and  a  non-invasive  method  of  assessing 
oxygenation, correlation between arterial oxygen saturations measured on 
PaO2 may be poor (Soubani 2001) and limits of accuracy for SpO
2% (Soubani 2001).  
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Edition), 1989] 
1.4.2.1  Limitations in assessment and definition of hypoxia in children 
Pulse oximetry provides the main assessment tool for oxygenation in children. A source of 
light originates from the oximeter probe at two wavelengths (665nm –red and 880nm - 
infrared).  The  light  is  partly  absorbed  by  haemoglobin  (Hb),  by  amounts  which  differ 
depending  on  whether  it  is  saturated  or  desaturated  with  oxygen.  By  calculating  light 
absorption at the two wavelengths the processor can compute the proportion of Hb which is 
invasive  method  of  assessing 
measured on pulse oximetry 
may be poor (Soubani 2001) and limits of accuracy for SpO2 are   33 
1.3.3 Pathophysiology of alveolar hypoxia 
Hypoxia is a state of low oxygen levels, and alveolar hypoxia is a reflection of alveolar 
hypoventilation (West 2005). Alveolar PO2 (PAO2) is determined by two factors – i) the 
rate  of  removal  of  O2  by  pulmonary  capillary  blood  flow,  and  ii)  breath-by-breath 
replenishment by alveolar ventilation (West 2005). The rate of removal of oxygen depends 
on oxygen uptake (VO2) of the tissues, so is relatively constant at rest but significantly 
increases when VO2 is increased, for example during exercise. 
 
The lung is the key link in the chain of oxygen transport from air to the tissues. Having 
been  taken  up  by  the  pulmonary  capillaries  and  distributed  by  systemic  arterial  blood, 
oxygen diffuses to mitochondria at tissue level to facilitate aerobic cellular metabolism. 
Therefore, any reduction in arterial pO2 (PaO2) must result in a decrease in pO2 at tissue 
level. For this reason, changes in SpO2 are likely to reflect changes in tissue pO2. 
 
1.3.4 Pathophysiology of hypoxaemia 
Hypoxaemia refers to the state of an abnormally low PaO2 due to impaired gas exchange. 
There are four potential causes of hypoxaemia (West 2005), namely: 
-  Alveolar hypoventilation 
-  Shunt 
-  Diffusion 
-  V/Q mismatching 
 
1.3.4.1 Alveolar hypoventilation and hypoxaemia 
PAO2 depends upon rate of removal of oxygen by the bloodstream (a rate governed by 
metabolic demand),  and the rate of  replenishment of oxygen by alveolar ventilation. If 
alveolar ventilation reduces, an ensuing fall in PAO2 as well as a rise in alveolar pCO2 
(PACO2)  will  occur.  The  alveolar  gas  equation  (below)  is  used  to  calculate  the 
corresponding rise in PACO2 that accompanies any fall in PAO2: 
 
PAO2 = PIO2 – PACO2 + F      
        R 
 
where PIO2 refers to inspired oxygen concentration, R is the respiratory exchange ratio - the 
ratio of CO2 elimination (VCO2) to oxygen uptake (VO2), and F is a small correction factor.    34 
Thus, alveolar hypoventilation will always result in hypoxaemia unless inspired oxygen 
concentrations are enriched. 
 
Alveolar hypoventilation can be central in origin, relating to respiratory control and drive to 
breathe.  Such  causes  can  be  primary,  for  example  congenital  central  hypoventilation 
syndrome. Secondary causes of central hypoventilation include structural changes affecting 
brainstem function (i.e. Arnold-Chiari malformations), obesity and as a result of drug side-
effects (e.g. respiratory depression due to opiates). Alveolar hypoventilation may also occur 
as  a  result  of  ventilatory  muscle  weakness  or  paralysis;  or  due  to  increases  in  airway 
resistance, for example in severe obstructive sleep apnoea (OSA) (Marcus 2001). 
 
1.3.4.2 Hypoxaemia and shunting 
Shunting refers to blood that enters the arterial system without going through ventilated 
areas of the lung (West 2005). In the healthy lung, this includes bronchial arterial blood that 
is collected by the pulmonary  veins after it has perfused its bronchi  and is thus partly 
depleted  of  O2.  The  effect  of  adding  poorly  oxygenated  blood  depresses  PaO2.  Some 
patients  have  abnormal  vascular  connections  within  the  lung  (pulmonary  arteriovenous 
malformations), whilst in those with cardiac disease a direct addition of venous blood to 
arterial  blood  may  occur  across  a  right  to  left  shunt  through  an  intracardiac  defect  at 
ventricular or atrial level.  
 
1.3.4.3 Hypoxaemia and impaired diffusion  
As  blood  traverses  the  pulmonary  capillary,  PaO2  approaches  that  of  the  PAO2.  The 
alveolar-arterial  pO2  differences  in  the  healthy  lung  at  rest  are  small.  During  exercise, 
however, pulmonary blood flow is markedly increased, so that the time spent by a red cell 
within the pulmonary capillary is reduced to 1/3 of the resting time, meaning that the time 
available  for  oxygenation  is  less  (West  2005).  If  the  blood-gas  barrier  is  thickened  by 
disease so that oxygen diffusion is impeded, then the rate of rise of PO2 in the red blood 
cells  is  slower,  and  PaO2  may  not  reach  that  of  PAO2  before  the  time  available  for 
oxygenation has run out.  
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1.3.4.4 Hypoxaemia and ventilation/perfusion (V/Q) mismatching 
A normal V/Q ratio can be altered by changing ventilation or by changing perfusion. For 
example if alveolar ventilation is abolished then the V/Q ratio would be zero, whereas a 
complete interruption in perfusion would lead the ratio to tend towards infinity. Regional 
differences in gas exchange exist such that the V/Q ratio is higher at the top of the lung 
where blood flow is minimal, and much lower at the bottom of the lung (West 2005). 
 
This may be important during exercise in those with a large dead space, where shallow 
rapid  respirations  may  accentuate  these  regional  V/Q  mismatches  and  promote 
hypoxaemia. During infections and pneumonia, inflamed areas of lung parenchyma may 
have increased blood flow, yet impaired ventilation and resultant hypoxaemia may ensue. 
 
1.3.5 Hypoxia in Cystic Fibrosis 
Episodic  hypoxaemia  may  occur  at  times  of  physiologic  stress  in  CF,  such  as  sleep 
(Bradley et al. 1999, Darracott et al. 2004), exercise (Narang et al. 2003), during infective 
exacerbations of CF, and with air travel (Buchdahl et al. 2001). 
 
During sleep,  minute ventilation  decreases  and  may  cause  a  degree  of  hypoventilation. 
Furthermore, V/Q mismatch may be accentuated by differences in regional gas exchange 
during  sleep.  Finally,  obstructive  hypoventilation  can  contribute  to  hypoxaemia  for 
example, as a result of nasal polyps. This will be discussed in more detail in section 1.3.5.2. 
 
During exercise, as a result of enlarged physiological dead space; the pattern of shallow, 
rapid  respirations  required  to  maintain  alveolar  ventilation  may  cause  V/Q  mismatch 
(Godfrey and Mearns 1971). Gas exchange in the upper parts of the lung is less efficient 
than lower regions, and this coupled with the increased blood flow on exercise that may 
alter diffusion kinetics, may result in hypoxaemia. This will be discussed in more detail in 
section 1.3.5.3. 
 
In a CF chest exacerbation, hypoxaemia is likely to result primarily from V/Q mismatching. 
For example areas of lung inflammation may impair ventilation, yet blood flow to this 
inflamed tissue is increased accentuating mismatch. This will be discussed in more detail in 
section 1.3.5.4.   36 
During commercial air travel, both barometric pressure and partial pressure of oxygen fall 
with  altitude.  This  means  that  the  passenger  is  breathing  air  with  an  inspired  oxygen 
concentration (FiO2) of 15%. This alteration in inspired oxygen concentration thus affects 
the PAO2 and results in hypoxaemia. This will be discussed in more detail in section 1.3.5.5. 
 
1.3.5.1 Resting daytime hypoxia in CF 
Studies have demonstrated significantly lower mean resting SpO2 in children with CF when 
compared to controls (Betancourt et al. 1991). Resting hypoxia in CF has been described as 
awake SpO2 less than 95% (Coffey et al. 1991). 
 
1.3.5.2 Sleep hypoxia in CF 
Overnight SpO2 have been shown to be lower in stable adult (Bradley et al. 1999) and 
childhood (Darracott et al. 2004) CF subjects when compared to controls. Additionally, an 
increased incidence of desaturation events during sleep has been noted, even in those with 
only mildly reduced lung function (Uyan et al. 2007). During sleep in those with already 
reduced vital capacity, tidal volume falls due to reduced respiratory drive, precipitating 
hypoxia (Bradley et al. 1999) as a result of the mechanisms of alveolar hypoventilation 
(section 1.3.4.1)  as  well  as accentuating  regional  differences  in  gas  exchange and V/Q 
mismatching (section 1.3.4.4). Upper airway obstructive pathology such as nasal polyps or 
OSA may additionally contribute. 
 
1.3.5.2.1 Normal sleep 
Sleep is a requirement of all animals although its function remains unknown. Those who 
are deprived of sleep suffer physically, emotionally and intellectually, yet nobody knows 
how sleep restores the brain. 
 
1.3.5.2.1.1 Sleep Patterns 
There are two different kinds of sleep: Rapid eye movement or REM sleep and non-REM 
or slow-wave sleep. The proportion spent in REM sleep is proportionally greater in children 
than in adults, such that a neonate may spend 2/3 sleep time in REM compared with 20-
25% in adults (Marcus 2001). 
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1.3.5.2.1.1.1 Non-REM (Slow-wave) sleep 
Non-REM sleep is divided into four stages. These stages can be formal assessment of brain 
activity using electroencephalography (EEG): 
Stage 1 – The stage of sleep which a person first enters on falling asleep. This stage is 
characterized by low-amplitude, fast frequency EEG activity. 
Stage 2 – Sleep spindles appear in stage 2. These are bursts of electrical activity occurring 
at a frequency of 10-14 per second. They are similar in appearance to the alpha waves seen 
in awake individuals at rest with eyes closed. 
Stage 3 – The EEG pattern becomes slower in frequency and increased in amplitude. 
Stage 4 – The EEG is maximally slowed in stage 4, and deep sleep is characterized by a 
pattern of rhythmic slow waves. 
 
1.3.5.2.1.1.2 REM Sleep 
During REM sleep, the EEG pattern becomes irregular with rapid, low-voltage activity as 
well as rapid, roving movements of the eyes. REM sleep is not however interrupted, and the 
threshold for arousal is much higher than in non-REM sleep. Skeletal muscle tone falls 
during REM sleep and contributes to changes in respiration during sleep. This occurs due to 
increased activity in the reticular inhibiting system in the medulla. 
 
A typical night of sleep would involve passing through stage 1 and then stage 2 sleep, 
followed by a longer period in stages 3 and 4 sleep. A REM period will follow this and the 
cycle will be repeated at regular intervals through the night such that a total of 4-6 periods 
of REM will ensue (Ganong 1989). It should be noted that babies will sleep for longer 
periods than adults, as well as having proportionally longer periods of REM sleep (Marcus 
2001). Additionally the periods spent in stage 3 and 4 sleep are longer in children than in 
young adults, and decrease with age (Ganong 1989). 
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1.3.5.2.1.2 Changes in respiration during sleep 
During sleep, there is a decrease in minute ventilation, and in the childhood population such 
reductions  may  occur  due  to  decreases  in  either  tidal  volume  (Tabachnik  et  al.  1981), 
respiratory rate (Hoppenbrouwers et al. 1978), or both. Additionally there is an increase in 
upper airway resistance (Lopes et al. 1983), and a reduction in functional residual capacity 
during sleep (Hudgel and Devadatta 1984). 
   
The  ventilatory  drive  decreases,  particularly
  during  rapid  eye  movement  (REM)  sleep 
(Douglas et al. 1982), and in REM sleep breathing is erratic, with variable respiratory rate 
and
  tidal  volume. Additionally,  in  REM  sleep,  the  skeletal  muscle  hypotonia  described 
above may affect the intercostal and upper airway musculature further impairing breathing. 
This is especially important
 in children, as they sleep more than adults, and have relatively
 
more REM sleep (Marcus 2001).  
 
1.3.5.2.1.3 Sleep-disordered breathing 
Sleep-disordered breathing may be reflected by the presence of gas exchange abnormalities 
during sleep and/or the presence of arousals – the presence of broken sleep. Arousal is a 
defence mechanism against sleep-disordered breathing, as one breathes better whilst awake 
than when asleep. In
 general, children have a higher arousal threshold than adults (Marcus 
2001).
 Numerous studies have shown that moderate hypoxemia is a poor
 stimulus to arousal 
in children with only 25-50% of subjects arousing (Marcus 2001).
  This is in contrast to
 
hypercapnia and increased upper airway resistance which are both potent
 stimuli to arousal 
in all ages (Marcus et al. 1998). 
However, hypoxia during sleep is known to be predictive of impairment in mathematic 
ability  (Urschitz  et  al.  2005),  whilst  evidence  exists  that  correction  of sleep-disordered 
breathing can lead to improvement in cognitive functioning (Friedman et al. 2003) and 
school performance (Gozal 1998). 
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1.3.5.2.1.4 Normative values for oxygenation during sleep 
Normative data for baseline arterial oxygen saturation (SpO2) levels at night is available for 
infants (Hunt et al. 1999, Horemuzova et al. 2000), and older children (Gries et al. 1996, 
Urschitz et al. 2003). Urschitz and colleagues undertook home oximetry on 100 school-age 
children, and reported that median SpO2 were 97%, whilst desaturations below 92% were 
unusual. Similar average SpO2 values have been found in other childhood studies (Poets et 
al. 1993, Uliel et al. 2004). Urschitz’s group further worked out measures of SAT10 – SpO2 
below which children spent 10% of the artefact-free recording time. Median SAT10 was 
97% (IQR 97-98). In a hospital-based study of 350 patients including 180 aged 1-10 years 
and 46 aged 10-20 years (Gries et al 1996), mean SpO2 was 96.8% in the 1-10 year olds 
and 96.5% in the 10-20 year olds. Mean SAT10 was 95.1% (sd 1.5) for the 1-10 year olds 
and 94.5% (sd 1.8) for those aged 10-20 years.  
 
1.3.5.2.2 Defining sleep hypoxia in CF 
Sleep-disordered breathing in CF was first described more than 25 years ago (Tepper et al. 
1983). Desaturation (Tepper et al. 1983, Braggion et al. 1992), cough (Stokes et al. 1980), 
sleep  fragmentation  (Milross  et  al.  2002),  and  arousals  (Spier  et  al.  1984),  are  all 
documented during sleep in CF patients. It is proposed that sleep disturbance in CF occurs 
due to coughing (Milross et al. 2004) as well as hypoxia, and that sleep fragmentation 
arising from these events affects daytime function and quality of life. Sleep quality (using 
the Pittsburgh Sleep Quality Index) has been assessed as poor in 38% CF patients. Patients 
with worse sleep quality had increased sleep fragmentation, and associations between poor 
sleep quality and reduced FEV1 are also reported (Milross et al. 2002 B). 
 
No single definition of sleep hypoxia in CF exists, and published work has used a number 
of methods to quantify nocturnal SpO2 in CF. These include percentage of time spent with 
SpO2 below 90% (Frangolias et al. 2001), minimum sleep SpO2 (Tepper et al. 1983), mean 
sleep  SpO2  (Coffey  et  al.  1991,  Milross  et  al.  2001),  and  lowest  hourly  mean  SpO2 
(Versteegh et al. 1990). A definitive measure is yet to be determined, and e-mail survey of 
UK paediatric CF centres (2000 children) conducted by the University of Liverpool (Dr. K 
Southern – Personal Communication), concluded that less than a quarter of UK CF centres 
have a definition of nocturnal hypoxia in CF. A review of some of the definitions of sleep 
hypoxia that have been reported in CF is presented below (Table 1.1).  
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1.3.5.2.3 Predicting sleep hypoxia in CF 
1.3.5.2.3.1 Daytime SpO2 
It is routine practice in paediatric CF clinics to record resting SpO2. Awake SpO2 < 93% 
is reported to indicate a high risk of nocturnal  hypoxaemia in CF  (Versteegh  et al. 
1990). Although highly specific, resting SpO2<93% is poorly sensitive as an indicator 
of sleep hypoxia. A recent study reported 36% CF subjects with resting SpO2>93% 
became  hypoxic  at  night  (Frangolias  et  al.  2001).  Similarly,  it  is  reported  that,  in 
children  with  significant  nocturnal  hypoxaemia  (mean  sleep  SpO2  <90%),  19%  had 
resting  SpO2  >94%  and  therefore  would  have  been  missed  without  a  sleep  study 
(Milross et al. 2001).  
 
1.3.5.2.3.2 FEV1 
Two studies suggest that a FEV1 below 65% predicted may be a useful predictor of 
nocturnal hypoxia in CF. Firstly, Versteegh and colleagues studied 24 adolescents and 
young adults with CF (Versteegh et al. 1990). Extrapolation of their data suggests that 
whilst 88% sensitive, such a cut off is only 50% specific, and has a positive predictive 
value of 47%. Second, Frangolias and co-authors studied 70 older individuals with CF 
(Frangolias et al. 2001). Using the same cut-off (FEV1<65% predicted), this was 93% 
sensitive and 44% specific, with a positive predictive value of 51%. Of note however, in 
the latter study was that even for individuals with an FEV1 of 30% predicted, the time 
spent with SpO2<90% varied from 0 to 100% of sleep time. These studies suggest that it 
may be useful in clinical practice, to perform a sleep study in all CF patients with a 
FEV1 below 65% predicted. 
 
1.3.5.2.3.3 Exercise SpO2 
It is previously reported that hypoxia in CF occurs more frequently during sleep than 
during exercise (Coffey et al. 1991, Bradley et al. 1999), suggesting that a sleep study 
may be indicated for all CF patients with exercise hypoxia. The mechanisms of hypoxia 
during  exercise are likely  to differ from those  during sleep (as discussed in section 
1.3.5.),  and  this  is  borne  out  by  the  reported  relationships  between  %drop  in  SpO2 
during exercise and mean sleep SpO2 (r
2=0.13) or time spent with SpO2<90% (r
2=0.17) 
(Frangolias et al. 2001). 
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1.3.5.2.4 Prevalence of sleep hypoxia in CF 
The lack of definition of nocturnal hypoxia hampers the description of the prevalence of 
CF  hypoxia  in  clinical  practice,  and  perhaps  has  led  to  both  under-recognition  and 
under-treatment of this potentially important clinical entity. Currently, only 1-2% UK 
CF patients receive long-term oxygen therapy (LTOT) at night (Balfour-Lynn et al. 
2005, Southern 2004), and no guidelines exist on when to start LTOT in CF.  
 
1.3.5.3 Exercise hypoxia in CF 
Regional differences in oxygen uptake and ventilation exist within the normal lung with 
greater oxygen utilization in lower rather than upper zones (West 2005) due to increased 
perfusion in these areas. Subjects with CF may have an enlarged physiological dead 
space  (VD) (Godfrey  and Mearns 1971),  and ability to maintain alveolar ventilation 
during exercise is determined by increasing breathing frequency in the absence of an 
ability to increase tidal volumes (VT). The implication of hyperventilation in subjects 
with  enlarged  VD  is  that  dynamic  hyperinflation  occurs  in  association  with  rapid, 
shallow respirations and the resultant V/Q mismatching that results from accentuation 
of  regional  gas  exchange  differences  gives  rise  to  hypoxaemia.  An  additional 
contribution to hypoxaemia is made from changes in diffusion characteristics related to 
increases in pulmonary blood flow and decreases in red cell transit time through the 
pulmonary capillaries on exercise (West 2005). 
 
Exercise-testing  protocols  form  part  of  CF  annual  assessment  in  many  centres,  and 
include  measurement  of  SpO2  on  exercise  (Pike  et  al.  2001,  Narang  et  al.  2003). 
Various  exercise  testing  protocols  exist  dependent  upon  the  facilities  and  levels  of 
expertise available in each CF centre. The gold-standard cardiopulmonary exercise test 
with  breath-by-breath  ventilatory  gas  analysis  measures  oxygen  uptake  (VO2)  and 
carbon dioxide elimination (VCO2) as workload incrementally increases. This allows 
peak  oxygen  uptake  (peak  VO2)  to  be  measured,  whilst  SpO2  can  be  monitored 
throughout the test. Such a test is of prognostic usefulness, as peak VO2 has been shown 
to be an independent predictor of mortality in CF (Nixon et al. 1992, Pianosi et al. 
2005). 
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More usual however, is that a non-incremental field test will be performed in an out-
patient  clinic  setting.  This  may  be  a  six-minute  walk  test  i.e.  distance  walked  in  6 
minutes (Lammers et al. 2008), or a three-minute step test - stepping up and down on a 
single step for a 3 minute period (Balfour-Lynn et al. 1998). During each of these tests, 
changes in heart rate and SpO2 are recorded, along with patient-derived measures of 
breathlessness using a visual analogue scale. The concern is that such tests are sub-
maximal,  except  for  those  with  severe  CF  lung  disease,  and  as  such,  clinically 
significant potential desaturations may be missed. 
 
Exercise hypoxia in CF is defined as a fall in SpO2 of >4% from baseline (Narang et al. 
2003).  This  definition  has  also  been  used  in  healthy  children  (Nourry  et  al.  2004). 
Clearly, if this represents a fall in SpO2 from 93% to 89%, one may deem this likely to 
represent a significant physiological drop in PaO2, however the definition holds less 
well in an elite athlete whose SpO2 fall from 100% to 96% at the end of exercise. Such 
falls in SpO2 are known in elite athletes, and postulated to be due to intrapulmonary 
shunting,  diffusion  limitation,  and  ventilation-perfusion  mismatching  (Prefaut  et  al. 
2000). Further work is required to establish clinically significant parameters.  
 
1.3.5.4 Hypoxia during CF chest exacerbations 
Children  with  CF  face  challenges  to  their  pulmonary  reserve  at  times  of  CF  chest 
exacerbations.  At  such  times,  due  to  areas  of  consolidation  and/or  mucus  plugging, 
ventilation-perfusion  mismatching  may be exaggerated, and hypoxaemia  may  ensue. 
Admission  to  hospital  provides  an  opportunity  for  SpO2  monitoring.  In  adult  CF 
patients, it is reported that minimum SpO2 are lower and time spent with SpO2 <90% is 
greater in patients with chest exacerbations than those with stable CF (Dobbin 2005), 
and that by treating the chest exacerbation SpO2 are significantly improved. This is 
supported by earlier work, which showed improvement in mean SpO2 on discharge as 
compared with admission, as well as a correlation between mean SpO2 and FEV1 (Pond 
and Conway 1995). 
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1.3.5.5 In-flight hypoxia in children with CF 
Flying heightens the risk of hypoxaemia in susceptible individuals, as both barometric 
pressure and partial pressure of oxygen fall with altitude. This means that a commercial 
flight passenger is breathing air with an inspired oxygen concentration (FiO2) of 15% 
instead of the usual sea-level FiO2 of 21%. Children with CF have additional pulmonary 
risks  imposed  on  them  when  flying,  namely  the  acquisition  of  respiratory  virus 
infections due to recirculating cabin air, as well as in-flight dehydration that may dry up 
respiratory secretions (Webb 2001). 
 
The main methods used to predict hypoxia in ‘fitness to fly’ assessments have been to 
perform a pre-flight hypoxic challenge challenge (monitoring of SpO2 when in a FiO2 of 
15%), or to predict in-flight hypoxaemia on the basis of baseline PaO2 or spirometric 
measures  such  as  FEV1.  Evidence  (Buchdahl  et  al.  2001,  Oades  et  al.  1994)  is 
conflicting as to which method most usefully predicts in-flight desaturation in children 
and British Thoracic Society guidelines suggest that children with CF should undergo a 
pre-flight  assessment  which  may  include  “hypoxic  challenge  testing  in  addition  to 
spirometric tests” (BTS 2002). In-flight hypoxia in children with CF is defined as a fall 
in  SpO2  to  <90%,  necessitating  the  need  for  supplemental  oxygen  on  long  distance 
flights (BTS 2002). 
 
1.3.5.6 Summary of methods of assessment of hypoxia in CF 
No  consensus  on  the  definition  of  hypoxia  in  CF  exists,  nor  which  mechanism  of 
hypoxia  causation  may  be  more  important.  Chapter  3  will  consider  a  variety  of 
definitions  for  sleep  and  exercise  hypoxia,  and,  by  using  receiver-operator  curve 
statistics,  assess  the  relationships  between  measures  of  inflammation  and  hypoxia 
definitions.  These  data  will  be  used  to  select  an  optimal  definition  of  hypoxia  in 
children with CF.   45
1.4 CFTR function 
 
CFTR  protein  is  an  adenosine  triphosphate  (ATP)-binding  protein  that  acts  as  a 
unidirectional solute pump. CFTR is an epithelial ion channel expressed in the apical 
membranes of epithelial cells lining the airways, intestines, pancreatic ducts and renal 
tubules  (Fuller  and  Benos  1992).  In  health,  CFTR  regulates  liquid  volumes  on  the 
surface of cells, e.g. airway surface liquid (ASL), by chloride secretion and inhibition of 
sodium reabsorption (Figure 1.1). In the sweat glands, however, CFTR functions in the 
opposite direction, by facilitating chloride reabsorption.  
 
In CF, failure of the CFTR-gated chloride channel to function is postulated to lead to 
depletion  of  liquid  on  the  cell  surface  (Davies  et  al.  2007),  and  ensuing  thickened 
secretions in the airways, pancreatic ducts, biliary tree, vas deferens and gastrointestinal 
tracts of individuals with CF. Furthermore, CFTR dysfunction in the sweat gland leads 
to chloride efflux. This forms the basis for sweat testing, the gold-standard diagnostic 
test for CF.  
 
When the chloride ion cannot
 be transported by CFTR at the above sites, fluid secretion 
is insufficient,
 and the protein portions of the secretions may become more viscid
 or 
precipitate and cause luminal obstruction, leading to plugging and
 dysfunction at the 
organ  level.  This  directly  contributes  to  a  number  of  pathological  entities  including 
mucous plugging and bacterial entrapment within the airways (due to ASL depletion), 
exocrine  pancreatic  insufficiency,  biliary  stasis,  infertility  and  distal  intestinal 
obstruction syndrome.  
 
Biogenesis of CFTR protein begins in the endoplasmic reticulum (ER). Conformational 
maturation  of  wild-type  CFTR  is  inefficient,  and  75%  of  newly-synthesised  CFTR 
molecules  are  degraded  by  cytoplasmic  proteasomes.  CFTR  then  matures  and  is 
delivered via the Golgi apparatus to the plasma membrane where it is endocytosed into 
sub-apical vesicles and  recycled to the plasma  membrane where it  can be  activated 
(Gelman and Kopito 2002). This process may be interrupted in a number of ways, and 
the manifold numbers of CFTR mutations are classed within 5 groups (section 1.4.1) 
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1.4.1 Classes of CFTR mutation 
Five classes of CFTR mutation are reported (Tsui 1992, McCauley and Elborn 2000).  
I)  Mutations associated with no production of CFTR protein 
II)  Mutations altering cellular maturation of CFTR protein 
III)  Mutations disturbing regulation of chloride channel 
IV)  Mutations altering conduction of chloride channel 
V)  Mutations associated with diminished production of CFTR protein 
 
1.4.2 ∆ ∆ ∆ ∆F508 – the commonest CFTR mutation 
The majority of CF patients (>90%) have an allele coding for a mutant CFTR lacking 
phenylalanine at the 508 position (∆F508) (Fuller and Benos 1992). ∆F508 is a class II 
mutation that blocks protein maturation in the endoplasmic reticulum (ER), resulting in 
protein breakdown (Kopito 1999). Only a small amount of mutant ∆F508 CFTR makes 
it to the cell membrane, (Kalin et al 1999) and it is known that the amount of functional 
CFTR protein reaching the cell surface correlates with disease severity (Figure 1.3). 
  
Figure 1.3 
Correlation of clinical disease severity with amount of CFTR protein expressed at the 
cell surface 
 
 
 
Improved CFTR function in ∆F508 homozygotes would rely on methods to increase 
plasma membrane levels of CFTR (Drumm 1999). Potential methods of achieving this 
include elevation of ∆F508 CFTR expression i.e. by improving CFTR trafficking, or by 
altering the intracellular environment to improve CFTR folding and processing (Drumm 
1999). In the ∆F508 population, work has centred on ‘molecular chaperoning’ (Accurso 
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2004,  Morello  et  al.  2000)  to  guide  abnormal  ∆F508  CFTR  protein  through  the 
endoplasmic reticulum to the cell surface. A number of methods for improving CFTR 
function by both chemical and environmental manipulation have been described, and 
these are summarised in Table 1.2. 
 
Exciting preliminary work on the role of oxygen in facilitating improvement in CFTR 
trafficking  (Bebok  et  al.  2001,  Guillembot  et  al.  2008),  suggests  that  hypoxia  may 
inhibit CFTR function. These reports suggest a potential novel role for oxygen therapy 
in increasing functional amounts of CFTR protein at the airway epithelial cell surface. 
The notion of hypoxia being associated with functional outcomes in CF forms the basis 
for undertaking this thesis. 
 
Table 1.2 
Potentiators/Inhibitors of CFTR Function 
 
Agent/Condition  Reference 
 
POTENTIATORS OF CFTR FUNCTION 
 
Hypothermia   
 
 
Glycerol 
 
Sodium 4-Phenylbutyrate   
 
 
Deuterated Water 
 
Trimethylamine-N-oxide 
 
Dimethylsulfoxide 
 
Genistein 
 
Gentamicin 
 
Curcumin 
No effect for Curcumin 
 
 
Oxygen     
Drumm et al. 1991 
Denning et al. 1992 
 
Sato et al. 1996 
 
Rubenstein et al. 1997 
Rubenstein et al. 1998 
 
Brown et al. 1997 
 
Brown et al. 1997 
 
Bebok et al. 1998 
 
Suaud et al. 2002 
 
Wilchanski et al. 2003 
 
Egan et al. 2004 
Grubb et al. 2004, Grubb et al. 2006 
Song et al. 2004 
 
Bebok et al. 2001 
 
INHIBITORS OF CFTR FUNCTION 
 
Hypoxia 
 
 
Cigarette smoking 
Mairlbaurl et al. 2003 
Guimbellot et al. 2008 
 
Cantin et al. 2006   48
1.4.3 CFTR function and hypoxia 
In vitro evidence exists to support a beneficial role for oxygen in enhancement of CFTR 
function  (Bebok  et  al.  2001).  Marin-Darby  canine  kidney  cell  lines  (which 
endogenously express low levels of CFTR) were cultured in air-liquid interfaces with a 
pO2  gradient  increasing  from  2.5%  to  20%.  It  was  found  that  improved  cellular 
oxygenation  led  to  increased  CFTR  maturation  and/or  increased  CFTR  trafficking 
(Bebok et al 2001). Furthermore, hypoxia is reported to reduce CFTR mRNA, protein 
expression and function in human cell lines (Guimbellot et al. 2008). Thus far, similar 
work in a ∆F508-homozygous CF cell-line has yet to be described. 
 
Animal work using a murine model shows that mice subjected to hypoxia (FiO2 of 10% 
for  7  days)  in  vivo  had  lower  levels  of  CFTR  mRNA  expression  in  airways, 
gastrointestinal  tissues  and  liver,  when  compared  with  normoxic  control  mice 
(Guimbellot et al. 2008). 
 
Limited human in vivo work also suggests a link between hypoxia and CFTR function. 
First, a study of mountaineers with high-altitude pulmonary oedema (HAPE) analysed 
CFTR expression in those who went on to develop HAPE and a control group. At low 
altitude  (normoxia),  no  difference  in  CFTR  expression  was  found.  However,  under 
hypoxic  conditions  (4559m),  a  60%  decrease  in  CFTR  expression  was  seen  in  the 
HAPE  group  (Mairbaurl  et  al.  2003).  Control  subjects  who  did  not  develop  HAPE 
however, had normal CFTR levels despite the same hypoxic stimulus. Secondly, CFTR 
mRNA expression was seen to be reduced in pulmonary tissues taken from hypoxaemic 
lung transplant recipients at the time of transplantation, when compared to the levels of 
CFTR mRNA seen in the lung epithelia of non-hypoxaemic donors (Guimbellot et al. 
2008). 
 
Therefore,  there  is  in  vitro,  rodent  and  in  vitro  work  supporting  a  role  for  hypoxia 
having  deleterious  action  on  CFTR  function.  Since  it  is  known  that  the  amount  of 
functional  CFTR  protein  reaching  the  cell  surface  correlates  with  clinical  disease 
severity (Figure 1.3), a novel therapeutic role for oxygen in Cystic Fibrosis is suggested. 
Other reported potentiators and inhibitors of CFTR function are in summarised in Table 
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1.5 CF airway disease 
The most widely-accepted explanation for the causation of airway disease in CF is the 
“low volume” hypothesis - namely that reduced ASL, as a result of CFTR dysfunction, 
leads  to  impaired  mucociliary  clearance  and  consequent  failure  to  effectively  clear 
inhaled bacteria (Matsui et al. 1998). If hypoxia does indeed inhibit CFTR function, 
then this may prove a contributory factor to reduction in ASL and predisposition to 
bacterial airways infection. 
 
Abnormal ASL leads to bacterial entrapment and recurrent lower respiratory infections. 
This causes airway remodelling which, in turn, results in increased airway resistance, 
gas trapping, V/Q mismatching and increased work of breathing. The airway is thought 
to be normal at birth with no evidence of infection, and probably no inflammation is 
present  (Davies  et  al.  2007).  However,  the  end  result  of  the  sequence  of  events 
described  above  is  irreversible  airway  damage  with  bronchiectasis  and  consequent 
respiratory failure.  
 
Thus, in advanced CF, hypoxia may ensue as a result of worsening V/Q mismatch. 
However,  a  circular  relationship  is  proposed,  whereby  hypoxia  itself  may  lead  to 
perpetuation of neutrophilic inflammation and parenchymal lung damage, contributing 
to  a  downward  pathophysiological  spiral.  The  mechanisms  by  which  this  is 
hypothesised to occur will be discussed below. 
 
1.5.1 CF airway inflammation 
Debate  rages  on  the  causal  signalling  mechanisms  for  inflammation  in  CF. 
Inflammation in the CF airway is typified by the presence of neutrophils along with 
their protein products, including elastase. Neutrophils are attracted to the airway by 
interleukin-8 (IL-8), a chemokine released by airway epithelial cells and macrophages 
as part of the innate immune response to infection. Levels of IL-8, along with other pro-
inflammatory cytokines such as tumour necrosis factor -alpha (TNFα), interleukins 1-
beta (IL-1β) and 6 (IL-6) are increased in the CF airway. Levels of IL-8 (the initiating 
step of neutrophilic inflammation in CF) are regulated by transcription factors of the 
nuclear factor kappa B (NFκB) family.    50
1.5.1.1 NFκ κ κ κB signalling and the innate immune system 
The  innate  immune  system  is  a  host-defence  system  found  in  all  multi-cellular 
organisms  which  has  the  ability  to  demonstrate  self  from  non-self  (Medzhitov  and 
Janeway Jr. 1997). The receptors of the innate immune system are known as pathogen 
recognition  receptors  (PRRs)  due  to  their  ability  to  recognise  pathogen  associated 
molecular patterns (PAMPs).   
The most prominent family of PRRs are the toll-like receptor (TLR) family of proteins, 
and  prominent  PAMPs  include  bacterial  lipopolysaccharide  (LPS)  –  the  major 
constituent of Pseudomonas aeruginosa (PA) cell wall, and lipoproteins (found in the 
cell walls of organisms such as Staphylococcus aureus). Following binding of a TLR to 
a pathogen-associated molecular pattern, such as binding of LPS to toll-like receptor 4 
(TLR4), a cascade of protein interactions begins (Muzio et al. 2000). Via a series of 
intracellular signalling mechanisms, NFκB is activated. 
 
NFκB is essential in driving transcription of several inflammatory cytokines (Dinarello 
1996). Therefore, following NFκB activation, expression of pro-inflammatory cytokines 
is increased, and resultant neutrophil chemoattraction and inflammation ensues. 
 
 
1.5.1.2 NFκ κ κ κB signalling and CF airway inflammation 
There are a number of postulated mechanisms by which NFκB activation may occur in 
CF, namely bacterial infection, CFTR dysfunction, cytokine stimulation and possibly by 
hypoxia (Figure 1.4). 
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Figure 1.4 
Simplified mechanisms for NFκB signalling and the CF airway  
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1.5.1.2.1 Bacterial infection leading to NFκ κ κ κB activation in CF 
The interaction of LPS and TLR4 is of importance in the CF lung, where the LPS-
producing organism, Pseudomonas aeruginosa (PA) is abundant. 73% children with CF 
have evidence of PA infection by age 3 years (Burns et al. 2001), and the cause of death 
in almost all CF patients is progressive lung inflammation associated with unremitting 
PA infection (Davis et al. 1996). The mechanism by which PA activates NFκB remains 
poorly understood, but differential NFκB activation in response to PA occurs in CF 
compared with healthy airways (Hajjar et al. 2002). LPS produced by PA is usually 
penta-acylated, but in the CF airway, PA synthesizes hexa-acylated LPS. Human TLR4 
recognises this configuration change, and NFκB activation is 100 times greater with the 
hexa-acylated form of LPS (Hajjar et al. 2002). Thus, in the CF airway, differential LPS 
recognition may lead to massive activation of the innate immune response. The pro-
inflammatory cytokine response to PA is protracted in CF cell lines with increases in 
IL-6 and IL –8, compared with non-CF cells (Kube et al. 2001). Toll-like receptor 2 
(TLR2) also signals via NFκB and is likely to be important in CF, as TLR2 recognises 
bacterial lipoprotein associated with Staphylococcus aureus (Lien et al. 1999), another 
common pathogen in the CF lung. 
 
1.5.1.2.2 CFTR protein dysfunction leading to NFκ κ κ κB activation in CF 
Normal innate immune response to PA is thought to involve CFTR (Pier et al. 1996), 
with work suggesting that PA LPS binds to wild-type CFTR protein with CFTR acting 
as a PRR, facilitating translocation and activation of NFκB (Schroeder et al. 2002). In a 
∆F508 CFTR cell-line however, there was a failure to endocytose LPS and a failure to 
translocate NFκB. The implication of this may be that whilst a non-CF patient quickly 
phagocytoses  PA,  the  CF  subject  cannot;  leading  to  persistent  PA  infection  and 
inflammation. This is borne out by evidence suggesting CFTR-null mice have increased 
levels of inflammatory mediators (including TNFα), and increased mortality after PA 
infection (van Heeckeren et al. 1997).  
 
One may postulate that if CFTR is lacking at the airway epithelial surface then the 
propensity  for  pattern  recognition  in  response  to  PA  is  lost  and  an  airway  defence 
mechanism is lacking, but this fails to explain how patients with channel mutants of 
CFTR  that  reach  the  cell  surface  (i.e.  G551D)  are  as  susceptible  to  PA  as  patients 
lacking CFTR at the cell surface (e.g. ∆F508) (Chmiel and Davis 2003). In vivo work 
has shown that inflammatory response to PA assessed by cell counts and cytokine levels   53
in  bronchoalveolar  lavage  (BAL)  fluid  was  comparable  between  classes  of  CFTR 
mutation and independent of whether CFTR reaches cell surface (Van Heeckeren et al. 
2004). Additionally, in vitro work showed increased IL-8 levels in CF cell lines exposed 
to PA that were independent of CFTR mutation class (Scheid et al. 2001). 
 
There is however evidence suggesting that patients with ∆F508 CFTR have an ongoing 
process of NFκB-driven hyperinflammation, in both the presence and absence of PA. It 
is suggested that while NFκB activation in response to bacterial LPS is an exogenous 
means of NFκB activation, endogenous NFκB activation occurs in patients with ∆F508. 
The  implication  of  this  is  that  neutrophilic  inflammation  in  the  CF  airway  may  be 
associated with CFTR dysfunction as well as with infection. This is suggested to be due 
to cell stress caused by the accumulation of mutant CFTR in the endoplasmic reticulum 
(Baeuerle and Baltimore 1995).  
 
1.5.1.2.2.1  
In vitro evidence for inherent inflammation due to CFTR dysfunction 
NFκB activation and increased IL-8 expression in ∆F508 CF cell lines when compared 
with wild-type CFTR cells is reported (Weber et al. 2001), along with reversal of higher 
baseline NFκB activation by the introduction of normal CFTR (Stecenko et al. 2001). 
There is indirect evidence to support this from studies which have measured increased 
IL-8 levels and neutrophil predominance in vitro, in animal models, and also in vivo. In 
vitro work has shown increased levels of IL-6, TNFα and IL-8 secretion in CF tracheal 
cells  when  compared  with  non-CF  cell  lines  (Kammouni  et  al.  1997)  and  also  in 
tracheal xenografts of human CF airway in immunodeficient mice (Tirouvanziam et al. 
2000).  
 
There are, however, also studies showing that NFκB activation (Scheid et al. 2001, 
Becker et al. 2004) and IL-8 expression (Schwiebert et al. 1999, Scheid et al. 2001, 
Becker et al. 2004) do not differ between CF and non-CF cell lines at baseline, that 
differences between CF and non-CF cell lines are inconsistent (Aldallal et al. 2002), and 
even evidence to show that CF cell  lines secrete less IL-8 than wild type cell lines 
(Massengale et al. 1999). 
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1.5.1.2.2.2  
In vivo evidence for inherent inflammation due to CFTR dysfunction  
In vivo work has found increased levels of inflammatory mediators including IL-8, and 
neutrophil numbers in BAL fluid of young children (Balough et al. 1995, Noah et al. 
1997)  and  infants  (Khan  et  al.  1995)  with  CF  in  the  absence  of  clinical  or 
microbiological  evidence  of  infection.  Additionally,  IL-8  mRNA  expression  is 
increased  in  young  CF  patients  compared  with  age-matched  non-CF  controls 
(Muhlebach et al. 2004).  
 
However,  it  is  also  reported  that  in  the  absence  of  infection  BAL  profiles  were 
comparable with control subjects and only the presence of infection was associated with 
raised inflammatory markers (Armstrong et al.1997). Analysis of BAL fluid in children 
with  CF  and  those  with  other  chronic  respiratory  problems  during  acute  infective 
exacerbations found increased levels of both IL-8 and neutrophils in the infected CF 
patients  compared  with  the  infected  non-CF  patients  (Muhlebach  et  al.  1999).  The 
protracted proinflammatory cytokine response in CF cell lines exposed to PA (Kube et 
al. 2001) may explain the findings of increased IL-8 expression in young children with 
no bacteria on BAL i.e. a prolonged response to a previous bacterial infection may be 
being measured. 
 
1.5.1.2.2.3 Cytokines perpetuating NFκ κ κ κB activation in CF 
The  proinflammatory  cytokine  TNFα  is  also  known  to  be  an  activator  of  NFκB 
(Brightbill and Modlin 2000) leading to perpetuation of inflammation, a phenomenon 
that is characteristic of airway inflammation in CF.  
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1.5.1.3 NFκ κ κ κB signalling and hypoxia 
There is in vitro evidence also that hypoxia may activate NFκB (Koong et al 1994, 
Leeper-Woodford  and  Detmer  1999),  and  also  increase  TNFα  activity  (Leeper-
Woodford and Detmer 1999). Although the authors suggest that it is enhanced NFκB 
activity which may account for TNF activation (Leeper-Woodford and Detmer 1999), it 
is plausible that the reverse may be true in view of the role of TNFα as an activator of 
NFκB (Brightbill and Modlin 2000).  
 
The  NFκB  pathway  is  thought  to  have  an  oxygen-sensing  mechanism,  by  which 
hypoxia  can  regulate  NFκB  activation  and  modulate  inflammatory  gene  expression 
(Taylor  and  Cummins  2009).  Thus,  hypoxia,  by  expression  of  pro-inflammatory 
cytokines, which in turn leads to recruitment of neutrophils may initiate and propagate 
CF airway inflammation.  
 
Before viewing correction of hypoxia with oxygen as a potential new anti-inflammatory 
therapy, one must also consider that evidence (also in vitro) suggests that hyperoxia also 
activates NFκB (Horowitz 1999), possibly via increased pulmonary TNFα expression 
(Shea et al. 1996), and that an increase in NFκB-mediated inflammatory markers in 
exhaled breath of chronic obstructive pulmonary disease (COPD) patients treated with 
oxygen (Carpagno et al. 2004) has been reported. 
 
The  effects  of  hypoxia  on  NFκB-mediated  inflammation  in  CF  and  non-CF  airway 
epithelial cells are presented in chapter 6, and contrasted with the effects of a known 
stimulus of NFκB, namely LPS from PA. 
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1.5.1.4 Inhibitors of the NFκ κ κ κB signalling pathway 
NFκB is potentially an attractive target for anti-inflammatory therapy in cystic fibrosis 
(Wright and Christman 2003, Koehler et al. 2004). By diminishing production of pro-
inflammatory cytokines, neutrophilic inflammation may be decreased and lung damage 
minimised. Corticosteroids are known to exert an inhibitory effect on NFκB signalling 
pathways (Kube et al. 2001, Escotte et al. 2003), and non-steroidal anti-inflammatory 
drugs  (NSAIDs)  also  inhibit  NFκB  activation  (Yin  et  al.  1998,  Wahl  et  al.  1998), 
providing  some  rationale  for  the  beneficial  effects  on  lung  function  seen  with  both 
prednisolone (Auerbach et al 1985) and ibuprofen (Konstan et al.1995) therapy in CF. 
 
Other suggested inhibitors of NFκB include cardiac glycoside drugs (Yang et al. 2004), 
recombinant IL-10 (Chmiel et al. 1999), genistein (Tabary et al. 1999), and curcumin 
(Rahman and MacNee 1998). Given that the latter two are postulated to improve CFTR 
trafficking - curcumin (Egan et al. 2004), and genistein (Suaud et al. 2002) - a potential 
mechanism for their inhibitory effects on NFκB may be suggested. 
 
1.5.1.5 The NFκ κ κ κB signalling pathway in CF – A summary 
NFκB signalling may be key to inflammation in the CF airway. NFκB is activated by a 
number  of  factors  including  cytokines,  infection,  and  possibly  CFTR  dysfunction. 
NFκB activation will result in increased IL-6 and IL-8 expression, promoting neutrophil 
chemoattraction,  which  initiates  and  propagates  chronic  airway  inflammation.  A 
number  of  possible  therapeutic  modalities  in  CF  may  rely  upon  inhibition  of  this 
pathway for their beneficial action, most notably corticosteroids and NSAIDs.  
 
Hypoxia may impact on the NFκB signalling pathway at a number of stages: 
-  Direct effect of hypoxia on NFκB signalling (section 1.5.1.3) 
-  Impairment of CFTR trafficking and resultant CFTR dysfunction (section 1.4.3) 
-  Propagation of Pseudomonas aeruginosa (section 1.6.2.1) 
 
Hypoxia in CF is postulated to lead to activation of the inflammatory cascade that is 
represented  in  Figure  1.4,  and  as  yet  the  effects  of  oxygen  therapy  on  this  process 
remain  uninvestigated.  Using  a  cell  culture  model,  the  effects  of  hypoxia  on  this 
inflammatory process in CF cells will be presented in Chapter 6 of this thesis.   57
1.6 Potential effects of hypoxia on clinical and psychological state in 
CF 
A repeated hypoxic insult, such as that occurring on a nightly basis during sleep, and to 
a lesser extent the repeated periods of hypoxia that may occur on exercise or flying may 
be deleterious to the health of the child with CF, impacting on the pulmonary circulation 
and quality of life, as well as theoretical effects on exacerbating lung inflammation. 
 
1.6.1 Hypoxia and inflammation 
Hypoxia may contribute to the decline in lung function by switching on NFκB-mediated 
inflammation (section 1.5), as well as encouraging the growth of PA, the key pathogen 
associated with CF lung disease. LPS produced by PA activates NFκB and impacts on 
the neutrophilic inflammatory cascade of Figure 1.4. Hypoxia may exert a role on this 
process,  as  PA  biofilms  prove  almost  impenetrable  for  antibiotics  under  hypoxic 
conditions, leading to a more intense and prolonged innate immune response. 
 
In non-CF models of childhood nocturnal hypoxia i.e. obstructive sleep apnoea (OSA), 
elevated  IL-8  levels  are  reported  when  compared  with  healthy  controls  (Tam  et  al. 
2006),  whilst  adult  OSA  models  also  report  increases  in  IL-8  (Alzoghaibi  and 
Bahammam 2005). Other downstream cytokines of NFκB, namely  IL-6 and TNF-α 
have also been shown to be elevated in OSA (Alberti et al. 2003), whilst animal models 
of  intermittent  hypercapnic  hypoxia  mimicking  OSA  resulted  in  corresponding 
increases in IL-6 (Tam et al. 2007). 
 
1.6.1.1 Effect of hypoxia on Pseudomonas aeruginosa (PA) growth 
PA is an aerobic bacterium that grows equally well in aerobic and anaerobic conditions 
(Worlitzsch et al. 2002). This is important in CF, where in vivo oxygen depletion has 
been demonstrated in PA-infected CF airways (Worlitzsch et al. 2002). Additionally, 
within PA biofilms, large regions of anoxia have been demonstrated (Borriello et al. 
2004).  PA  changes  phenotype  under  hypoxic  conditions  by  increasing  alginate 
production and forming biofilms. Hypoxia and the resultant biofilm state of PA leads to 
antibiotic  resistance  (Park  et  al.  1991,  Borriello  et  al.  2004)  and  an  increased 
(Muhlebach et al. 1999) and prolonged (Kube et al. 2001) innate immune response. 
These factors contribute to persistent PA infection and the chronic airway destruction 
that is characteristic of CF. A postulated antimicrobial benefit for oxygen is suggested, 
due to the potential for altering PA growth patterns i.e. if oxygen therapy penetrates   58
distal  airways  and  prevents  biofilm  formation,  increased  antibiotic  sensitivity  and 
decreased  PA  growth  and  immune  response  may  ensue.  However,  a  steep  oxygen 
concentration gradient exists between the airway lumen and interior of mucous in CF 
(Worlitzsch et al. 2002) meaning oxygen therapy is not only required to reach the distal 
airways, but must also penetrate the mucous therein. 
 
1.6.1.2 Effect of hypoxia on Staphylococcus aureus growth 
Under in vitro anaerobic conditions, Staphylococcus aureus (SA) also switches from a 
non-mucoid to a mucoid phenotype (Cramton et al. 2001), indicating that hypoxia may 
serve as a virulence factor for SA growth in the CF mucous environment. 
 
1.6.1.3 Effector mechanisms for reduction in inflammation with oxygen 
A potential anti-inflammatory role for oxygen therapy may lie in inhibition of NFκB. 
While NFκB activation due to hypoxia may be a direct effect, it is likely that other 
signalling pathways are involved to effect this action. The effect of oxygen on CFTR 
trafficking (section 1.4.3) is one such area of potential importance, which may impinge 
on NFκB-driven inflammation, and if CFTR trafficking were improved with oxygen 
therapy,  as  suggested  in  an  in  vitro  model  (Bebok  et  al.  2001),  then  less  CFTR 
degradation in the ER could be expected to take place with a resultant reduction in 
NFκB-driven inflammation. Additionally, a reduction in PA burden and its’ associated 
immune  response  (section  1.6.1.1)  could  also  be  a  potential  effector  mechanism  by 
which oxygen therapy may decrease inflammation in CF. 
 
1.6.1.4 Sequelae of inflammation as a result of hypoxia in CF 
Inflammation  is  increased  in  CF.  Whether  this  is  intrinsic  hyperinflammation,  or  a 
heightened response to microbial stimuli remains debatable, as discussed in previous 
sections. It is known that existence in a pro-inflammatory state promotes body wasting. 
Levels of pro-inflammatory cytokines including IL-6, IL-8 and TNF-α are raised in 
chronic  obstructive  pulmonary  disease  (COPD)  (Gan  et  al.  2004),  promoting 
catabolism,  and  muscle-wasting  (Debigare  et  al.  2003);  and  the  catabolic  effects  of 
ongoing lung inflammation in CF have been shown to be associated with reduced bone 
mineral density (Haworth et al. 2004).  
 
Therefore  if  hypoxia  activates  NFκB,  and  leads  to  upregulation  of  proinflammatory 
cytokines, it is possible that this may have a detrimental effect on muscle bulk, bone 
density, and nutritional status.    59
1.6.2 Hypoxia and the pulmonary circulation 
The  first  case  report  of  cor  pulmonale  in  a  CF  patient  was  published  in  1946 
(Wiglesworth 1946). The pulmonary circulation in CF responds to alveolar hypoxia by 
increasing pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR). 
Graded decreases in PAO2 produce similar increases in PVR (Bright-Thomas and Webb 
2002).  Chronic  alveolar  hypoxia  results  in  pulmonary  artery  remodelling,  with 
muscularisation of pulmonary arterioles proliferation of intimal smooth muscle in the 
pulmonary arteries, and progressive intimal fibrosis. Post-mortem studies in children 
with CF have shown that all had some degree of pulmonary artery muscle hypertrophy, 
and that muscle wall thickness was related to degree of right ventricular hypertrophy 
(Ryland and Reid 1975). 
 
Systolic  PAP  (sPAP)  can  be  estimated  by  measuring  the  peak  velocity  of  tricuspid 
regurgitation  blood  using  Doppler  echocardiography,  and  correlates  closely  with 
invasive  sPAP  (Yock  and  Popp  1984).  A  significant  association  between  sPAP  and 
mean SpO2 during sleep (r = -0.56) and exercise (r = -0.78)
 in adults with CF is reported 
(Fraser et al. 1999), although these associations have yet to be quantified in children.  
 
Various agents have been tried in CF to reduce pulmonary vascular resistance (PVR), 
including  calcium-channel  antagonists  (Davidson  et  al.  1989)  and  pulmonary 
vasodilators  (Geggel  et  al.  1985),  with  no  evidence  of  benefit.  The  only  selective 
pulmonary vasodilator shown to decrease PAP and PVR (Davidson et al. 1989) and 
improve RV performance (Alpert et al. 1987) in CF is oxygen. Therefore, oxygen in CF 
may be beneficial to the right heart, protecting against the development and progression 
of pulmonary hypertension.  
 
1.6.3 Hypoxia and quality of life 
 The only reported randomised controlled trial of oxygen therapy ever undertaken in CF 
(Zinman et al. 1989) reported that, over a 12-month period, school and work attendance 
was significantly better maintained in the oxygen-treated group, compared with those 
randomised to air (83% versus 20%, p<0.01), which may suggest a reduced quality of 
life for hypoxic subjects.   
 
1.6.4 Hypoxia and sleep quality 
Sleep  quality  (Pittsburgh  Sleep  Quality  Index),  and  sleep  duration  are  reported  to 
correlate with minimum sleep SpO2 (Milross et al. 2002B).    60
1.7 Oxygen as a therapy in CF 
Oxygen use in CF can be divided into long-term use, or use on a short-term basis such 
as during exacerbations, on exercise, or during air travel. 
 
1.7.1  Long-term and nocturnal oxygen therapy 
Little  has  been  written  on  the  criteria  for  starting  oxygen  in  children  with  CF,  and 
currently only 1-2% of UK paediatric CF patients receive long-term oxygen therapy 
(Balfour Lynn et al. 2005, Douglass et al. 2008). The Cochrane review of oxygen as a 
therapy in CF (Mallory et al. 2005) suggests that “…oxygen should be reserved for 
those  individuals  with  objective  evidence  of  hypoxemia  whether  awake  or  during 
exercise or sleep.” Given the lack of a uniform definition of what constitutes important 
hypoxia in each of these situations, implementation of such a policy appears fraught. 
 
Dinwiddie  and  colleagues  (Dinwiddie  et  al.  1999)  suggested  the  following  as 
indications for home oxygen therapy in CF: Resting SpO2 <90%, PaO2 <7.3 kPa, PaCO2 
>6 kPa and adult lung function measures of FVC < 2.0L and FEV1 < 1.5L. The US 
consensus guidelines on adult CF care (Yankaskas et al. 2004) recommend night-time 
oxygen if SpO2 are below 88-90% for >10% of sleep time, whilst previous guidelines 
suggested  long-term  oxygen  therapy  in  CF  should  be  reserved  for  bringing  about 
symptomatic  relief  (Schidlow  et  al.  1993),  a  view  shared  by  the  British  Thoracic 
Society (BTS) Home Oxygen Working Party (Balfour Lynn et al. 2009). 
 
In assessing short-term benefit, SpO2 during sleep in CF improve with supplemental 
oxygen (Spier et al. 1990, Gozal 1997) although no change in sleep architecture and no 
reduction in number of arousals is reported (Spier et al. 1990). In the only long-term 
oxygen trial in CF (Zinman et al. 1989), twenty-eight CF subjects were randomised to 
receive either air or oxygen therapy, and followed up for up to 3 years. Although no 
differences  in  mortality  or  hospitalisation  were  found,  83%  of  those  in  oxygen 
maintained school/work attendance at 12 months compared with only 20% of the air 
group (p<0.01). Further work is needed on the role of oxygen during sleep in patients 
with CF, with regards to improving daytime function and potentially conferring survival 
benefits (Milross et al 2004). Additionally non-invasive ventilation (NIV) may become 
more widely used in hypoxic individuals if accompanying hypercapnia co-exists.  
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1.7.1.1 Non-invasive ventilation (NIV) in CF 
The  commencement  of  NIV  along  with  supplementary  oxygen  may  be  indicated  in 
hypoxic CF individuals if accompanied by hypercapnia (Hodson et al. 1991, Moran et 
al. 2007, Noone 2008, Young et al. 2008). Although the BTS NIV standards of care 
document was cautious about routine NIV use in CF because of excessive secretions 
(BTS 2002), NIV actually augments airway clearance in CF (Bradley et al. 2006). Clear 
benefit on nocturnal hypoventilation and daytime functioning was seen from the use of 
nocturnal NIV over oxygen or placebo was seen in a 6-week cross-over trial in a small 
number (n=8) of hypoxic and hypercapnic Melbourne CF patients (Young et al. 2008). 
NIV may also be used during exercise, with documented benefits on exercise endurance 
as well as reduction in dyspnoea (Menadue et al. 2009). 
 
1.7.2  Oxygen therapy during exercise 
Exercise should be recommended for all patients with CF, and disease severity should 
not be an exclusion to participation in exercise (Webb et al. 1995). The 2004 adult CF 
care  consensus  report  (Yankaskas  et  al  2004)  advocates  the  use  of  oxygen  during 
exercise if SpO2 falls below 88-90% during exercise, whilst McKone and colleagues 
studied the role of oxygen therapy during sub-maximal exercise in a group of eight 
patients,  and  found  that  patients  were  able  to  exercise  for  longer  and  maintained 
significantly higher SpO2 in oxygen therapy (McKone et al. 2002). Previous authors 
have also reported improved SpO2 and increased exercise tolerance in CF patients who 
received supplemental oxygen during exercise (Marcus et al. 1992). The mechanism by 
which oxygen is thought to act to improve exercise tolerance is that by minimising 
hypoxic drive to breathe, the rate of increase in respiratory rate in hypoxic subjects is 
lower (Snider 2002), leading a reduction in dynamic hyperinflation and improvement in 
physiological  lung  volumes  (O’Donnell  et  al.  2001).  Thus  dead  space  is  lower  and 
instead  of  rapid,  shallow  respirations,  more  useful  gas  exchange  can  take  place, 
reducing fatigue and improving tolerance. 
 
Although SpO2 improve with oxygen during exercise, studies have reported minimal 
(Marcus et al. 1992) or no (Nixon 1990) improvement in VO2max during exercise in 
oxygen in patients with CF. A cross-over design study (n=14) undertaken at both low 
altitude (Dead Sea) and sea-level (Falk et al. 2006) reported modest improvements in 
both SpO2 and increased VO2max at low altitude, however, with the assumption being 
that the enriched FiO2 at lower altitude may account for these differences.    62
In  CF  subjects  with  exercise-induced  hypoxia,  oxygen  supplementation  appears  to 
prevent hypoxia and may have benefits on exercise capacity and duration. Although it is 
tempting to speculate that longer-term oxygen supplementation during exercise in CF 
subjects might have cumulative benefits, there are no studies upon which to base this 
recommendation (Mallory et al. 2005). In an analogous chronic lung disease – chronic 
obstructive pulmonary disease (COPD), however a beneficial role for oxygen therapy 
alongside a pulmonary exercise rehabilitation programme has been reported (Emtner 
2003) and this may be an area that warrants further investigation in patients with CF.  
 
1.7.3 Oxygen during CF chest exacerbations  
It is known that is nocturnal hypoxia may be exaggerated during chest exacerbations, 
(Pond and Conway 1995, Dobbin 2005), and that treating the exacerbation leads to 
improved SpO2. In a recent review (Smyth and Elborn 2008) on the management of 
exacerbations in CF, oxygen is not mentioned  other than in the treatment of  young 
children  with  chest  exacerbations  as  a  result  of  respiratory  syncytial  virus  (RSV). 
Although no evidence exists, a pragmatic view would be that oxygen is indicated during 
a chest exacerbation if periods of hypoxia are apparent on either nursing observations or 
oximetry recordings 
 
1.7.4 In-flight Oxygen 
In-flight hypoxia in children with CF is defined as a fall in SpO2 to <90%, necessitating 
the need for supplemental oxygen on long distance flights (BTS 2002). It should also be 
noted that there are cost implications for in-flight oxygen ranging from nil (with Virgin 
airlines), to £100 each way with British Airways. 
 
1.7.5 Potential risks and benefits of oxygen as a therapy in CF 
Caveats  exist  to  starting  oxygen  therapy  in  CF  however,  which  fall  broadly  into  3 
groups. First, children with CF already carry a heavy burden of care (Hunter 2003). 
Oxygen may be poorly tolerated due to wheeze or tightness (Dodd et al. 1998), has 
household  safety  implications  (Laubscher  2003),  and  may  necessitate  changes  in 
parental behaviour, namely smoking cessation. Oxygen may be perceived as palliative 
rather  than  active  therapy,  and  one  should  not  underestimate  the  accompanying 
psychomorbidity.  The  only  trial  of  long-term  oxygen  therapy  in  CF  (Zinman  et  al. 
1989) highlights this, as, of 146 subjects approached to take part, only 28 entered the 
study. Secondly, oxygen therapy may blunt respiratory drive, and although no rise in 
PaCO2 was seen after one year of oxygen therapy in CF (Zinman et al. 1989), other   63
studies report small (but probably clinically insignificant) rises in transcutaneous CO2 in 
CF adults receiving supplemental oxygen (Gozal 1997, Young et al. 2008). Finally, 
hyperoxia may itself cause toxicity and activate lung inflammation (Carpagno et al. 
2004). 
 
 
 
1.8 Summary 
Review of the basic science and rodent literature suggests that hypoxia may have a 
deleterious impact on measures of clinical status by mechanisms including inhibition of 
CFTR  function  and  also  activation  of  NFκΒ-mediated  inflammation,  as  well  as 
promotion  of  growth  of  bacteria  including  Pseudomonas  aeruginosa  and 
Staphylococcus aureus.  
 
Although  human  data  are  sparse,  such  data  as  do  exist  would  also  support  this 
conjecture: CF patients with periods of hypoxia may have increased pulmonary artery 
pressures,  increased  lung  inflammation,  greater  levels  of  Pseudomonas  aeruginosa 
burden,  reduced  exercise  ability  and  skeletal  muscle  strength,  and  perhaps  most 
importantly of all worse sleep quality and quality of life. 
 
Perhaps due to the lack of adequate definitions and subsequent lack of appropriately-
powered trials, there is no consensus as to when (and if) oxygen therapy should be 
initiated,  nor  for  its  mode  or  duration  of  delivery.  A  uniform  approach  to  defining 
hypoxia needs to be developed, along with guidelines for prescribing oxygen therapy in 
children with CF.  
 
The  need  for  studies  to  document  the  prevalence  and  potential  adverse  effects  of 
hypoxia in CF patients is thus apparent. Following this, a trial of oxygen therapy (or 
other means of restoration of normoxia) in those with demonstrable hypoxia may be 
worthy of further exploration.    64
1.9 Study aims 
The  aims  of  this  thesis  were  to  interrogate  the  relationship  between  hypoxia  and 
inflammation in order to select an optimal definition of hypoxia in children with CF 
(Chapter  3).  This  definition  was  then  used  to  study  the  association  of  hypoxia  and 
measured clinical and psychological parameters (Chapters 4 and 5), whilst the in vitro 
effects  of  varying  degrees  of  hypoxia  upon  NFκB-mediated  inflammation  in  a  CF 
airway epithelial cell culture model were studied (Chapter 6). 
 
1.9.1 Selection of optimal definition of hypoxia 
The  effects  of  hypoxia  upon  inflammation  in  CF  have  been  discussed  throughout 
Chapter 1. Hypoxia may directly stimulate the NFκB pathway (Leeper-Woodford and 
Detmer 1999, Taylor and Cummins 2009), and may exert indirect effects on NFκB-
mediated inflammation by promoting biofilm growth of Pseudomonas aeruginosa - PA 
(Worlitzsch et al. 2002) and Staphylococcus aureus (Cramton et al. 2001), as well as 
inhibition of CFTR trafficking (Bebok et al. 2001, Guillembellot et al. 2008).  
 
Thus,  a  number  of  existing  and  de  novo  definitions  of  nocturnal  hypoxia  were 
considered and analysed for their ability to detect abnormal inflammatory measures in a 
group of children with CF (Chapter 3). These included measures of inflammation that 
have direct relevance to the NFκB pathway namely interleukin-8, C-reactive protein 
(CRP), and peripheral blood neutrophil counts. NFκB is a key transcription factor for 
IL-8 (which promotes neutrophil chemoattraction), and also IL-6, which in turn is a 
precursor of CRP production (Heikkila et al. 2007). The sensitivity and specificity of 
each hypoxia measure were studied using receiver-operator (ROC) characteristics, such 
that a definition of hypoxia that performed best in the detection of CF inflammation 
could be selected. 
 
Upon  selection  of  an  optimal  hypoxia  definition,  dichotomisation  of  the  study 
population into hypoxic groups could be carried out and comparison of hypoxic subjects 
with their normoxic counterparts enabled the study of the association of hypoxia and 
clinical status (Chapters 4 and 5). 
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1.9.2 Outcome Measures for analysing the effects of hypoxia 
The effect of hypoxia on exercise capacity was selected as the primary clinical outcome 
measure because of the suggested mechanism by which hypoxia may exert effects on 
function. As discussed above, hypoxia switches on inflammation
 (Leeper-Woodford and 
Detmer 1999) and encourages PA growth in the CF lung
 (Worlitzsch
 et al. 2002). These 
factors each may worsen lung damage and limit exercise ability. Additionally, hypoxia 
accelerates skeletal muscle wasting
 (Gan et al. 2004), and contributes to the aetiology of 
pulmonary  hypertension  (Fraser  et  al.  1999),  which  may  also  impact  on  exercise 
capacity.  
 
Exercise may be key to halting decline in lung function, and ability to exercise has 
proven beneficial effects on airway clearance (Baldwin et al. 1994), aerobic exercise 
capacity  (Orenstein  et  al.  1981),  and  quality  of  life  in  CF
  (Klijn  et  al.  2004). 
Deteriorating  lung  function  combines  with  reduced  muscle  mass  to  limit  exercise 
capacity, setting up a ‘vicious circle’ (Figure 1.5) whereby decreased exercise ability 
reduces  sputum  clearance  and  encourages  bacterial  growth  within  the  CF  lung. 
Inflammation  may  thus  be  initiated  or  perpetuated  by  hypoxia,  leading  to  further 
reductions in both lung function and exercise ability.  
 
Figure 1.5 
Hypoxia and its purported effects on exercise  
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Furthermore, exercise capacity has been shown to be a measurable predictor of survival 
in children with CF. Exercise capacity has been shown to be an independent predictor of 
mortality in CF (Nixon et al. 1992), with peak VO2 levels < 32mls.kg
-1.min
-1 associated 
with a significantly increased mortality over the following 8 years (Pianosi et al. 2005). 
 
Exercise  capacity  (VO2)  at  anaerobic  threshold  (AT)  was  chosen  as  the  primary 
outcome  measure  for  this  study.  Because  cardiopulmonary  exercise  testing  is  a 
volitional test, peak VO2 measures rely on a near-maximal effort, whereas VO2 at AT 
(AT  VO2)  occurs  earlier  and  is  an  objective  measure  of  cardiopulmonary  exercise 
capacity that can be obtained on sub-maximal testing (Wasserman et al. 2004). AT VO2 
is a repeatable measure both within subjects and also between subjects. 
 
Secondary  outcome  measures  included  the  effects  of  hypoxia  on  measures  of  lung 
function (spirometry and plethysmography), lung structure (X-ray scoring), respiratory 
and skeletal muscle strength, echocardiographic measures, bone  mineral density  and 
quality of life. 
 
The hypothesis tested in the laboratory work of Chapter 6 is that hypoxia exerts an in 
vitro effect on NFκB-mediated inflammation in CF airway epithelial cells. The effects 
of  variable  degrees  of  hypoxia  upon  NFκB-mediated  inflammation  (as  assessed  by 
cellular IL-8 production) in both CF and non-CF cell lines was analysed over periods up 
to 96 hours. Furthermore, the effects of hypoxia on inflammation in CF and non-CF cell 
lines was compared and contrasted to the effects of a known stimulus of the NFκB 
cascade, namely bacterial lipopolysaccharide (LPS) from Pseudomonas aeruginosa.  
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CHAPTER 2: Subjects, Equipment and Methods 
2.1 The Study Population 
2.1.1 Subjects 
Subjects were recruited to the study when attending Great Ormond Street Hospital for 
Children (GOSH), London for their Cystic Fibrosis (CF) annual review appointment. 
Eighty-eight  patients  aged  8-16  years  of  age  were  identified  within  the  GOSH  CF 
service,  and  41  subjects  were  recruited  (Figure  2.1)  and  completed  the  full  testing 
protocol (Figure 2.2). The exclusions were for a number of reasons including current 
oxygen therapy, Burkholderia cepacia infection, size, infrequent clinic attenders who 
were not approached, and 11 who declined. The main reason for declining to take part 
was the need for an additional hospital visit and the time involved. 
Recruitment took place at annual review, as each child with CF under the care of GOSH 
attends for annual review. Recruitment at other times could introduce a selection bias as 
some children had more routine follow-up visits than others. 
 
2.1.2 Ethics Approval 
An application was made to the Institute of Child Health/Great Ormond Street Hospital 
Research Ethics Committee. Ethics approval for the study was granted in March 2005 
(REC number 05/Q0508/19). Copies of the confirmation of ethics approval are attached 
in Appendix 1.   68
Figure 2.1 
CF cohort studied 
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Figure 2.2 
Testing Schedule 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cystic Fibrosis patients aged 8-16 years in GOSH CF service 
RECRUITMENT PHASE 
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BASELINE TESTING 
 
•  Echocardiogram 
•  Spirometry 
•  Exercise testing protocol – CPET 
•  Assessment of skeletal muscle function 
•  Assessment of respiratory muscle function 
•  Measure markers of lung inflammation 
•  Assessment of sputum pathogens 
•  CFQ questionnaire   70
2.1.3 Power calculation 
Previous work from an exercise intervention study in CF (Blau et al. 2001) suggested 
that 10% differences in oxygen uptake at anaerobic threshold (AT VO2) were clinically 
significant. From the baseline measures of AT VO2 undertaken in the Blau study, a 
standard deviation of 8% in measures of AT VO2 across the study group was predicted. 
 
Differences of 10% in AT VO2 between hypoxic and normoxic CF patients that are 
thought to be of clinical importance:  
d=10 
 
The standard deviation in AT from previous evidence (Blau et al. 2001) is 8%. 
σ σ σ σ = 8 
 
A level of significance of 5% (p<0.05) and a power of 80% were considered sufficient 
(i.e. the study will incorrectly lead us to believe that a difference of 10% in AT exists 
when it doesn’t 1 time in 20, but correctly identifies the difference 80% of the time 
when it is there. 
 
A  table  of  F  values  (Wade  1999)  based  on  significance  levels  and  power  required, 
shows that accepting a 5% significance level with 80% power, leads to a value for F of 
7.85. 
 
F=7.85 
 
The following power calculation formula was used (Wade 1999): 
n>2F (σ/d)
2 
n> 2 x 7.85 (8/10)
2 = 10.04 
 
Therefore, 11 patients would be required in each group if sample sizes were equal. 
 
However, our projected groups sizes were likely to be unequal, and the normoxic group 
was estimated to be likely to be 4 times larger than the hypoxic group. 
   71
Based on GOSH CF Annual Review data from 2004, 6/72 patients aged 8 -16 years 
(8.3%)  had  evidence  of  daytime  hypoxia  (daytime  SpO2<93%),  and  6/72  patients 
(8.3%) experienced significant desaturation on exercise, 2 of whom had low daytime 
SpO2 also. Alder Hey Hospital, Liverpool had carried out overnight oximetry on their 
cohort  of  children  with  CF  (Southern  –  Personal  communication  2004).  Defining 
hypoxia as SpO2 <93% for >25% of sleep time, 12% of their study population (n=75) 
were hypoxic. The overlap between sleep and daytime hypoxia is hard to quantify. It 
has been shown that, in a group of adolescent and adult CF patients, hypoxia was more 
likely to occur during sleep than exercise
 (Coffey et al. 1991), so that although some 
patients with sleep hypoxia desaturate on exercise, there will be others in whom the 
desaturation only occurs during sleep. Also, whilst resting SpO2 are a highly specific 
predictor of nocturnal hypoxia, a significant proportion of patients with normal resting 
SpO2  will  be  hypoxic  during  sleep  (Frangolias  et  al.  2001,  Versteegh  et  al.  1990), 
indicating  the  need  for  overnight  sleep  study  to  confidently  rule  in/rule  out  sleep 
hypoxia.   
 
Extrapolating the daytime and exercise measures from GOSH, along with the Liverpool 
data, then we expected 8% to have daytime hypoxia and 8% to have exercise-induced 
hypoxia (25% of whom would also have low resting SpO2). Additionally, 12% might be 
expected to have nocturnal hypoxia
. Therefore the median number of hypoxic patients 
likely to be recruited is 20% (range 14-26), with 80% (74-86) normoxic controls. 
 
The following formula (Wade 1999) for unequal sample sizes was the applied: 
 
Total number required: 
N=   2n (1+k)
2       where k =  n1/n2  = 4
 
    4k 
N= 2x11x(1+4)
2  = 22x25  =34.3 
   4x4          16   
 
Group  sizes required are:  Hypoxic group:  N/1+k = 34.3/5  = 6.9 
Normoxic group:  kN/1+k = 137.5/5  = 27.5 
 
Therefore, our study required the recruitment of 35 patients to confidently detect a 10% 
difference in AT with 80% power and a level of significance of 5%. This equates to 28 
in the normoxic group and 7 in the hypoxic group.   72
2.2 Clinical Study Methods 
2.2.1 Home 
2.2.1.1 Home Oximetry 
Sleep studies were carried out in the subjects’ home by way of overnight pulse oximetry 
recording  using  the  Minolta  Pulsox-3i  oximeter  (Konica  Minolta  Holdings  inc., 
Singapore) as shown in Figure 2.3 below. 
 
 
 
 
 
 
 
 
 
Oximeters were despatched via the Royal Mail, and returned in the same fashion using a 
pre-paid  envelope.  Oximetry  recordings  were  carried  out  over  a  minimum  of  2 
consecutive  nights  to  control  for  night-to-night  variability  (Milross  2002)  and  data 
downloaded  using  the  Download  2001  software  package  (Stowood  Scientific 
Instruments, Oxford, UK). Home oximetry appears to be a reproducible measure of 
nocturnal  hypoxaemia  with  good  between  occasion  repeatability  (Montgomery  et  al 
1989) and limited night-to-night variability (Milross et al. 2002). 
 
Oximeters  are  calibrated  during  manufacture  and  automatically  check  their  internal 
circuits when they are turned on. They are accurate in the range of SpO2 of 70 to 100% 
(+/-2%), but less accurate below 70%. The oximeter utilizes a light source originating 
from the finger-probe at two wavelengths (665nm –red and 880nm - infrared). The light 
is partly absorbed by haemoglobin (Hb), by amounts which differ depending on whether 
it  is saturated  or  desaturated  with  oxygen.  By  calculating  the  absorption  at  the  two 
wavelengths the processor can compute the proportion of oxygenated Hb.  
 
Continuous measures of oxygen saturation (SpO2) and pulse rate were recorded. The 
SpO2 value is moving averaged over a period of 3 seconds, and displayed every second 
on  the  LCD.  SpO2  and  pulse  rate  values  are  sampled  and  stored  every  5  seconds, 
allowing downloading at a later date. The Minolta Pulsox 3i oximeter is accurate over a 
Figure 2.3 
Minolta Pulsox 3i device in use 
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range of SpO2 from 50-100% with precision of +/- 2%. Measured outcome measures 
were mean SpO2, lowest SpO2, and percentages of sleep time spent with SpO2 below 
94%, 93%, 92%, and 90%. Various methods of quantifying nocturnal SpO2 in CF are 
reported as detailed in Table 1.1. 
 
2.2.2 Hospital Visit 
 
2.2.2.1 Clinical Examination 
1) Height was measured using a Harpenden height stadiometer (Holtain Ltd, Crymych, 
Dyfed, UK) to the nearest millimetre. 
2) Body mass was measured with the subject wearing minimal clothing, using electronic 
scales (Seca [Model 861], Vogel and Halke, Germany) to the nearest 0.1 kilogram. 
3) Height, weight and body mass index were converted to standard deviation scores 
using the British 1990 growth reference data (Freeman et al. 1995, Cole et al. 1995), 
and associated computer package from the Child Growth Foundation. 
 
Body surface area was calculated using the following equation (Mosteller 1987): 
Surface area (m
2) =      Height (cm.) x Weight (kg) 
    3600 
4) All subjects underwent a cardiopulmonary physical examination.  
 
 
2.2.2.2 Resting Oximetry 
 
Transcutaneous oxygen saturations (SpO2) and heart rate were recorded at rest over a 3-
minute period, using a pulse oximeter (Nonin, USA) which was placed over the right 
supraorbital  artery.  Daytime  hypoxia  was  defined  as  a  resting  SpO2  <95%,  in 
accordance with the definition of Coffey and colleagues (Coffey et al. 1991). 
 
 
Following  clinical  examination  and  oximetry,  it  was  determined  if  the  subject  was 
allowed to proceed with cardiopulmonary exercise testing. A subject was to be excluded 
from  testing  if  SpO2  was  <  90%;  if  there  was  evidence  of  an  acute  upper/lower 
respiratory tract infection; if wheeze was present on examination; or they had a lower 
limb injury that would limit exercise performance.    74
2.2.2.3 Spirometry and measures of other lung parameters 
2.2.2.3.1 Spirometry methods 
Incentive spirometry was performed using a laboratory spirometer (Jaeger Masterscreen 
4.65) with computer package (Figure 2.4). The spirometer was calibrated before each 
set  of  measurements  with  a  three-litre  syringe.    Three  technically  acceptable 
manoeuvres were performed and forced expiratory volume in 1 second (FEV1), forced 
vital capacity (FVC), mid-expiratory (FEF75 and FEF50) flows and peak expiratory flow 
(PEF)  were  recorded  in  accordance  of  the  joint  American  Thoracic  Society  and 
European Respiratory Society (ATS/ERS) standards for spirometry (Miller et al. 2005).  
 
Figure 2.4 
Child performing incentive spirometry on Jaeger Masterscreen system 
 
 
 
2.2.2.3.2 Spirometry reference data 
The published Brompton paediatric reference data for spirometry (derived from a cross-
sectional study of 772 caucasian children) were used. Values from our study subjects 
were converted to standard deviation scores (SDS) using this validated reference data 
(Rosenthal et al. 1993).   75
2.2.2.3.3 Plethysmography 
Plethysmography was undertaken at Annual Review as part of each CF patient’s clinical 
evaluation. Plethysmography estimates measures of both residual volume (RV) and total 
lung capacity (TLC), and from these measures, an estimate of gas trapping can be made 
from the RV to TLC ratio. This was undertaken in accordance with the methodology of 
Stocks and Quanjer (Stocks and Quanjer 1995). 
 
2.2.2.3.4 Modified Chrispin Norman chest radiograph scoring 
The original Chrispin-Norman scoring system involves assessment of both frontal and
 
lateral chest radiographs (Chrispin and Norman 1974). The modified Chrispin-Norman 
scoring  system  (Benden  et  al.  2005)  assesses  only  a  frontal  postero-anterior  chest 
radiograph, which is scored according to a standardised
 scoring system for the typical 
abnormalities seen in CF. These include hyperinflation, increases in lung volume and 
the degree of diaphragm depression. Each individual item is given a score of: 0 - not 
present; 1 – present but not marked; 2 – marked; depending on the degree of change. 
  
The lung fields are then divided into four quadrants; right upper, left upper, right lower, 
left  lower.  Each  area  is  then  reviewed  for  parenchymal  lung  changes  which  are  a 
consequence of bronchial mucus plugging and infection. These are seen as bronchial 
wall thickening, ring shadows, mottled shadowing and areas of confluent consolidation 
– large soft shadows. A score of 0, 1 or 2 is given according to severity for each zone in 
relation  to  these  changes.  Scoring  is  performed  by  two  observers  simultaneously  in 
order  to  reduce  inter-individual  error.  The  proforma  used  for  the  scoring  process  is 
included in Appendix 2. 
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2.2.2.4 Respiratory Muscle Pressure Measurements 
Sniff nasal inspiratory pressure as well as mouth inspiratory and expiratory pressures 
were measured using a hand-held pressure meter (Micro RPM01, Micro Medical Ltd., 
Chatham, Kent, UK). Pressure is measured as that transduced across a piezoelectric 
crystal within the meter. Calibrations are factory set and are reported to remain stable 
indefinitely. However, in order to check pressure calibration, a 3-way tap connected to a 
syringe and attached to a manometer at one end, and the RPM01 at the other is used 
(Figure 2.5). The syringe is aspirated until a negative pressure of 200cm H2O is reached 
on the manometer. The respiratory muscle pressure meter should be reading the same 
pressure value. Adjustments can be made by turning a calibration screw in the outer 
housing of the meter until calibrations is reached. 
 
Figure 2.5 
Calibration of the RPM01 respiratory muscle pressure meter (Micro Medical, UK) 
 
 
Reproduced from operating manual of RPM01 respiratory muscle pressure meter 
2.2.2.4.1 Sniff Nasal Inspiratory Pressure (SnIP) 
The SnIP is a short, sharp voluntary manoeuvre performed whilst seated (Figure 2.6). 
Pressure is measured by wedging a nasal plug (Micro Medical Ltd., Chatham, Kent, 
UK) in one nostril whilst the other nostril remains unoccluded. The nasal plug allows a 
leak-free fit inside the nostril, and is connected to a 1.0mm ID polyethylene catheter that 
is attached to the pressure transducer of the hand-held pressure meter. The respiratory 
pressure meter was connected to a respiratory pressure database and analysis software 
(PUMA,  Micro  Medical  Ltd.),  via  a  desktop  personal  computer.  The  subject  sniffs 
through  the  obstructed  nostril  from  relaxed  end-expiration  (Functional  Residual   77
Capacity, FRC), to a maximum of 10 attempts. The pressure in the obstructed nostril 
corresponds to the transmitted pressure from alveoli to the nasopharynx, as a measure of 
respiratory  muscle  strength.  Most  subjects  are  able  to  attain  a  maximal  sniff  with 
practice (ATS statement), and there appears little gain in carrying out a greater number 
of sniffs (Fitting 2006). 
 
SnIPs were recorded using the software above, and maximum SnIP of three manoeuvres 
which  varied  by  less  than  5%  was  noted.  Sniff  measurements  were  rejected  if  the 
pressure tracing did not show smooth upstroke, or the total duration of the sniff was > 
500ms as suggested by previous authors measuring SnIP in children (Rafferty et al. 
2000). 
Figure 2.6 
SnIP being performed in a young child 
 
 
 
 
2.2.2.4.2 Mouth Inspiratory Pressure (MIP) 
Mouth  inspiratory  pressures  were  measured  using  a  standard  flanged  mouthpiece 
connected to the hand-held pressure meter.  Maximum pressure that is sustained over 1 
second was computed. Pressure-time plots were viewed in real-time using the PUMA 
analysis software package  
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A nose clip was worn during testing, and the subject was asked to perform a minimum 
of 5 and a maximum of 10 maximal inspiratory efforts from FRC, whilst seated.  Each 
effort  was  undertaken  1  minute  apart.  Subjects  were  asked  to  maintain  maximal 
pressures  for  at  least  2-3  seconds,  in  order  that  maximum  pressure  sustained  for  1 
second could be recorded. A leak is built into the mouthpiece in order to allow some 
airflow and prevent glottic closure on inspiration. Care was taken to ensure an adequate 
seal  around  the  mouthpiece  to  minimise  airleak,  and  the  highest  pressure  of  3 
manoeuvres which varied by less than 5% was noted. 
 
2.2.2.4.3 Mouth Expiratory Pressure (MEP) 
MEP  is  a  method  of  assessing  global  expiratory  muscle  strength  by  measuring  the 
maximal static pressure that can be generated at the mouth by performing a maximal 
expiratory  effort  (Valsalva  manoeuvre).  Mouth  expiratory  pressures  were  measured 
using a standard flanged mouthpiece connected to the hand-held pressure meter, and 
maximum pressure that is sustained over 1 second was computed. A leak is built into 
the mouthpiece in order to prevent buccal muscle involvement. Pressure-time plots were 
viewed in real-time using the PUMA analysis software package. 
 
The subject was asked to perform a minimum of 5 and a maximum of 10 maximal 
expiratory efforts from Total Lung Capacity (TLC), whilst seated and wearing a nose 
clip.  Each  effort  was  undertaken  1  minute  apart.  Subjects  were  asked  to  maintain 
maximal pressures for at least 2-3 seconds, so that maximum pressure sustained for 1 
second could be recorded. Care was taken to ensure that there was an adequate seal 
around the mouthpiece, and the highest pressure from 3 manoeuvres that varied by less 
than 5% was noted. 
 
 
2.2.2.4.4 Methodological issues around Respiratory Muscle Testing 
A number of methodological issues have been noted in the literature respiratory muscle 
pressure testing, the principal ones being: 
•  Nose-clip or no nose-clip? 
•  Measurement of Inspiratory Pressures from RV or FRC 
•  Measurement of Expiratory Pressures from TLC or FRC 
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The first of these issues centres on whether or not a nose-clip should be worn when 
carrying  out  mouth  pressures  measurements  (MIP  and  MEP).  The  reference  data 
available in children were derived with nose-clip in place (Stefanutti and Fitting 1999, 
Rafferty  et  al.  2000),  although  the  2002  American  Thoracic  Society/European 
Respiratory Society statement on respiratory muscle testing concludes that ‘noseclips are 
not required’ when testing static mouth pressures (ATS/ERS 2002).  
 
The  pressure  generated  during  respiratory  muscle  pressure  manoeuvres  reflects  the 
pressure  developed  by  the  respiratory  muscles  (Pmus),  plus  the  passive  elastic  recoil 
pressure of the respiratory system including the lungs and the chest wall (Prs). At FRC, the 
elastic recoil is zero, so that mouth pressure is equal to Pmus. However, at residual volume 
(RV), the Prs may be as much as –30cm H2O, and thus may contribute significantly to MIP 
values. Similarly at TLC, the Prs can be up to +40cm H2O, thus affecting the MEP values. 
Since it is difficult to estimate and subtract elastic recoil values, measures of inspiratory 
pressures were made from FRC. Ideally, MEP would also have been measured from 
FRC. However, in a group of children used to performing forced expiratory manoeuvres 
(spirometry) from TLC, MEP readings were measured from TLC. 
 
 
 
2.2.2.4.5 Respiratory Muscle Pressure Reference Data 
The paediatric reference data of Stefanutti and Fitting (1999) was used, where age and 
gender-specific means and standard deviations for SnIP, MIP(FRC) and MEP(TLC) are 
quoted. SnIP, MIP and MEP values from our study subjects were converted to standard 
deviation scores (SDS) using this validated reference data (Stefanutti and Fitting 1999). 
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2.2.2.5 Exhaled Breath Condensate (EBC) 
2.2.2.5.1 Exhaled Breath Condensate Collection  
Samples  were  collected  with  the  subject  in  a  seated  position  using  a  commercially 
available system (ECoScreen, Jaeger, Hoechberg, Germany) with a one-way inspiratory 
valve, cooling chamber and collection system (Figure 2.7).  
Figure 2.7 
Collection of EBC  
 
 
An  oral  inhalation,-oral  exhalation  method  was  used  and  a  nose-clip  was  worn  in 
accordance with the ATS/ERS recommendations (Horvath et al. 2005). Collection time 
used was 20 minutes, during which the subject undertook normal tidal breathing. After 
this time, between 2 and 4mls of exhaled water vapour were collected. 
 
Exhaled breath collection was carried out prior to any forced expiratory manoeuvres 
being  undertaken,  and  also  prior  to  exercise.  The  design  of  the  mouthpiece  for  the 
Ecoscreen  device  is  such  that  the  condenser  is  at  a  higher  level  than  that  of  the 
mouthpiece, minimising the risk of salivary contamination. Following collection, the 
samples were immediately, transferred to the Immunobiology laboratory, Institute of 
Child Health, eluted into cryovials (Nalge-Nunc International, Roskilde, Denmark) and 
stored at –80
OC. 
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2.2.2.5.2 Exhaled Breath Condensate Cytokine analysis  
Wide  discrepancy  in  reported  in  the  levels  of  detectable  IL-8  in  EBC  is  reported. 
Cunningham and colleagues studied 21 CF patients and detected IL-8 in EBC in 33% 
with median concentrations of 49 pg.mL
-1 (Cunningham et al. 2000). This contrasts 
with work reported by an Italian group (Bodini et al. 2005) who detected IL-8 in 90% 
CF patients and controls but with concentrations that are all <1 pg.mL
-1 i.e. 50-fold 
lower than Cunningham. In view of the discrepancies in levels of detectable cytokines 
found in EBC, two methods of analysis were chosen. First, the same ultrasensitive IL-8 
enzyme-linked immunosorbent assay – ELISA kit (KHC0084, BioSource International 
Inc.,  Camarillo,  California)  used  by  Bodini  and  colleagues  was  used  (Bodini  et  al. 
2005). This kit detects  IL-8 levels within the range of 0.39 pg.mL
-1 to 25 pg.mL
-1. 
Secondly, a 10-plex cytokine analysis system which detects 10 different cytokines – IL-
1β,  IL-2,  IL-4,  IL-5,  IL-6,  IL-8,  IL-10,  Interferon  gamma  (IFN-γ),  granulocyte  and 
macrophage colony stimulating factor (GM-CSF) and TNFα, (Human 10-plex cytokine 
assay,  BioSource  International  Inc.,  Camarillo,  California)  was  used.  For  IL-8,  the 
standard curve is such that IL-8 levels within the range of 16.5-4000 pg.mL
-1 can be 
detected.  i.e.  should  be  able  to  detect  IL-8  levels  similar  to  those  reported  by 
Cunningham and colleagues (Cunningham et al. 2000). 
 
2.2.2.5.2.1 Ultasensitive enzyme-linked immunosorbent assay (ELISA) for 
interleukin-8 
 (ELISA)  were  used  to  measure  the  concentration  of  IL-8  in  exhaled  breath.  An 
ultrasensitive IL-8 (KHC0084, BioSource International Inc., Camarillo, California) kit 
was  used,  which  detects  IL-8  over  a  range  from  0.39  pg.mL
-1  to  25  pg.mL
-1.The 
protocol was based on manufacturer’s instructions.  
 
A high-binding 96-well plate had already been pre-coated with capture antibody. Prior 
to the first incubation, samples in duplicate and serially-diluted standards were added at 
100µL/well.  Additionally,  a  patient  EBC  sample  was  spiked  with  a  known 
concentration  of  IL-8,  and  a  blank  sample  was  run  in  duplicate.  Standards  were 
generated  by  1:2  serial  dilutions  from  25  pg.mL
-1  down  to  0.39  pg.mL
-1.  The  first 
incubation consisted of 2 hours at room temperature, during which IL-8 antigen binds to 
the capture antibody on one site. 
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Wells  were  then  aspirated  and  washed  4  times  with  200µL  wash  buffer  per  well, 
following  which  a  biotinylated  antibody  specific  for  human  IL-8  was  added  at 
100µL/well. During this second incubation (1 hour at room temperature), this antibody 
binds to the immobilised human IL-8 captured during the first incubation.  
 
Wells were again aspirated and washed 4 times with 200µL wash buffer per well. After 
removal of excess of the second antibody, Streptavidin-horseradish peroxidase enzyme 
(Streptavidin-HRP)  is  added.  This  binds  to  the  biotinylated  antibody  to  complete  a 
‘four-member’  sandwich.  After  a  third  (30  minute,  room  temperature)  incubation, 
washing (x4) is again carried out, to remove all of the unbound enzyme. Thereafter, 
tetramethylbenzidine (TMB) was added (100µL/well). This is a substrate which is acted 
upon by the bound enzyme to produce colour. Plates were protected from light and 
incubated at room temperature for 30 minutes. The intensity of the coloured product is 
directly proportional to the concentration of human IL-8 present in the original sample. 
The colour reaction was stopped by the addition of a stop solution (1M hydrochloric 
acid) which was added at 100µL/well. 
 
Optical densities of each well were then read using an ELISA plate reader (Revelation 
4.02,  Dynex  Technology,  Chantilly,  VA,  USA)  at  450nm  (reference  filter  650nm). 
Cytokine concentrations in the unknown samples were read from the curve generated 
from a known standard included on each plate. This technique allowed confidence to 
detect IL-8 within the range of 0.39 to 25 pg.mL
-1. The highest coefficient of variation 
quoted for this kit for replication of responses on the same plate (intra-plate precision) is 
<6%,  and  coefficient  of  variation  for  responses  between  plates  is  <8%  (inter-plate 
precision).   83
Figure 2.8 
Methodology for human interleukin-8 ELISA 
 
 
 
30 minutes in dark 
Room temperature 
Aspirate and wash (x4) 
Incubate 100µL/well of biotinylated antibody 
 
Incubate 100µL/well of Streptavidin-HRP 
 
Aspirate and wash (x4) 
1 hour at room temperature 
30 mins at room temperature 
Aspirate and wash (x4) 
Add 100µL/well of chromogen substrate 
(TMB) 
Add 100µL/well of STOP solution 
(1M HCl) 
Incubate 100µL/well of samples and standards 
Read absorbance at 450nm on ELISA plate reader 
2 hours at room temperature 
96-well plates precoated with human IL-8 capture antibody   84
2.2.2.5.2.2 Human 10-plex cytokine assay 
A human 10-plex kit (BioSource International Inc., Camarillo, California) was used to 
assay levels of IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IFN-γ, GM-CSF and TNF-α. 
This  is  a  multiplex  analysis  protein  system  utilising  Luminex  technology.  The 
Luminex system uses uniformly sized microspheres which are internally labelled with 
graded proportions of a red and nearly red fluophore, 658nm and 712nm respectively, 
providing the capacity to interrogate and classify 100 discrete beads. This means that 
the  system  has  the  potential  for  measuring  up  to  100  analytes  in  a  single  sample. 
Essentially  the  procedure  is  an  ELISA  on  a  bead.  Beads  of  a  single  identity  are 
covalently coupled to a single capture antibody for the cytokine of interest. Samples and 
standards of known concentration are pipetted into the wells of a filter bottom 96-well 
plate and incubated for 2 hours. After washing the beads, cytokine-specific biotinylated 
detector antibodies are added to quantitate the amount of each cytokine captured on the 
bead. The detector antibody is incubated with the beads for 1 hour. After washing to 
remove  excess  biotinylated  detector  antibodies,  streptavidin  conjugated  with  a 
fluorescent  protein,  R-Phycoerythrin  (Streptavidin-RPE)  is  added.  A  30  minute 
incubation takes place, during which Streptavidin-RPE binds to the detector antibodies 
associated  with  the  immune  complexes  on  the  beads.  After  a  wash  to  remove  any 
unbound  beads,  the  beads  are  analysed  using  the  Luminex  xMAP  system  which 
incorporates  the  Luminex100  system  plate  analysis  (Luminexcorp,  Austin,  Texas, 
USA). 
 
This system has been validated for the measurement of serum cytokines (Zhao et al. 
2003),  though  no  data  for  the  analysis  of  EBC  exist.  Comparison  with  individual 
ELISAs  has  shown  that  Luminex  technology  is  of  equivalent  accuracy  for  the 
majority of cytokines (du Pont et al. 2005). The lower limits of detection and inter-
assay variations (BioSource International Inc., Camarillo, California) for each cytokine 
using this kit are tabulated below. 
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Table 2.1 
Lower detection limits and interassay variability for human 10-plex cytokine kit  
 
CYTOKINE 
LOWER LIMIT OF 
DETECTION 
pg.mL
-1 
INTERASSAY 
VARIATION 
GM-CSF  15  9.1% 
IFN-γ  5  9% 
IL-1β  15  8.8% 
IL-2  6  9.5% 
IL-4  5  8.7% 
IL-5  3  7.5% 
IL-6  3  7% 
IL-8  3  9.8% 
IL-10  5  9.8% 
TNF-α    10  8.3% 
 
The intra-assay variability is low, and the manufacturers quote correlation coefficients 
between 0.92 and 0.99 for the cytokines assayed. The schema for analysis is outlined 
below (Figure 2.9).   86
Figure 2.9 
Methodology for human 10-plex cytokine analysis 
 
 
 
Aspirate and wash (x4) 
Incubate 100µL/well of biotinylated antibody 
 
Incubate 100µL/well of Streptavidin-RPE 
 
Aspirate and wash (x4) 
1 hour at room temperature in 
dark on orbital shaker 
30 mins room temperature in 
dark on orbital shaker 
Add 100µL/well of wash buffer 
Shake for 2-3 minutes 
on orbital shaker 
Add samples (50µL/well) and standards (100µL/well) 
(100µL/well100µL/well) 
Read absorbance on Luminex xMap system 
2 hours at room temperature in dark on 
orbital shaker 
Antibody coated beads added to filter-bottomed 96-well plates 
Aspirate and wash (x4)   87
2.2.2.6 Blood Tests 
2.2.2.6.1 Sampling 
Blood was taken either by peripheral venepuncture or sampled from a total implantable 
venous access device (TIVAD), such as a Port-a-cath. The following samples were 
taken: 1ml Lithium-Heparin tube, 1ml ethylenediaminetetraacetic acid (EDTA) tube, 
5mls plain tube. In subjects in whom Angiotensin Converting Enzyme (ACE) genotype 
had  not  previously  been  established,  then  a  further  5ml  EDTA  tube  was  taken  and 
stored. In all cases, blood samples were taken prior to exercise being undertaken. 
 
2.2.2.6.2 Immediate sample processing 
Once taken, blood was sent to the Great Ormond Street Hospital Chemical Pathology 
laboratory  for  analysis  of  C-reactive  protein  (CRP),  and  also  to  the  Haematology 
laboratory  for  analysis  of  full  blood  count  with  white  cell  differential  and  also 
erythrocyte sedimentation rate (ESR). 
 
The  plain  tube  was  spun  in  a  centrifuge  (Rotina  46R,  Wolf  Laboratories  Limited, 
Pocklington,  UK)  at  3000  revolutions  per  minute  for  7  minutes.  Serum  was  then 
extracted and stored in cryovials (Nalge-Nunc International, Roskilde, Denmark) at –
80
OC for later cytokine analyses. In the event of deoxyribonucleic acid (DNA) being 
required  to  establish  ACE  genotype,  a  5ml  EDTA  sample  was  stored  at  –80
OC  for 
future DNA extraction and ACE genotyping. 
 
2.2.2.6.3 C-reactive protein 
C-reactive protein was measured in the Chemical Pathology laboratory at Great Ormond 
Street Hospital for Children using the Ortho Diagnostics 5.1 chemistry analyser (Ortho-
Clinical  Diagnostics,  High  Wycombe,  Buckinghamshire,  UK)  and  an  automated 
immune-rate  immunoassay  (Vitros  CRP  Slide,  Ortho-Clinical  Diagnostics,  High 
Wycombe,  Buckinghamshire,  UK).  This  uses  technology  that  is  very  similar  to  the 
ELISA technique described above (section 2.2.5.2.1). 
  
The  patient  sample,  when  added  will  bind  to  beads  coated  with  phosphorylcholine 
(capture beads). A monoclonal anti-CRP antibody labelled with horseradish peroxidise 
(HRP) acts as a signal generator for the assay. First, the patient sample is added to the 
slide. Secondly, CRP binds to the capture bead and also to the monoclonal anti-CRP   88
antibody/HRP complex. The addition of hydrogen peroxide results in enzyme mediated 
oxidation of dye, the optical density of which is measured at a wavelength of 670nm. 
The optical density is directly proportional to the CRP concentration of the sample. 
Calibration is regularly performed using the Vitros Chemistry Products calibration kit 7 
in order that accuracy of measurement can be analysed against standards of known CRP 
concentration. 
 
2.2.2.6.4 Full blood count 
An automated full blood count was performed in the Haematology laboratory at Great 
Ormond  Street  Hospital  for  Children,  along  with  measurement  of  differential  white 
blood cells including a neutrophil count using the Sysmex XE 2100 analyser (Sysmex 
Corporation, Kobe, Japan). The analyser is factory-calibrated, and undergoes in-house 
quality control testing on a daily basis. 
 
Paediatric tubes (EDTA) are manually introduced into the Sysmex XE 2100 machine 
via a sampler, from which blood is sampled and diluted. Blood then moves through a 
tube thin enough that cells pass by one at a time, so that cell characteristics can be 
assessed  in  five  channels,  by  a  combination  of  fluorescence  flow  cytometry  and 
electrical impedence techniques. This series of measurements enables a full differential 
white cell analysis to be obtained. 
 
2.2.2.6.5 Erythrocyte sedimentation rate (ESR) 
This test was performed in the Haematology laboratory at Great Ormond Street Hospital 
for  Children  using  a  manual  Westergren  method  (International  Council  for 
Standardization in Haematology Expert Panel on Blood Rheology  J Clin Pathol 1993). 
In  short,  venous  blood  was  mixed  with  an  aqueous  solution  of  sodium  citrate  and 
allowed to stand in an upright pipette tube, 200mm in length and filled to the zero mark. 
Erythrocyte  sedimentation  rate  (ESR)  was  measured  as  the  observed  fall  of  the  red 
blood cells, in millimetres over 1 hour. 
 
2.2.2.6.6 Serum cytokine analyses 
Enzyme-linked  immunosorbent  assays  (ELISA)  were  used  to  measure  serum  IL-8 
concentration, using an ultrasensitive IL-8 kit (KHC0084, BioSource International Inc., 
Camarillo, California), and identical methodology to section 2.2.2.5.2.1.     89
2.2.2.6.7 Angiotensin Converting Enzyme (ACE) genotyping 
Dr  Christina  Hubbart  (Research  Assistant,  Department  of  Cardiovascular  Genetics, 
Rayne Institute, University College London) undertook DNA extraction, and carried out 
angiotensin converting enzyme (ACE) genotyping on my behalf. 
 
DNA was extracted using a ‘salting-out’ protocol for extracting DNA from whole blood 
(Miller et al. 1988). 
 
ACE  genotype  was  determined  by  using  a  three-primer  technique  that  has  been 
previously  described  (O’Dell  et  al.  1995).  Primer  ratios  corresponded  to  50pmol  of 
ACE1 (D-specific oligonucleotide) and ACE3 (common oligonucleotide) and 10pmol of 
ACE2  (I-specific  oligonucleotide)  in  a  20µL  reaction.  This  yielded  amplification 
products of 84bp for the D allele and 65bp for the I allele. Amplification products were 
visualised  using  ethidium  bromide  staining  on  7.5%  polyacrylamide  ‘MADGE’ 
(Multiple Array Diagonal Gel Electrophoresis) gels. Accuracy was ensured by using 
replica PCRs set up without the I-specific primer (ACE2) to confirm the presence of the 
D allele. 
 
Figure 2.10 
PCR for ACE genotype using 3-primer system 
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2.2.2.7 Echocardiography 
Trans-thoracic  echocardiography  was  undertaken  on  all  study  patients,  using  a 
commercially  available  cardiovascular  ultrasound  system  (GE  Vivid  System  7,  GE 
Healthcare, UK). The timing of the echocardiogram was such that it was carried out in 
the  resting  state,  and  prior  to  cardiopulmonary  exercise  testing.  M-mode,  two-
dimensional and Doppler echocardiographic images were acquired from the standard 
parasternal,  apical  and  subcostal  views.  Echocardiogram  was  carried  out  with  the 
subject  either  supine,  or  in  the  left  lateral  position,  by  experienced  paediatric 
sonographers  (Gill  Riley,  Katie  Maslin,  and  Anna  Barlow)  from  the  Department  of 
Cardiology, Great Ormond Street Hospital for Children, London, UK.  
 
Cardiac  structure  and  morphology  were  assessed  before  moving  on  to  carry  out 
measures as laid out in the proforma of echocardiographic measures in CF devised for 
this study. The proforma is similar to that used in a study of cardiac function in adult CF 
patients  (Fraser  et  al.  1999),  and  was  agreed  independently  by  two  Consultant 
Paediatric  Cardiologists  at  Great  Ormond  Street  (Dr  Graham  Derrick  and  Dr  Jan 
Marek).  Standard  M-mode  measurements  at  end  diastole  were  made  measuring  left 
ventricular wall thickness at both interventricular septum and posterior wall (IVSd and 
LVPWd),  as  well  as  right  ventricular  wall  thickness  (RVWd).  Left  ventricular 
dimensions  were  measured  in  both  systole  and  diastole  (LVDs  and  LVDd).  These 
measures  were  taken  from  the  parasternal  long  axis  view  as  recommended  by  the 
American Society of echocardiography (Sahn et al. 1978). 
 
The  left  ventricle  fractional  shortening  (%)  was  assessed  by  M-mode  measures  of 
fractional shortening using the following equation (Quinones et al. 1978):  
LV fractional shortening (%) = LVD (end diastole) – LVD (end-systole) x100 
                                                      LVD (end-diastole) 
 
LV  ejection  fraction  (%)  was  derived  from  the  M-mode  measures  of  ventricular 
dimensions as follows (Feigenbaum et al.1972): 
 
LV ejection fraction (%) = [LVD (end diastole)]
3 – [LVD (end-systole)]
3 x100
 
                                                      [LVD (end-diastole)]
3 
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Systolic  pulmonary  artery  pressure  (or  sPAP)  was  measured  from  the  continuous 
Doppler signal of the tricuspid regurgitation (TR) gradient (if any TR present) using the 
modified Bernoulli equation described by Fraser et al. (1999) :  Dp=4v
2 where Dp is the 
calculated peak pressure difference between RV and right atrium (RA), and v is the 
measured peak flow velocity of tricuspid regurgitant jet. The Dp value is added to RA 
pressure which is assumed to be 5mmHg in children (Du et al. 2004). 
 
2.2.2.8 Cardiopulmonary Exercise Testing 
A cardiopulmonary exercise testing protocol was already in place for children attending 
the  exercise  laboratories  at  the  Institute  of  Child  Health.  Cardiopulmonary  exercise 
testing  was  carried  out  with  breath  by  breath  ventilatory  gas  analysis  using  a 
commercially available metabolic cart (MedGraphics, USA). Prior to each test, the mass 
flow  sensor  was  calibrated  using  a  standard  3  litre  syringe.  Two-point  sensor  gas 
calibration (Zirconium oxide fuel cell and infrared CO2 analyser) was performed prior 
to each test using standard calibration gases (16% O2:4% CO2:balance nitrogen and 24% 
O2:balance nitrogen, Scott Medical Gases, Breda, Holland). 12-lead electrocardiography 
(ECG) was  recorded before  and during all tests (CardioControl  Workstation,  Welch 
Allyn, Delft, Holland). The subjects were fitted with nose-clips and wore a full face 
mask (MedGraphics, USA), connected to an expiratory limb pneumotachograph. The 
pneumotachograph measured flow, and a sampling line monitored mouth tidal pCO2 
and pO2. This protocol can used to calculate maximal oxygen consumption (VO2max) 
during maximal exercise, and also peak oxygen consumption (VO2peak) and anaerobic 
threshold (AT) for patients with CF undergoing near-maximal or submaximal exercise.  
 
Subjects  were  exercised  on  an  electronically-braked  cycle  ergometer.  The  choice  of 
ergometer was dependent upon the height of the child. For children between 128 and 
135cm.  tall,  the  Ergoline  900  (Ergoline,  Blitz,  Germany)  was  used,  and  for  those 
>135cm.  tall,  the  Lode  Excalibur  (Lode,  Groningen,  Holland)  was  chosen. 
Transcutaneous oxygen saturations (SpO2) and heart rate were continuously recorded 
during exercise using a pulse oximeter (Nonin, USA) which was placed over the right 
supraorbital artery fixed with a bandanna, this site being the least prone to exercise 
artefact.  Oxygen  uptake  (VO2),  carbon  dioxide  production  (VCO2),  end-tidal  CO2 
(etCO2), tidal volume (VT) and respiratory rate were measured.    92
Figure 2.11 
Subject undergoing cardiopulmonary exercise testing (CPET) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.2.8.1 Cardiopulmonary Exercise Testing (CPET) Inclusion Criteria  
Inclusion Criteria  
Height >128cm (needed to reach pedals) 
Age >8 years [Cadence maintenance difficult below this age] 
 
Exclusion Criteria 
Aged <8years 
Height<128cm 
Contagious illness or colonisation 
i.e. Methicillin-resistant Staphylococcus aureus (MRSA) 
 
Mental or behavioural deficiency preventing use of ergometer 
Gross motor or neurological deficit preventing use of ergometer  
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2.2.2.8.2 Cardiopulmonary Exercise Testing (CPET) Protocol 
Subjects were advised to refrain from eating for at least 2 hours before the test, and to 
avoid strenuous exercise for 24 hours before CPET. Although clear fluids were allowed, 
caffeine-containing drinks were avoided on the day of testing. All subjects underwent a 
cardiopulmonary  physical  examination.  Resting  heart  rate  (HR)  and  SpO2  were 
recorded  using  a  pulse  oximeter  (Nonin,  USA),  which  was  placed  over  the  right 
supraorbital artery. 
 
Direct estimation of  maximal voluntary ventilation (MVV),  measured by  maximally 
deep and rapid respiration over a 12-second period was performed. As well as a direct 
measurement of MVV, a prediction was made using childhood CF-specific reference 
equations for calculating MVV (Stein et al. 2003). 
 
The exercise testing protocol was adjusted to each individual child, such that a ramping 
protocol of increasing workload was chosen to achieve 8 to 12 minutes of incremental 
exercise testing. The expected achievable workload of 3W/kg was adjusted dependent 
upon  the  fitness  quartile  into  which  the  child  places  themselves,  and  the  pre-test 
spirometry values to attain a suitable ramping protocol.  
 
Data will be collected over 4 phases of exercise: 
a.  Resting data [3 to 5 minutes] 
b.  Loadless cycling [3 minutes] 
c.  Incremental exercise test [8 to 12 minutes] 
d.  Recovery phase [4 minutes] 
 
a. Resting data [3-5 minutes] 
The subject was seated on the ergometer, and monitored during tidal breathing, until 
respirations became regular and gas-exchange measures stabilised. 
 
b. Loadless cycling [3 minutes] 
The subject cycled with no resistance (ergometer set to zero watts), whilst maintaining a 
steady cadence at 60-80rpm. This allowed muscles to warm up, and steady state gas 
exchange was achieved at the end of the warm-up phase. 
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c. Incremental exercise test [8-12 minutes] 
Using  a  predetermined  ramping  protocol,  exercise  was  undertaken  with  a  steadily 
increasing workload, whilst maintaining a cadence at 60-80rpm. The aim was to reach 
maximal exercise capacity in an 8-12 minute period. 
 
d. Recovery phase [4 minutes] 
The subject was monitored in the recovery period. Resistance was removed from the 
ergometer, and gentle pedalling (20-30rpm) was encouraged to prevent syncope. Gas 
exchange data was recorded for 4 minutes, and the ECG recording continues until heart 
rate returned to near-baseline. 
 
A summary of the full CPET protocol is provided in appendix 4. 
 
2.2.2.8.3 Cardiopulmonary Exercise Testing (CPET) Measured Parameters 
The following parameters were measured: 
•  Heart Rate 
•  Blood Pressure (checked manually every 1-2 minutes during CPET) 
•  Oxygen utilisation (VO2) - Measured by indirect calorimetry 
•  Carbon dioxide elimination (VCO2) - Measured by indirect calorimetry 
•  Work Rate (Watts) 
•  Respiratory Rate 
•  Tidal volumes 
•  Minute ventilation 
•  End-tidal CO2 (etCO2) 
•  Oxygen saturations (SpO2) 
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Clinically important outcome measures include: 
 
•  VO2 peak 
The peak oxygen consumption level during the test – i.e. level of oxygen utilisation at 
maximal exercise. 
 
•  (VO2 max) 
Although often quoted as a primary outcome measure in exercise-related research, the 
VO2 max is of limited usefulness in children for two reasons. Firstly, such volitional 
tests  may  be  submaximal,  and  secondly,  the  plateau  of  oxygen  uptake  at  maximal 
exercise occurs only in a proportion of childhood tests. 
 
•  Minute ventilation (VE) 
The product of tidal volume and respiratory rate, the minute ventilation on exercise 
represents the ventilatory adaptation to exercise. Using the measured or predicted MVV, 
an assessment of breathing reserve at the end of exercise can be made (VEmax – MVV). 
 
•  Anaerobic Threshold 
Anaerobic threshold is calculated as the level of exercise at which aerobic energy is 
supplemented by anaerobic mechanisms. The increasing lactic acid burden is buffered 
by bicarbonate, and the resultant carbon dioxide load removed through an increase in 
ventilation. The cycle test can determine the point at which this happens using the V-
slope  method  (explained  below)  to  ascertain  the  point  at  which  carbon  dioxide 
elimination increases. This is seen to be a reproducible measure of Anaerobic Threshold
 
(Thin et al 2002).   
 
Anaerobic Threshold has advantages over VO2max as a primary outcome as it is more 
easily  reproducible  between  occasions  and  between  patients.  The  reason  for  this  is 
because VO2max requires the patient to get up to maximal exercise capacity (perhaps a 
tall order for 8-16 year old CF patients), whereas AT is a sub-maximal measure. AT is 
quoted as the level of oxygen uptake at which significant metabolic supplementation 
through anaerobic metabolism takes place.    96
2.2.2.8.4 Cardiopulmonary Exercise Testing (CPET) Data Generation 
Following completion of a cardiopulmonary exercise test (CPET), a nine-panel plot of 
test data is generated. An example of such a plot taken from a healthy control subject is 
displayed below (Figure 2.12): 
 
Figure 2.12 
9-panel CPET testing plot from healthy subject 
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Each of the nine panels provides different information regarding the exercise test. 
 
The ventilatory responses are best assessed in panels 1, 4 and 7.  
 
 
 
Panel 1 is a plot of minute ventilation (VE, green) and respiratory rate (RR, orange) 
against time. Panel 4 is a plot of minute ventilation versus carbon dioxide elimination 
(VCO2), and panel 7 is a plot of VE against tidal volume (VT). 
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Cardiac indices are best assessed using panels 2, 3 and 5. 
 
 
 
 
 
 
Panel 2 shows heart rate (HR, brown) and oxygen uptake per heart beat (VO2/HR – the 
so-called ‘oxygen pulse’, purple) against time. The oxygen pulse provides an indirect 
measure of the contribution made by stroke volume to cardiac output. Panel 3 shows 
oxygen  uptake  (VO2,  red),  carbon  dioxide  elimination  (VCO2,  blue),  and  workload 
(black) plotted against time. Panel 5 illustrates HR (brown) and VCO2 (blue) against 
time. The point at which an upkick in CO2 production occurs can be assessed from this 
plot – the so-called V-slope method - and it is likely that this is the point at which 
anaerobic  threshold  (AT)  has  been  reached.  The  buffering  of  lactate  results  in  an 
obligatory increase in VCO2 relative to VO2 at AT due to increased CO2 production as 
HCO3
- buffers lactate. In addition to V-slope analysis, the point at which AT occurs 
requires confirmation in panels 6 and 9.  
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Panel 6 and 9 reflect the responses of the pulmonary vasculature during exercise. 
 
 
 
 
 
Panel 6 shows the ventilatory equivalents for oxygen (VE/VO2, red) and carbon dioxide 
(VE/VCO2, blue) plotted against time, whereas panel 9 illustrates oxygen saturations 
(SpO2, green), and end-tidal concentrations of oxygen (etO2, red) and carbon dioxide 
(etCO2, blue) against time. 
 
Anaerobic  threshold  (AT)  occurs  at  a  point  where  VE/VO2  begins  to  rise  whilst 
VE/VCO2 is either falling or has reached a plateau (panel 6). i.e. hyperventilation occurs 
with respect to O2 but not CO2 at the point where AT occurs due to a period of isocapnic 
buffering. This period is so-called because there is a lack of ventilatory compensation 
for the evolving metabolic acidosis (Wasserman 1978). During this period, circulating 
HCO3
- buffers the metabolic acid produced, and the period lasts for around 1-2 minutes, 
after which ventilatory compensation is required leading to an increase in the ventilatory 
equivalent for CO2 (↑VE/VCO2). On panel 9, the point at which AT occurs is marked 
by a rise in end-tidal oxygen (etO2) levels as a result of hyperventilation., though etCO2 
remains constant due to the phenomenon of isocapnic buffering described above.   100
Panel  8  is  an  assessment  of  the  metabolic  response  to  exercise  and  is  a  plot  of 
respiratory exchange ratio (RER, green) against time. 
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2.2.2.9 Assessment of skeletal muscle function 
Measures  of  both  proximal  (quadriceps  maximal  isometric  voluntary  strength),  and 
distal (hand-grip strength dynamometry) muscle strength were made on each subject. 
 
2.2.2.9.1 Quadriceps maximal isometric voluntary contraction 
To quantify quadriceps muscle strength, maximal voluntary isometric contractions were 
measured using a custom-built isometric dynamometer (University College [Royal Free 
Campus] Medical School Physiology Department). Briefly, the subject was sat in an 
upright  position  with  knee  flexed  to  90
O.  A  clamp  placed  just  above  the  ankle 
transmitted knee extensor force via an inextensible chain to a strain gauge bar. A secure 
strap was placed around the hips to prevent hip extension. The subject was instructed to 
try to extend their knee and generate as much force as possible (Figure 2.13). Subjects 
were requested to maintain the maximal contraction for 2-3 seconds and then relax. 
Forces from the strain gauge bar were amplified and displayed on a chart recorder. The 
sartine gauge was calibrated with a set of known masses, in order to derive a regression 
equation for force measurement. Regular 3-point calibrations with 5 and 20kg masses 
were undertaken during the duration of the study. 
 
 
 
Figure 2.13 
Quadriceps muscle strength 
testing 
 
 
 
 
 
2.2.2.9.2 Quadriceps force reference data 
The reference data of Backman et al. (1989) was used, where age and gender-specific 
means and standard deviations for maximal quadriceps contraction are given. Maximal 
forces  achieved  by  voluntary  quadriceps  contraction  in  our  study  subjects  were 
converted  to  standard  deviation  scores  (SDS)  using  this  validated  reference  data 
(Backman et al. 1989). 
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2.2.2.9.3 Handgrip Strength Dynamometry 
An  estimation  of  distal  skeletal  muscle  strength  was  made  using  peak  force 
measurements made using a Jamar hydraulic hand dynamometer (Sammons Preston, 
Bolingbrook, IL, USA). Prior to testing, each child was instructed on how to use the 
Jamar dynamometer. Testing was carried out with the child standing straight with their 
back against a wall, and arm held in 90 degrees of elbow flexion (Figure 2.14).  
 
Grip strength was tested with the dynamometer in the second position, as used in the 
collection of the quoted reference data (Mathiowetz et al. 1986). Alternate measures of 
dominant and non-dominant hand grip strength were made one minute apart, to a total 
of three measures on each side. The maximal force generated was recorded. 
Figure 2.14 
Child performing handgrip strength dynamometry 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.2.9.4 Handgrip Strength Reference Data 
The paediatric reference data of Mathiowetz et al. (1986) was used, where age and 
gender-specific means and standard deviations for dominant and non-dominant hand 
grip strength are given. Maximal handgrip strength values from our study subjects were 
converted  to  standard  deviation  scores  (SDS)  using  this  validated  reference  data 
(Mathiowetz et al. 1986). 
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2.2.2.10 Bone densitometry 
Bone mineral content (BMC) was assessed in 8 to 12 year-old CF subjects using dual 
X-ray absorptiometry (DXA) scanning of the lumbar spine (Lunar Prodigy, GE Medical 
Systems) – Figure 2.15. This was used to estimate bone mineral density (BMD) for a 
given bone area: BMD = BMC/Bone area. BMD was expressed as a standard deviation 
score related to an age-matched population. However, it is known that a BMD z score 
measure will underestimate BMD in a small subject, and overestimate in tall subjects 
(Fewtrell et al. 2003). Therefore, a volumetric assessment – the bone mineral apparent 
density (BMAD) was undertaken to adjust for calculated bone volume rather than bone 
area.  
 
Figure 2.15 
Child undergoing a DXA scan 
 
 
   104
2.2.2.11 Quality of life assessment: Cystic Fibrosis Questionnaire [CFQ] 
Psychological well-being was assessed using the Cystic Fibrosis Questionnaire (CFQ). 
The CFQ is a quality of life assessment that was developed in  France (Henry et al 
1997). It has since been adapted for use in a number of countries (Rozov et al. 2006) 
including  Spain,  Germany  (Henry  et  al  1998),  USA  (Quittner  et  al  2000),  Holland 
(Klijn et al 2004), as well as current adaptation for UK use (Bryon 2004). In each of 
these  translations,  both  backward  and  forward  translations  were  completed  and  re-
validation of the questionnaire was carried out. A CD-ROM package that accompanies 
the questionnaire enables nine quality of life (QOL) dimensions to be assessed (Table 
2.2).  
 
Table 2.2 
Quality of life dimensions that are assessed by the UK-CFQ 
 
1  Physical functioning 
2  Energy/well-being 
3  Emotions 
4  Social limitations 
5  Role 
6  Embarrassment 
7  Body image 
8  Eating disturbances 
9  Treatment burden 
 
 
This study used the UK-translated CFQ (Bryon 2004 – Personal communication). The 
CFQ-14+ was used for children aged over 14 years, and is a self-assessed questionnaire 
that takes around 10 minutes to complete. A self-reporting format for 12 and 13 year-
olds was used for this age group. The CFQ child P is a parent-proxy evaluation used for 
children  aged  6  to  13  and  was  used  for  the  younger  children  in  our  study.  An 
interviewer format questionnaire for children aged 6-11 year-olds is also available but 
was  not  used  in  this  study.  Statistical  analyses  were  carried  out  to  assess  overall 
differences in quality of life, or in individual QOL dimensions with respect to hypoxia. 
Copies of the various CFQ questionnaires used are attached in Appendix 3.   105
2.3 In vitro Study Methods 
2.3.1 Tissue Culture – Cell lines and incubator conditions 
Tissue culture was carried out using immortalised cell lines (Dieter Gruenert, University 
of Vermont, USA). Firstly, a non-CF airway epithelial cell line was chosen - 1HAEo
-, a 
transformed human airway epithelial cells which form tight junctions (Cozens et al. 
1994). Secondly a Cystic Fibrosis airway epithelial cell line was chosen - CFBE41o
-, a 
transformed cystic fibrosis bronchial epithelial cell line that maintains cell polarity. 
 
The  cells  were  grown  in  25ml  flasks  (T25,  Nalge-Nunc  International,  Roskilde, 
Denmark), in a standard tissue culture incubator (Galaxy-R, Wolf Laboratories Limited, 
Pocklington,  UK)  maintained  at  37
OC  and  with  a  CO2  level  of  5%.  Humidity  was 
maintained by keeping a filled tray with a water-copper sulphate mixture at the base of 
the incubator. 
 
Each 500ml of tissue culture media (SIGMA M7278 minimum essential medium) was 
enriched  with  foetal  calf  serum  (50mls),  L-glutamine  (5mls)  and  a  procaine 
penicillin/Streptomycin (PenStrep) mixture (5mls). Media was changed every 2-3 days, 
and passaging of cells was carried out on a twice weekly basis with cells being split 1 in 
5.   106
2.3.2 Tissue Culture – Hypoxic conditions 
2.3.2.1 Hypoxia as single variable 
Hypoxia  was  controlled  by  a  Pro-Ox  controller  (Biospherix  Limited,  Redfield, 
NY13437,  USA),  regulating  oxygen  concentration  within  a  two-shelf  tissue  culture 
chamber  (Biospherix  Limited),  housed  in  a  standard  incubator  (Galaxy-R,  Wolf 
Laboratories  Limited,  Pocklington,  UK)  as  illustrated  below  (Figure  2.16).  Carbon 
dioxide  within  the  cell  culture  chamber  was  maintained  at  5%  using  a  Pro-CO2 
controller (Biospherix Limited, Redfield, NY13437, USA).  
 
Figure 2.16 
a) Cell culture chamber and Pro-Ox controller during hypoxia experiments 
b) How controller supplies gas to chamber 
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In  order  to  maintain  a  control  environment,  cells  were  incubated  simultaneously  in 
normoxic conditions (incubator) alongside hypoxic conditions (tissue culture chamber) 
as shown below (Figure 2.17). For the purpose of these experiments, cells were seeded 
in 25ml flasks (T25, Nalge-Nunc International, Roskilde, Denmark) at a seeding density 
of 0.7x10
6 per flask in 5mls media. Flasks for time zero, 8 hours, 24 hours and 48 hours 
were  each  placed  in  the  chamber/incubator  for  each  cell  line  and  environmental 
condition. i.e. Samples for each cell line and under hypoxic and normoxic conditions 
with a separate flask for each time-point.  
 
Figure 2.17 
Regulation of hypoxia using Nitrogen flow via Pro-Ox controller  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CELL CULTURE: 
A - HAE in hypoxic conditions 
B - CFBE in hypoxic conditions 
C - HAE in air (normoxia) 
D - CFBE in air (normoxia) 
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Simultaneous incubation of air versus hypoxia for each of the cell lines was carried out 
over a 48 hour period. Sampling of cell supernatant was carried out at time zero, and 
then at 8, 24 and 48 hours thereafter.  
The following conditions were studied: 
 
TC Chamber           Incubator 
Normoxia 21%            Normoxia (Control) 
Hypoxia 10%            Normoxia (Control) 
Hypoxia 5%            Normoxia (Control) 
Hypoxia 1%            Normoxia (Control) 
Hypoxia 0.1%           Normoxia (Control) 
 
 
 
2.3.2.2 Hypoxia and lipopolysaccharide stimulation of cells 
As above, hypoxia within the tissue culture chamber was controlled using a Pro-Ox 
controller, and a Pro-CO2 controller was used to maintain CO2 at a level of 5%. Tissue 
culture media were enriched with lipopolysaccharide (LPS) derived from Pseudomonas 
aeruginosa (L9143 Sigma-Aldrich, St Louis, MO, USA), with either high (50µg.mL
-1 
media), or low (10µg.mL
-1) levels of LPS added, or none. 
 
Cells were seeded in 25ml flasks (T25, Nalge-Nunc International, Roskilde, Denmark) 
and  incubated  simultaneously  in  normoxic  conditions  (incubator)  alongside  hypoxic 
conditions (tissue culture chamber). Seeding density was 0.7x10
6 cells per flask in 5mls 
media.  Flasks  for  time  zero,  24  hours  and  48  hours  were  each  placed  in  the 
chamber/incubator for each cell line and environmental condition. i.e. High, low and no 
LPS  samples  for  each  cell  line  and  under  hypoxic  and  normoxic  conditions  with  a 
separate flask for each time-point.  
 
Cells were studied at 10%, 1% and 0.1% levels of hypoxia and compared to normoxic 
cells that had been grown simultaneously. 
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2.3.2.3 Hypoxia and LPS prolonged time course experiment 
The previous time-course experiments described ran for 48 hours.  A further experiment 
was carried out comparing extreme hypoxia (0.1%) with normoxia over a 4-day period 
with sampling carried out at 0, 24, 48, 72 and 96 hours. 
 
Flasks  had  either  high-dose  LPS  (50µg.mL
-1  media)  added  or  no  LPS  at  all.  This 
enabled  comparison of  cell lines with  and without  LPS under extreme hypoxic and 
normoxic conditions at each timepoint. 
 
2.3.3 Sampling of cell supernatant 
At each timepoint in the experiments, cell supernatant was sampled from the T25 flask, 
and stored in cryovials (Nalge-Nunc International, Roskilde, Denmark) at –80
OC for 
later cytokine analyses. 
 
2.3.4 Cell counting 
Following aspiration of supernatant, the remaining cells within the flask were washed 
with phosphate-buffered saline (PBS). 2mls of Trypsin-EDTA solution was then added 
and the flask was replaced in the incubator for a further 5 minutes to ensure that cells 
had separated and were floating. 5mls of tissue culture media was then added to the 
flask to inactivate the trypsin. The resulting solution was placed in a 15ml tube, and 
centrifuged at 1200 rpm for 5 minutes. Following this, a pellet representing the cells 
was found at the bottom of the centrifuge tube. Media was aspirated and the pellet was 
re-suspended in 5mls medium and thoroughly mixed using a vortex mixer. 
  
16 µL of Trypan blue solution (T8154 Sigma-Aldrich, St Louis, MO, USA) was added 
to 16 µL of the cell suspension, and cells were counted using a haemocytometer and 
microscope (Carl-Zeiss, Jena, Germany). Cells are selective in the compounds that pass 
through the membrane, and in a viable cell Trypan blue is not absorbed; however, it 
traverses the membrane in a dead cell. Hence, dead cells are shown as a distinctive blue 
colour under a microscope. Live cells or tissues with intact cell membranes are not 
coloured.  Since  live  cells  are  excluded  from  staining,  this  staining  method  is  also 
described as a dye exclusion method.   110
2.3.5 Enzyme-linked immunosorbent assay (ELISA) for interleukin-8 (IL-8) 
Enzyme-linked immunosorbent assay (ELISA) was used to measure the concentration 
of IL-8 in tissue culture cell supernatant for both human airway epithelial cells and CF 
bronchial epithelial cells. A human IL-8 (ELH-IL8-001, RayBiotech Inc., Norcoss, GA, 
USA) ELISA kit was used, which detects IL-8 levels in the range of 5 pg.mL
-1 to 2000 
pg.mL
-1. In order for IL-8 levels to be detected in our cell supernatant samples, the 
samples were centrifuged (Rotina 46-R, Wolf Laboratories Limited, Pocklington, UK) 
to allow cell debris to sink to the bottom of the tube, and then diluted to 1 in 100 using 
an  assay  diluent  provided  with  the  ELISA  kit.  The  protocol  was  based  on 
manufacturer’s instructions. The procedure is very similar to that described in section 
2B  2.4.2.1,  utilising  a  96-well  plate  that  had  already  been  pre-coated  with  capture 
antibody. Standards were generated by 1:3 serial dilutions from 2000 pg.mL
-1 down to a 
lowest of 2.74 pg.mL
-1. Some differences are noted between this method and that used 
in section 2.2 2.5.2.1, and these are summarised below (Figure 2.18). 
 
Optical densities of each well were read using an ELISA plate reader (Revelation 4.02, 
Dynex Technology, Chantilly, VA, USA) at 450nm (reference filter 650nm). Cytokine 
concentrations in the unknown samples  were read from the  curve  generated  from  a 
known standard included on each plate. This technique allowed confidence to detect IL-
8 within the range of 2.74 to 2000 pg.mL
-1.  
 
The highest coefficient of variation quoted for this kit for replication of responses on the 
same plate (intra-plate precision) is <10%, and coefficient of variation for responses 
between plates is <12% (inter-plate precision).   111
Figure 2.18 
Methodology for human interleukin-8 ELISA (RayBiotech) 
 
 
 
30 minutes in dark 
Room temperature 
Aspirate and wash (x4) 
Incubate 100µL/well of biotinylated antibody 
 
Incubate 100µL/well of Strepatividin-HRP 
 
Aspirate and wash (x4) 
1 hour at room temperature 
45 mins at room temperature 
Aspirate and wash (x5) 
Add 100µL/well of chromogen substrate 
(TMB) 
Add 50µL/well of STOP solution 
(2M H2SO4) 
Incubate 100µL/well of samples and standards 
Read absorbance at 450nm on ELISA plate reader 
2.5 hours at room temperature 
96-well plates precoated with human IL-8 capture antibody   112
2.4 Statistical Methods  
2.4.1 Data Storage   
The  results  of  the  clinical  examination,  lung  function  tests,  skeletal  and  respiratory 
muscle strength measures, sleep and exercise study data, measures of inflammation and 
also  responses  to  the  Cystic  Fibrosis  questionnaires  were  entered  into  an  Excel 
spreadsheet (Microsoft Office 2000, Seattle, USA). When all the data was collected, the 
Excel spreadsheet was copied into a single database in the statistics package, Statistical 
Package for the Social Sciences (SPSS) for windows v13.0 (SPSS, Chicago USA). It 
was from this SPSS database that all of the results were analysed. 
 
2.4.2  Data Analysis 
In order to select an optimal definition of clinically-important hypoxia in CF, receiver-
operator (ROC) curves were used to quantify (or directly observe) the sensitivity and 
specificity characteristics of a number of definitions of hypoxia (both existing and de 
novo) for a variety of outcome measures pertaining to CF inflammation.  
 
The index study group were studied as a whole, as well as dichotomised into hypoxic 
and normoxic subgroups that were compared and contrasted with each other. The data 
were analysed in this  format to establish specifically  whether  any differences noted 
between groups can be attributed to hypoxia. Comparisons between the groups were 
done using Mann-Whitney analyses. Gene frequencies for ACE genotype were analysed 
for  Hardy-Weinberg  equilibrium  using  chi-squared  statistics.  The  raw  data  for  this 
calculation is added in Appendix 5.  
 
Assessments  of  association  between  parameters  were  made  using  Spearman  rank 
correlation co-efficients, expressed as r
2 values. Limits of agreement between measures 
were assessed using the methodology of Bland and Altman (Bland and Altman 1986).  
 
Repeatability of in vitro data was assessed using repeated measures analysis of variance 
(ANOVA)  tests.  Bonferroni  corrections  for  multiple  contrasts  not  assuming  equal 
variances were used.    113
CHAPTER 3:  
Investigation of arterial oxygen saturations during sleep, at 
rest and during exercise in children with cystic fibrosis 
 
3.1 Introduction 
Episodes of hypoxia may occur at times of physiological stress in CF, namely during 
sleep,  exercise,  air  travel,  and  infective  CF  chest  exacerbations.  Repeated  hypoxic 
insults (such as those during sleep and exercise) may exacerbate lung inflammation, and 
impair the pulmonary circulation and quality of life (see Chapter 1). However, there is 
no consensus as to how hypoxia should be defined in CF, and no universal definitions 
of hypoxia exist in CF regardless of disease state.   
 
The lack of definition of nocturnal hypoxia hampers the description of the prevalence of 
CF  hypoxia  in  clinical  practice,  and  perhaps  has  led  to  both  under-recognition  and 
under-treatment of this potentially important clinical entity. 
 
Although arterial oxygen sampling is carried out in adult practice, this is not routine in 
children as it is painful. Pulse oximetry remains the main tool by which arterial oxygen 
saturation (SpO2) is assessed in children with CF. Traditionally, resting awake values 
are recorded in clinic, with most centres also undertaking some form of annual exercise 
test during which SpO2 will be measured.  
 
The definition of exercise-induced arterial hypoxia (EIAH) is also controversial and 
different definitions are used in clinical exercise testing. EIAH has been defined as a fall 
in SpO2 of >4% from baseline in CF (Narang et al. 2003), and also in healthy children 
(Nourry et al. 2004). If this represents a fall in SpO2 from 93% to 89%, one could deem 
this likely to represent a significant physiological drop in PaO2 from 70 to 60mmHg. 
However the definition holds less well in a very fit child whose SpO2 fall from 99% to 
95% during exercise (PaO2 fall from 100 to 80mmHg).  
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3.2 Aims 
The aim of this chapter is to delineate the definition of hypoxia which has the best 
sensitivity/specificity  characteristics  in  the  detection  of  elevated  markers  of 
inflammation, in order to select an optimal definition of hypoxia in children with CF. 
 
3.3 Methods 
3.3.1 Assessment and definition of hypoxia in CF 
Existing sleep hypoxia definitions used in paediatric practice and in the CF literature 
(see  Section  3.3.1.2),  as  well  as  several  new  definitions,  were  applied  to  various 
markers of inflammation measured in our study population. Receiver-operator (ROC) 
curves were used to quantify (or directly observe) the hypoxia cut-off with the best 
trade-off between sensitivity and specificity for each given measure of inflammation. 
From these analyses, a definition of hypoxia can be obtained that best associates with 
inflammation (the purported effector mechanism by which hypoxia may contribute to 
lung disease), and this can then be used to dichotomise the study population. The inter-
relationship of hypoxia and clinical status can then be explored (Chapter 4). 
 
3.3.1.1 Resting Hypoxia in CF 
Resting SpO2 was obtained in all subjects using a supraorbital probe (Nonin, USA) - 
Section 2.2.2.2. Resting hypoxia in CF has been previously defined as an awake SpO2 < 
95% (Coffey et al. 1991).  
 
3.3.1.2 Nocturnal Hypoxia in CF 
Briefly, overnight pulse oximetry recording was carried out in the subjects’ home using 
a Minolta Pulsox-3i oximeter (Konica Minolta Holdings inc., Singapore) – see section 
2.2.1.1. Data were downloaded using the Download 2001 software package (Stowood 
Scientific  Instruments,  Oxford,  UK)  as  per  section  2.2.1.1.  The  various  methods  of 
defining nocturnal hypoxia in CF are discussed in detail in chapter 1, and include: 
1. Specified time with low saturations: 
a. SpO2 <90% for >5% night (Frangolias et al. 1999)  
b. >25% sleep time with SpO2 below 93%  
- Alder Hey definition (Southern, Personal Communication 2004) 
c. Greater than 10 minutes of continuous sleep recording with SpO2 <92%  
- CHoP definition (Narang, Personal Communication 2007) 
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2. Minimum sleep SpO2:  (Tepper et al. 1983, Bradley et al. 1999)  
3a. Measures of mean sleep SpO2: (Coffey et al. 1991) 
3b. Lowest hourly mean sleep SpO2 below 90%:  (Versteegh et al. 1990) 
 
3.3.1.3 Exercise Induced Hypoxia in CF 
Transcutaneous oxygen saturations (SpO2) and heart rate were continuously recorded 
during exercise using a pulse oximeter (Nonin, USA) placed over the right supraorbital 
artery, and fixed with a bandanna (Section 2.2.2.8). 
 
Exercise-induced arterial hypoxia (EIAH) has been classified as a 4% drop in SpO2 
from  baseline  in  both  CF  (Narang  et  al.  2003)  and  non-CF  (Nourry  et  al.  2004) 
children. 
 
3.3.2 Measures of inflammation 
 
3.3.2.1 C-Reactive Protein (CRP) 
CRP  was  analysed  in  the  Chemical  Pathology  department,  GOS  Hospital,  London, 
using an Ortho Diagnostics 5.1 chemistry analyser (as per section 2.2.2.6.3). Elevated 
CRP was taken as >7mg.L
-1, for although the published upper limit of normal CRP is 
3.1 mg.L
-1(Kratz et al. 2004), the analyser could not accurately quantify values  below 
7mg.L
-1. 
 
3.3.2.2 Full blood count and Erythrocyte Sedimentation Rate (ESR) 
FBC and differential, along with ESR were analysed in the department of Haematology, 
GOS Hospital, London (as per sections 2.2.2.6.4 and 2.2.2.6.5). An elevated white cell 
count was taken as >11x10
9.mL
-1, and elevated peripheral blood neutrophil count as >8 
x10
9.mL
-1 in keeping with published upper limits (Kratz et al. 2004). 
 
3.3.2.3 Serum cytokine analysis 
An ultrasensitive ELISA assay for quantification of serum interleukin-8 (IL-8) levels 
was undertaken, as described in section 2.2.2.6.3. Elevated  IL-8 was classified as a 
level>10pg.mL
-1 (Zeigenhagen et al.1999). 
 
3.3.2.4 Number of intravenous antibiotic courses in year preceding study 
Data on the number of intravenous antibiotic courses that the patient had received in the 
year prior to the study were obtained from the GOS hospital CF database.   116
3.4 Results 
3.4.1 Resting daytime Hypoxia  
None of our subjects had resting SpO2 below 95%. Median recorded resting SpO2 was 
99% (range 95% to 100%).  
 
3.4.2 Nocturnal Hypoxia 
3.4.2.1 Demographic data 
Overnight oximetry was successfully performed in all forty-one study subjects (Figure 
3.1).  
Figure 3.1 
Oximetry data regarding success of recordings 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The study demographics are shown below (Table 3.1). 
 
Study Population 
n=41 
Initial study successful 
(n=39) 
Initial study unsuccessful 
(n=2) 
Batteries missing 
(n=1) 
Successfully 
Repeated 
Insufficient sleep 
data (n=1) 
Repeated -Sleep data 
still insufficient 
Successfully 
Repeated   117
Table 3.1 
Distribution of nocturnal SpO2 in our study population 
 
    Median  Range  p-value 
 
Age (years) 
   
12.7 
 
8-16.2 
 
 
Mean sleep SpO2 (%) 
   
95.7 
 
90.6-97.9 
 
 
Mean sleep SpO2 (%) 
by Sex 
 
20 Male 
21Female 
 
96.6 
94.8 
 
91-97.8 
90.6-97 
 
p=0.02 * 
 
Mean sleep SpO2 (%) 
by CFTR Genotype 
- ∆F508/∆F508 
- ∆F508/Other 
- Other/Other 
 
 
 
25 
13 
3 
 
 
 
96.1 
94.6 
95.5 
 
 
 
91-97.8 
90.6-97.2 
95.4-97.3 
 
 
 
 
p=0.19** 
 
Mean sleep SpO2 (%)  
 
by Pseudomonas 
aeruginosa status 
- Previous Infection 
- Never infected 
 
 
 
 
 
37 
4 
 
 
 
 
 
95.6 
96.2 
 
 
 
 
 
90.6-97.8 
94.1-97 
 
 
 
 
 
p=0.54* 
 
Mean sleep SpO2 (%) 
by Staphyloccus 
aureus status 
- Previous Infection 
- Never infected 
 
 
 
 
33 
8 
 
 
 
 
95.7 
95.5 
 
 
 
 
90.6-97.8 
91.7-96.6 
 
 
 
 
p=0.49* 
 
* Mann-Whitney U-test 
** Kruskal-Wallis test 
 
 
These data suggest that female patients have a statistically lower mean sleep SpO2 than 
do their male counterparts. This is displayed graphically below (Figure 3.2) showing 
individual mean sleep SpO2 plots for boys and girls along with group medians and 95% 
confidence interval data. 
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Figure 3.2 
Distribution of nocturnal mean sleep SpO2 in boys (n=20) and girls (n=21) with CF 
 
      Group median 
      95% Confidence intervals 
 
 
This difference would be in keeping with previous observations of a gender gap in CF 
mortality (Rosenfeld et al. 1997). There is a spread of values however, and numbers are 
small.  
 
The small numbers in our study precluded meaningful multivariate analysis to adjust for 
potential covariates such as age, genotype differences, lung function, infective status, 
exercise capacity and physical activity levels (Selvadurai et al. 2004).  
 
 
p=0.02;  
Mann-Whitney U test   119
3.4.2.2 Classification of nocturnal hypoxia 
As outlined above in chapter 1 and also in section 3.3.1.2, a number of definitions for 
sleep hypoxia in CF and means of quantifying hypoxia have been proposed. Each of 
these definitions was then applied to our study population. 
 
3.4.2.2.1 Nocturnal Hypoxia defined as SpO2 <90% for >5% night 
This  definition  was  applied  to  a  Canadian  adult  CF  population  aged  17-53  years 
(Frangolias et al 1999). Applying this definition to our study population, 3 subjects 
(8%) meet criteria for nocturnal hypoxia (Table 3.2). 
Table 3.2 
Demographics of study patients with nocturnal hypoxia using Frangolias’ definition 
 
  Median 
(IQR)  Age 
Sex   Mean (sd) 
Sleep SpO2 
Median 
(IQR) time 
spent <93% 
Hypoxic Group 
[SpO2 <90% for >5% sleep time] 
(n=3) 
15.3 
(14.5,15.5) 
2F/1M  91.6 (1.3)  81% (33,92) 
Normoxic Group 
(n=38) 
12.4 
(10, 14.2) 
19F/19M  95.5 (1.6)  0.1% (0) 
 
 
Applying  a  definition  of  SpO2  below  90%  for  >10%  sleep  time  (Smith  et  al.1994) 
detected the same three patients as the Frangolias definition of SpO2 below 90% for 
>5% sleep time (3.3.2.2.1).  
 
3.4.2.2.2 Alder Hey definition 
On  applying  a  definition  of  SpO2  <93%  for  >25%  study  (Southern,  Personal 
Communication  2004)  to  our  study  population,  6  subjects  (15%)  from  our  study 
population met criteria for nocturnal hypoxia (Table 3.3). 
Table 3.3 
Demographics of study patients with nocturnal hypoxia using Alder Hey definition 
 
  Median 
(IQR)  Age 
Sex   Mean (sd) 
Sleep SpO2 
Median 
(IQR) time 
spent <93% 
Hypoxic Group 
[SpO2 <93% for >25% sleep time] 
(n=6) 
14.9  
(12.5-15.7) 
2M : 4F  91.8 (0.9)  75.2% 
(45.5-83.7 ) 
Normoxic Group 
(n=35) 
12.3 
(10-14.2) 
19M : 
17F 
95.8 (1.3)  0.1% 
(0-2.5)   120
3.4.2.2.3 Children’s Hospital of Philadelphia (CHoP) definition 
The CHoP definition (SpO2 below 92% for >10 minutes of continuous sleep recording, 
in the absence of obstructive sleep apnoea) was applied to our study population (Table 
3.4).  Although  an  assumption  is  made  that  the  desaturation  in  CF  is  not  due  to 
obstruction, the same six individuals were identified as with the application of the Alder 
Hey definition (Section 3.4.2.2.2) to our study population. 
Table 3.4 
Demographics of study patients with nocturnal hypoxia using CHoP definition 
 
  Median 
(IQR)  Age 
Sex   Mean (sd) 
Sleep SpO2 
Median 
(IQR) time 
spent <92% 
Hypoxic Group 
[SpO2 <92%for 10 continuous 
minutes of sleep] (n=6) 
14.9  
(12.5-15.7) 
2M : 4F  91.8 (0.9)  163 (82-265) 
minutes 
Normoxic Group 
(n=35) 
12.3 
(10-14.2) 
19M : 
17F 
95.8 (1.3)  0 (0-4) 
minutes 
 
 
3.4.2.2.4 Lowest hourly mean sleep SpO2 below 90%  
The software package used in the methodology was unable to calculate lowest hourly 
mean SpO2, preventing this methodology being applied to our study population. 
 
3.4.2.2.5 Minimum sleep SpO2  
Data on minimum sleep SpO2 in CF have been previously reported [Tepper et al. 1983, 
Bradley et al. 1999]. However, no definition of the extent of desaturation required to 
constitute sleep hypoxia was given in either study.  
 
3.4.2.2.6 Mean sleep SpO2  
Although mean sleep SpO2 has been reported by previous authors, no definition of the 
mean sleep SpO2 below which hypoxia exists is given. Data collected were used to 
investigate associations with other clinical parameters. A relationship appears to exist 
between mean SpO2 and the time spent with SpO2 below 93%. This is illustrated below 
(Figure 3.3). 
  
Figure 3.3 
Mean sleep SpO2 versus % time spent with SpO
 
 
However, mean sleep SpO
not normally distributed about a mean. Rather, periods of low saturation occur during 
REM sleep due to lower tidal volumes as a result of skeletal muscle inactivity, with 
higher SpO2 in non-REM phases, resulting in negative skew of Gaussian distribut
This is illustrated clearly in Figure 3.3 above, whereby subjects 1, 2 and 3 all have mean 
SpO2 around 93% but spend approximately 35, 25 and 15% of the night respectively 
with SpO2 below 93%.
 
A cut-off value taken where hypoxia is considered to be i
93%) does therefore appear a more useful measure. A cut
point  on  the  oxygen  dissociation  curve  at  which  small  changes  in  pO
exponential decreases in % SaO
suggests that a SaO2 value of 93% equates to a pO
 
versus % time spent with SpO2 below 93% 
However, mean sleep SpO2 are a poor indicator of oxygenation during sleep. SpO
not normally distributed about a mean. Rather, periods of low saturation occur during 
REM sleep due to lower tidal volumes as a result of skeletal muscle inactivity, with 
REM phases, resulting in negative skew of Gaussian distribut
This is illustrated clearly in Figure 3.3 above, whereby subjects 1, 2 and 3 all have mean 
around 93% but spend approximately 35, 25 and 15% of the night respectively 
below 93%. 
off value taken where hypoxia is considered to be important (such as time below 
93%) does therefore appear a more useful measure. A cut-off of 93% is taken from the 
point  on  the  oxygen  dissociation  curve  at  which  small  changes  in  pO
exponential decreases in % SaO2. Extrapolation from the followi
value of 93% equates to a pO2 of around 70mmHg (9kPa).
1. → 
2. → 
3. → 
93% 
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indicator of oxygenation during sleep. SpO2 are 
not normally distributed about a mean. Rather, periods of low saturation occur during 
REM sleep due to lower tidal volumes as a result of skeletal muscle inactivity, with 
REM phases, resulting in negative skew of Gaussian distribution. 
This is illustrated clearly in Figure 3.3 above, whereby subjects 1, 2 and 3 all have mean 
around 93% but spend approximately 35, 25 and 15% of the night respectively 
mportant (such as time below 
off of 93% is taken from the 
point  on  the  oxygen  dissociation  curve  at  which  small  changes  in  pO2  result  in 
. Extrapolation from the following graph (Figure 3.4) 
of around 70mmHg (9kPa).   122
Figure 3.4 
The oxygen-haemoglobin dissociation curve 
[Source: Ganong WF, Review of Medical Physiology (14
th Edition), 1989] 
 
 
 
 
SaO2 93% ----   123
3.5 Development of optimal definition for nocturnal hypoxia 
3.5.1 Application of existing and de novo hypoxia definitions to the detection of 
clinically-important adverse outcomes 
One of the main objectives of this study was to define a level of sleep hypoxia that is 
clinically relevant to patient well-being in children with CF. Existing sleep hypoxia 
definitions were taken and compared to newly-derived cut-offs for hypoxia in CF to 
assess their sensitivity and specificity in the detection of adverse outcomes with regard 
to CF inflammation.  
 
For the reasons defined in section 3.3.2.2.6 above, time spent with SpO2 below 93% 
was  considered  to  be  potentially  the  most  important  ‘cut-off’  point  at  which  the 
deleterious effects of hypoxia might be seen. The percentage of sleep time with SpO2 
below 93% at which sensitivity and specificity for predicting occurrence of adverse 
effects is optimal remains to be established. Proportions of acceptable quality sleep time 
spent below 93% were considered thus, along with existing definitions: 
 
•  30% sleep time spent with SpO2 below 93% 
•  25% sleep time spent with SpO2 below 93% (Alder Hey definition) 
•  20% sleep time spent with SpO2 below 93% 
•  15% sleep time spent with SpO2 below 93% 
•  10% sleep time spent with SpO2 below 93% 
•  5% sleep time spent with SpO2 below 93% 
•  5% sleep time spent with SpO2 below 90% (Frangolias) 
•  10 continuous minutes of sleep with SpO2 below 92% (CHoP definition) 
 
The adverse clinical outcomes considered were: 
•  Elevated C-reactive protein 
•  Elevated Erythrocyte Sedimentation Rate 
•  Elevated white blood cell counts 
•  Elevated neutrophil counts  
•  Elevated serum interleukin-8 levels 
•  Need for intravenous antibiotic therapy   124
In order to develop a de novo definition of clinically-important sleep hypoxia, these 
measures  were  used  to  assess  sensitivity  and  specificity  for  each  of  the  cut-offs 
considered. ROC curves were used to quantify (or directly observe) the hypoxia cut-off 
with  the  best  trade-off  between  sensitivity  and  specificity  for  each  given  outcome 
measure. 
 
Hypoxia is a stimulus of the NF-κB pathway of inflammation, both directly and also has 
a  potential  indirect  effect  by  inhibition  of  CFTR  trafficking  (Bebok  et  al.  2001, 
Guillembot  et  al.  2008)  and  facilitation  of  PA  growth  (Worlitzsch  et  al.  2002). 
Upregulation of NFκB via direct or indirect (CFTR-mediated) pathways would promote 
IL-8 production, and neutrophil recruitment as well as increases in IL-6 - a precursor for 
CRP production (Heikkila et al. 2007), and TNFα. 
 
•  C-reactive protein >7mg.L
-1 
Upregulation of the NFκB inflammatory cascade may result in increases in IL-6 and 
consequent C-reactive protein (CRP) production. Elevated CRP was taken to be a level 
>7mg. L
-1. The upper limit of published normal laboratory reference values (Kratz et al.  
2004) is 3.1mg.L
-1, but our laboratory was only able to measure with precision those 
CRP values>7mg.L
-1. 
 
•  Elevated Erythrocyte Sedimentation Rate  
[>17mm.hr
-1 (men) and >25mm.hr
-1 (women)] 
Erythrocyte sedimentation rate (ESR) is a non-specific marker for systemic 
inflammation. Elevated ESR was taken to be a level > 17mm.hr
-1 for men and > 
25mm.hr
-1 for women in accordance with published normal laboratory reference values 
(Kratz et al.  2004). 
 
•  Total  white cell count >11 x10
9.mL
-1 
Upregulation  of  the  NFκB  inflammatory  cascade  may  result  in  increases  in  IL-8 
production, and subsequent neutrophil chemoattraction. A total white cell count (WBC) 
>11 x10
9.mL
-1, was defined as abnormally high in accordance with published normal 
laboratory reference values (Kratz et al. 2004).  
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•  Peripheral blood neutrophil count >8 x10
9.mL
-1 
Upregulation  of  the  NFκB  inflammatory  cascade  may  result  in  increases  in  IL-8 
production, and subsequent neutrophil chemoattraction. A peripheral blood neutrophil 
count (neutrophils) >8 x10
9.mL
-1, was defined as abnormally high in accordance with 
published normal laboratory reference values (Kratz et al. 2004).  
 
•  Serum interleukin-8 (IL-8) >10pg.mL
-1 
Upregulation of the NFκB inflammatory cascade may result in increases in IL-8 
production. A serum IL-8 value >10pg.mL
-1 was taken to represent an elevated IL-8 
level, for IL-8 levels in the sera and plasma of healthy individuals are reported to be 
<10pg.mL
-1 (Ziegenhagen et al. 1999). 
 
•  Need (or absence of need) for intravenous antibiotic courses 
This was analysed in a binary fashion i.e. those requiring no intravenous antibiotic 
courses were compared with those requiring 1 or more courses. 
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3.5.1.1 Sleep Hypoxia and CRP 
The ability of cut-offs for nocturnal hypoxia in detecting elevated CRP levels (>7mg.L
-
1) was assessed, as shown in Figure 3.5. The full range of hypoxia definitions were 
assessed using Chi-square statistics (Fisher’s exact test), with a summary of existing 
definitions and the most sensitive and specific de novo definition presented in Table 3.5. 
 
Figure 3.5 
ROC curve of performance of various cut-offs of nocturnal hypoxia in the identification 
of childhood CF subjects with CRP>7mg. L
-1 
 
 
Area under curve: 
SpO2 <93% for >25% study (Alder Hey definition)      = 0.61 
SpO2 <92% for >10 continuous sleep minutes (CHoP definition)  = 0.61 
SpO2 <93% for >10% study            = 0.76 
SpO2 <90% for >5% study (Frangolias et al.  2001)     = 0.55 
 
The three existing definitions as well as the most sensitive and specific new definition 
are  presented.  The  area  under  the  curve  is  greatest  for  the  definition  of  hypoxia  as 
SpO2<93% for >10% study. This appears to be the most sensitive and specific cut-off of 
nocturnal hypoxia in identifying subjects with elevated CRP.   127
Table 3.5 
Summary of identification of subjects with abnormal CRP (n=6) using different 
definitions of nocturnal hypoxia   
 
* 40/41 subjects had a CRP measured 
 
 
Kappa  scores  >0.41  are  considered  to  show  moderate  agreement;  >0.61,  good 
agreement; and those >0.81, very good agreement (Altman 1992).  
 
These  data  therefore  suggest  that  there  is  moderate  agreement  between  hypoxia  as 
defined by SpO2 <93% for >10% study and abnormal CRP defined as CRP>7mg.L
-1 i.e. 
by  using  nocturnal  hypoxia  as  a  marker  for  inflammation,  we  are  able  to  achieve 
moderate  agreement  in  identifying  those  patients  at  risk  of  an  elevated  CRP.    The 
greatest level of agreement is reached by using a hypoxia definition of SpO2 <93% for 
>10% study. 
 
The cut-off of 7 mg.L
-1 for normal CRP may have been set too high, and the use of a kit 
to measure high sensitivity CRP (hsCRP) may have been useful. CRP has been used to 
assess cardiovascular risk, and the American Heart Association (AHA) and Center for 
Disease Control (CDC) joint statement suggests CRP cut-offs of <1 mg.L
-1 (low risk), 
1-3 mg.L
-1 (average risk) and >3 mg.L
-1 (high-risk) for cardiovascular disease (Pearson 
et al. 2003).  Therefore, if a pro-inflammatory state is suggested by hsCRP >3 mg.L
-1, 
valuable subject information may have been missed by using a less sensitive testing kit, 
and differences between hypoxic and normoxic groups may have been missed. 
  NEW 
SpO2 <93% for 
>10% study 
ALDER HEY 
SpO2 <93% for 
>25% study 
CHoP 
SpO2 <92% for 
10 continuous 
study minutes 
FRANGOLIAS 
SpO2 <90% for 
>5% study 
CRP>7mg. L
-1  4 Hypoxic/  
2 Normoxic 
2/4  2/4  1/5 
CRP<7mg. L
-1  5/29  4/30  4/30  2/32 
Chi-square statistic 
p-value 
(Fisher’s exact test) 
7.9 
p=0.02 
1.9 
p=0.21 
1.9 
p=0.21 
0.9 
p=0.39 
Kappa score 
p-value 
0.43 
p=0.05 
0.22 
p=0.17 
0.22 
p=0.17 
0.13 
p=0.36   128
3.5.1.2 Sleep Hypoxia and ESR  
The performances of the chosen potential definitions for nocturnal hypoxia in detecting 
abnormal ESR were  also analysed (Figure 3.6). The full range of potential hypoxia 
definitions  were  analysed  using  Chi-Square  statistics  (Fisher’s  exact  test),  with  a 
summary of existing definitions and the most sensitive and specific de novo definition 
given in Table 3.6.  
 
Figure 3.6 
ROC curve of performance of various cut-offs of nocturnal hypoxia in the identification 
of childhood CF subjects with elevated ESR (> 17mm.hr
-1 in males, > 25mm.hr
-1 in 
females)
 
 
 
 
Area under curve: 
SpO2 <93% for >25% study (Alder Hey definition)      = 0.61 
SpO2 <92% for >10 continuous sleep minutes (CHoP definition)  = 0.61 
SpO2 <93% for >10% study            = 0.70 
SpO2 <90% for >5% study (Frangolias et al.  2001)     = 0.60 
 
The three existing definitions as well as the most sensitive and specific new definition 
are  presented.  The  area  under  the  curve  is  greatest  for  the  definition  of  hypoxia  as 
SpO2<93% for >10% study. This appears to be the most sensitive and specific cut-off of 
nocturnal hypoxia in identifying subjects with elevated ESR.   129
Table 3.6 
Summary of identification of subjects with abnormal ESR (n=10) using different 
definitions of nocturnal hypoxia  
 
  NEW 
SpO2 <93% for 
>10% study 
ALDER HEY 
SpO2 <93% for 
>25% study 
CHoP 
SpO2 <92% for 
10 continuous 
study minutes 
FRANGOLIAS 
SpO2 <90% for 
>5% study 
Abnormal ESR  5 Hypoxic 
/5 Normoxic 
3/7  3/7  2/8 
Normal ESR  3/25  2/26  2/26  0/28 
Chi-square statistic 
p-value 
(Fisher’s exact test) 
6.8 
p=0.02 
3.4 
p=0.10 
3.4 
p=0.10 
5.9 
p=0.06 
Kappa score 
p-value 
0.42 
p=0.01 
0.27 
p=0.07 
0.27 
p=0.07 
0.27 
p=0.02 
* 38/41 subjects had an ESR measured 
 
The  hypoxia  definition  of  SpO2  <93%  for  >10%  study  has  moderate  agreement  in 
detecting subjects with an abnormal ESR. 
 
3.5.1.3 Sleep Hypoxia and White Cell Count 
The ability of cut-offs for nocturnal hypoxia in detecting elevated white cell counts (>11 
x10
9.mL
-1)  was  assessed  -  Figure  3.7.  The  full  range  of  hypoxia  definitions  were 
assessed using Chi-square statistics (Fisher’s exact test), with a summary of existing 
definitions and the most sensitive and specific de novo definition presented in Table 3.7. 
 
Figure 3.7 
ROC curve of performance of various cut-offs of nocturnal hypoxia in the identification 
of childhood CF subjects with white blood cell count >11x10
9.mL
-1 
 
Area under curve: 
SpO2 <93% for >25% study (Alder Hey definition)      = 0.72 
SpO2 <92% for >10 continuous sleep minutes (CHoP definition)  = 0.72 
SpO2 <93% for >10% study          = 0.83 
SpO2 <90% for >5% study (Frangolias et al.  2001)      = 0.61 
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The area under the curve is greatest for the definition of hypoxia as SpO2<93% for 
>10% study, which appears to be the most sensitive and specific cut-off of nocturnal 
hypoxia in identifying subjects with elevated white cell counts. 
 
Table 3.7 
Summary of identification of subjects with abnormal white cell count (n=8) using 
different definitions of nocturnal hypoxia  
 
  NEW 
SpO2 <93% for 
>10% study 
ALDER HEY 
SpO2 <93% for 
>25% study 
CHoP 
SpO2 <92% for 
10 continuous 
study minutes 
FRANGOLIAS 
SpO2 <90% for 
>5% study 
White Cell Count  
> 11x10
9 mL
-1 
6 Hypoxic/ 
2 Normoxic 
4/4  4/4  2/6 
White Cell Count  
< 11x10
9 mL
-1 
3/29  2/30  2/30  1/31 
Chi-square statistic 
p-value 
(Fisher’s exact test) 
15.8 
p=0.001 
9.6 
p=0.01 
9.6 
p=0.01 
4.4 
p=0.10 
Kappa score 
p-value 
0.63 
p<0.001 
0.48 
p=0.002 
0.48 
p=0.002 
0.29 
p=0.04 
* 40/41 subjects had a white cell count measured 
 
The hypoxia definition of SpO2 <93% for >10% study has good agreement in detecting 
subjects with an abnormal white cell count. 
 
3.5.1.4 Sleep Hypoxia and peripheral blood neutrophil counts 
The performances of the chosen potential definitions for nocturnal hypoxia in detecting 
abnormal neutrophil counts were also analysed (Figure 3.8). The full range of potential 
hypoxia definitions were analysed using Chi-Square statistics (Fisher’s exact test), with 
a summary of existing definitions and the most sensitive and specific de novo definition 
given in Table 3.8. 
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Figure 3.8 
ROC curve of performance of various cut-offs of nocturnal hypoxia in the identification 
of elevated peripheral blood neutrophil counts (neutrophils >8 x10
9 mL
-1)  
 
The area under the curve is greatest for the definition of hypoxia as SpO2 <93% for 
>10% study. This appears the most sensitive and specific cut-off of nocturnal hypoxia 
in identifying childhood CF subjects with a neutrophil count >8x10
9 mL
-1.  
 
Table 3.8 
Summary of identification of subjects with abnormal peripheral blood neutrophil counts 
(n=6) using different definitions of nocturnal hypoxia  
 
  NEW 
SpO2 <93% for 
>10% study 
ALDER HEY 
SpO2 <93% for 
>25% study 
CHoP 
SpO2 <92% for 
10 continuous 
study minutes 
FRANGOLIAS 
SpO2 <90% for 
>5% study 
Neutrophils  
> 8x10
9 mL
-1 
5 hypoxic / 
1 normoxic  
3/3  3/3  1/5 
Neutrophils  
< 8x10
9 mL
-1 
4 /30  3/31  3/31  2/32 
Chi-square statistic 
p-value 
(Fisher’s exact test) 
15 
p=0.001 
6.8 
p=0.03 
6.8 
p=0.03 
0.86 
p=0.4 
Kappa score 
p-value 
0.59 
P<0.001 
0.41 
p=0.009 
0.41 
p=0.009 
0.14 
P=0.36 
* 40/41 subjects had a neutrophil count measured 
 
The hypoxia definition of SpO2 <93% for >10% study has good agreement in detecting 
subjects with an abnormal neutrophil count. 
Area under curve: 
SpO2 <93% for >25% study (Alder Hey definition)      = 0.71 
SpO2 <92% for >10 continuous sleep minutes (CHoP definition)  = 0.71 
SpO2 <93% for >10% study          = 0.86 
SpO2 <90% for >5% study (Frangolias et al.  2001)      = 0.55 
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 3.5.1.5 Sleep Hypoxia and IL-8 
The ability of cut-offs for nocturnal hypoxia in detecting elevated serum IL-8 levels 
(>10 pg.mL
-1) was assessed - Figure 3.9. The full range of hypoxia definitions were 
assessed using Chi-square statistics (Fisher’s exact test), with a summary of existing 
definitions and the most sensitive and specific de novo definition shown in Table 3.9. 
 
Figure 3.9 
ROC curve of performance of various cut-offs of nocturnal hypoxia in the identification 
of childhood CF subjects with serum interleukin 8 (IL-8) >10pg.mL
-1 
 
The area under the curve is greatest for the definition of hypoxia as SpO2 <93% for 
>10% study. This appears the most sensitive and specific cut-off of nocturnal hypoxia 
in identifying childhood CF subjects with serum IL-8 levels >10pg.mL
-1.  
 
Table 3.9 
Summary of identification of subjects with abnormal serum IL-8 (n=12) using different 
definitions of nocturnal hypoxia  
 
  NEW 
SpO2 <93% for 
>10% study 
ALDER HEY 
SpO2 <93% for 
>25% study 
CHoP 
SpO2 <92% for 
10 continuous 
study minutes 
FRANGOLIAS 
SpO2 <90% for 
>5% study 
IL-8 >10pg.mL
-1  6/6  4/8  4/8  2/10 
IL-8 <10pg mL
-1  3/25  2/26  2/26  1/27 
Chi-square statistic 
p-value 
(Fisher’s exact test) 
7.4 
p=0.01 
4.5 
p=0.06 
4.5 
p=0.06 
2.1 
p=0.21 
Kappa score 
p-value 
0.42 
p=0.01 
0.31 
p=0.03 
0.31 
p=0.03 
0.17 
p=0.15 
* 40/41 subjects had a serum IL-8 measured 
 
The hypoxia definition of SpO2 <93% for >10% study has reasonable agreement in 
detecting subjects with an abnormal serum IL-8 level. 
Area under curve: 
SpO2 <93% for >25% study (Alder Hey definition)      = 0.63 
SpO2 <92% for >10 continuous sleep minutes (CHoP definition)  = 0.63 
SpO2 <93% for >10% study          = 0.70 
SpO2 <90% for >5% study (Frangolias et al.  2001)      = 0.57 
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In non-CF models of childhood nocturnal hypoxia i.e. obstructive sleep apnoea (OSA), 
elevated IL-8 levels have been observed when compared with healthy controls (Tam et 
al. 2006), whilst adult OSA models also report increases in IL-8 when compared with 
controls (Alzoghaibi and Bahammam 2005). Other downstream cytokines of the NFκB 
inflammatory cascade, namely IL-6 and TNF-α have also been shown to be elevated in 
OSA (Alberti et al. 2003), whilst animal models of intermittent hypercapnic hypoxia 
mimicking OSA resulted in corresponding increases in IL-6 (Tam et al. 2007). 
 
3.5.1.6 Sleep Hypoxia and need for intravenous antibiotics 
Analysis of the chosen potential definitions for nocturnal hypoxia in the detection of 
those  subjects  who  required  at  least  one  course  of  intravenous  antibiotics  in  the 
preceding year (Figure 3.10), was also undertaken. The full range of potential hypoxia 
definitions  was  analysed  using  Chi-Square  statistics  (Fisher’s  exact  test),  with  a 
summary of existing definitions and the most sensitive and specific de novo definition 
given in Table 3.10. 
 
Figure 3.10 
ROC curve of performance of various cut-offs of nocturnal hypoxia in the identification 
of children with CF requiring intravenous antibiotics 
 
 
The area under the curve is greatest for the definition of hypoxia as SpO2 <93% for 
>10% study. This appears the most sensitive and specific cut-off of nocturnal hypoxia 
in identifying childhood CF subjects in whom intravenous antibiotics were required. 
 
Area under curve: 
SpO2 <93% for >25% study (Alder Hey definition)      = 0.6 
SpO2 <92% for >10 continuous sleep minutes (CHoP definition)  = 0.6 
SpO2 <93% for >10% study          = 0.68 
SpO2 <90% for >5% study (Frangolias et al.  2001)      = 0.58 
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Table 3.10 
Summary of identification of subjects in need of intravenous antibiotics (> 1 course per 
year) (n=20), using different definitions of nocturnal hypoxia  
 
  NEW 
SpO2 <93% for 
>10% study 
ALDER HEY 
SpO2 <93% for 
>25% study 
CHoP 
SpO2 <92% for 
10 continuous 
study minutes 
FRANGOLIAS 
SpO2 <90% for 
>5% study 
>1 intravenous 
antibiotic course in 
preceding year 
8 hypoxic / 
12 normoxic  
5/15  5/15  3/17 
Zero intravenous 
antibiotic course in 
preceding year 
1/20  1/20  1/20  0/21 
Chi-square statistic 
p-value 
(Fisher’s exact test) 
7.4 
p=0.009 
3.6 
p=0.09 
3.6 
p=0.09 
3.4 
p=0.11 
Kappa score 
p-value 
0.36 
p=0.006 
0.21 
p=0.07 
0.21 
p=0.07 
0.15 
P=0.07 
*Antibiotic data was analysed for all 41 subjects 
 
These data therefore suggest poor agreement between measures of nocturnal hypoxia 
and requirement for intravenous antibiotic therapy. The greatest level of agreement is, 
however, again achieved using a hypoxia definition of SpO2 <93% for >10% study.  
 
 
 
 
The hypoxia definition of SpO2 <93% for >10% study appears to be the definition of 
sleep hypoxia which best predicts NFκB mediated inflammation in the form of IL-8, 
CRP, and neutrophil counts. Furthermore, it also is the definition with best sensitivity 
and specificity trade-off in detecting abnormal white cell count and ESR, as well as 
those requiring intravenous antibiotics for CF lung disease.   135
3.6 Exercise Hypoxia 
Having considered the various sleep hypoxia definitions in sections 3.4 and 3.5, the 
exercise data will now be reviewed, and the sensitivity and specificity characteristics of 
existing and de novo EIAH definitions will, be compared with the proposed new sleep 
hypoxia  definition  in  the  ability  to  detect  clinically  relevant  outcome  measures  in 
children with CF. 
 
3.6.1 Demographic data 
Cardiopulmonary exercise testing and exercise SpO2 recording (Section 2.2.2.8) was 
undertaken (Figure 3.11) in forty of the 41 study subjects. 
 
Figure 3.11 
Data regarding success of exercise SpO2 recordings 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The failure of patient number 1 (height 122.9cm.) due to their being too small for the 
cycle ergometer led to revision of the inclusion criteria for the study, with minimum 
height increasing from 120 to 128cm. The distribution of exercise SpO2 data for the 
study population is shown below (Table 3.11). 
Study Population 
n=41 
Initial study successful 
(n=39) 
Initial study unsuccessful 
(n=2) 
Too small for cycle 
ergometer (n=1) 
No study 
obtained 
Equipment failure 
(n=1) 
Successfully 
Repeated   136
 
Table 3.11 
Distribution of exercise SpO2 in our study population 
 
    Median  Range 
Age (years)    12.9  8-16.2 
Resting SpO2 (%)    99  95-100 
Pre-exercise SpO2 (%)  19 Male 
21 Female 
99 
99 
95-100 
95-100 
Lowest Exercise SpO2 (%)    98  85-100 
Change in SpO2 during exercise 
[￿SpO2 (%)] 
  -1  -13 to +4 
 
 
 
3.6.2 Exercise Hypoxia in CF study population 
Exercise induced arterial hypoxia (EIAH) in CF is defined as a fall in SpO2 during 
exercise of >4% from baseline (Narang et al. 2003), and this is a definition that has also 
been used in healthy individuals (Nourry et al. 2004). Application of this definition to 
our study population identifies 8 subjects with evidence of EIAH (Table 3.12).  
 
Table 3.12 
Subjects with >4% fall in SpO2 during exercise  
 
Subject 
ID 
Age  Sex  Baseline 
SpO2 (%) 
Lowest 
exercise  
SpO2(%) 
Absolute 
fall in 
SpO2 (%) 
 
Relative fall in SpO2 
(%) 
(Baseline SpO2– Lowest SpO2) 
Baseline SpO2 
3  10.72  M  98  90  8  8.2 
6  14.20  M  95  91  4  4.2 
8  12.08  M  98  85  13  13.3 
10  15.34  M  99  94  5  5.1 
29  14.46  F  98  91  7  7.1 
34  15.66  M  99  95  4  4 
36  9.26  F  98  94  4  4.1 
37  9.33  F  100  96  4  4 
 
Comparing this to sleep hypoxia, the demographics of the study population are as 
follows (Figure 3.12): 
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Figure 3.12 
Venn diagram illustrating overlap of exercise and sleep hypoxia in study population 
(n=41) using the following definitions: 
 
Sleep hypoxia:    SpO2 <93% for >10% sleep time 
Exercise hypoxia:  Fall in SpO2 during exercise of >4% from baseline 
   
 
 
 
 
 
   
Sleep 
Hypoxia 
Exercise 
Hypoxia 
Normoxia 
n=3  n=6  n=5 
n=27  
The definition of EIAH as a fall in SpO
however, seem intrinsically flawed. Clearly, if this represents a fall in SpO
to 91% (Subject A), one could deem this to
drop in PaO2, however the definition holds less well 
from 100% to 96% at the end of exercise (Figure 3.13). 
 
Figure 3.13 
Change in exercise SpO
 
 
 
Further work is needed to establish clinically significant parameters. 
of 93% (the point on the oxygen dissociation curve where 
exponential decreases in % SpO
saturation is below 93% as hypoxic, the  number of subjects with exercise hypoxia 
would fall to only 4 (Figure 3.14). 
 
It  would  make  physio
important level of exercise desaturation. Furthermore, those with a nadir of SpO
93% also had the greater falls from baseline. In one subject a 13% dip in SpO
recorded on exercise. Su
applied hypoxic insults to the patient with CF.
The definition of EIAH as a fall in SpO2 during exercise of >4% from baseline does, 
however, seem intrinsically flawed. Clearly, if this represents a fall in SpO
to 91% (Subject A), one could deem this to represent a likely significant physiological 
, however the definition holds less well for subject B, whose 
from 100% to 96% at the end of exercise (Figure 3.13).  
Change in exercise SpO2 versus lowest exercise SpO2  
 
Further work is needed to establish clinically significant parameters. 
of 93% (the point on the oxygen dissociation curve where small changes in pO
exponential decreases in % SpO2), and categorise those in whom the nadir of exercise 
saturation is below 93% as hypoxic, the  number of subjects with exercise hypoxia 
would fall to only 4 (Figure 3.14).  
It  would  make  physiological  sense  for  a  cut-off  of  93%  to  be  deemed  a  clinically 
important level of exercise desaturation. Furthermore, those with a nadir of SpO
93% also had the greater falls from baseline. In one subject a 13% dip in SpO
recorded on exercise. Such exercise-related dips in SpO2 below 93% may be regularly 
applied hypoxic insults to the patient with CF. 
Line representing a 4% dip in SpO
B 
A 
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4% from baseline does, 
however, seem intrinsically flawed. Clearly, if this represents a fall in SpO2 from 95% 
represent a likely significant physiological 
for subject B, whose SpO2 fall 
Further work is needed to establish clinically significant parameters. If we use a cut-off 
small changes in pO2 result in 
), and categorise those in whom the nadir of exercise 
saturation is below 93% as hypoxic, the  number of subjects with exercise hypoxia 
off  of  93%  to  be  deemed  a  clinically 
important level of exercise desaturation. Furthermore, those with a nadir of SpO2 below 
93% also had the greater falls from baseline. In one subject a 13% dip in SpO2 was 
below 93% may be regularly 
r
2=0.77 
p<0.001 
Spearman rank test 
Line representing a 4% dip in SpO2  
SpO2  93%    139
Figure 3.14 
Venn diagram illustrating overlap of exercise and sleep hypoxia in study population 
(n=41) using the following definitions: 
 
Sleep hypoxia:    SpO2 <93% for >10% sleep time 
Exercise hypoxia:  ↓SpO2 during exercise of >4% and nadir of SpO2 <93%   
    
 
 
3.7 Development of optimal definition for EIAH 
3.7.1 Application of existing and de novo hypoxia definitions to EIAH and 
comparison with optimal sleep definition 
An optimal sleep definition having been identified, the performance of EIAH in 
detecting adverse clinical outcomes appears worthy of study.  
Definitions considered therefore were: 
•  EIAH defined as >4% dip in SpO2 on exercise 
•  EIAH defined as >4% dip in SpO2 on exercise with lowest SpO2 <93% 
•  10% sleep time spent with SpO2 below 93% 
 
The adverse clinical outcomes considered were as above: 
•  Elevated C-reactive protein 
•  Elevated Erythrocyte Sedimentation Rate 
•  Elevated white blood cell counts 
•  Elevated neutrophil counts  
•  Elevated serum interleukin-8 levels 
•  Need for intravenous antibiotic therapy 
Sleep 
Hypoxia 
Exercise 
Hypoxia 
Normoxia 
n=2  n=7  n=2 
n=30   140
3.7.1.1 EIAH, Sleep Hypoxia and CRP 
ROC statistics were used to compare the sensitivity  and specificity for measures of 
sleep and exercise hypoxia in the detection of abnormal CRP (Figure 3.15). 
 
Figure 3.15 
ROC curve of performance of sleep hypoxia and EIAH definitions in the identification 
of childhood CF subjects with CRP> 7mg.mL
-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The area under the curve is greatest for the definition of hypoxia as SpO2 <93% for 
>10% study, suggesting that this is a more sensitive and specific definition than either 
of the EIAH definitions in identifying childhood CF subjects with CRP> 8mg.mL
-1.  
This reiterated in Table 3.13. 
 
Table 3.13 
Summary of identification of abnormal CRP using sleep and exercise hypoxia 
definitions  
 
  De novo SLEEP 
SpO2 <93% for 
>10% study 
EIAH 
>4% fall in SpO2 
on exercise  
EIAH 
>4% fall in SpO2 on 
exercise and lowest 
exercise SpO2<93%  
CRP>7mg.mL
-1  4 Hypoxic/  
2 Normoxic 
1/5  1/5 
 
CRP<7 mg.mL
-1  5/29  7/26  3/30 
Chi-square statistic 
p-value 
(Fisher’s exact test) 
7.9 
p=0.02 
0.1 
p=0.64 
0.3 
p=0.50 
Kappa score 
p-value 
0.43 
p=0.05 
-0.04 
p=0.8 
0.09 
p=0.57 
* 39/41 subjects had exercise data and a measured CRP 
   
Area under curve: 
SpO2 <93% for >10% study    = 0.83 
Existing EIAH definition  
(>4% fall in SpO2 on exercise)    = 0.42 
De novo EIAH definition  
(>4% fall in SpO2 on exercise  
and lowpoint of SpO2 <93%)    = 0.58 
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3.7.1.2 EIAH, Sleep Hypoxia and ESR 
ROC statistics were used to compare the sensitivity  and specificity for measures of 
sleep and exercise hypoxia in the detection of abnormal ESR - Figure 3.16. 
 
Figure 3.16 
ROC curve of performance of sleep hypoxia and EIAH definitions in the identification 
of childhood CF subjects with abnormal ESR 
 
 
The area under the curve is greatest for the definition of hypoxia as SpO2 <93% for 
>10% study, suggesting that this is a more sensitive and specific definition than either 
of the EIAH definitions in identifying childhood CF subjects abnormal ESR. This is 
reiterated in Table 3.14. 
 
Table 3.14 
Summary of identification of abnormal ESR using sleep and exercise hypoxia 
definitions  
 
  De novo SLEEP 
SpO2 <93% for 
>10% study 
EIAH 
>4% fall in SpO2 
on exercise  
EIAH 
>4% fall in SpO2 on exercise 
and lowest exercise 
SpO2<93%  
Abnormal ESR  5 Hypoxic/ 
5 Normoxic 
3/7   
1/9 
Normal ESR  3/25  4/23  2/25 
Chi-square statistic 
p-value 
(Fisher’s exact test) 
6.8 
p=0.02 
1.1 
p=0.27 
0.1 
p=0.62 
Kappa score 
p-value 
0.42 
p=0.01 
0.16 
p=0.3 
0.04 
p=0.80 
* 38/41 subjects had exercise data and a measured ESR 
Area under curve: 
SpO2 <93% for >10% study    = 0.69 
Existing EIAH definition  
(>4% fall in SpO2 on exercise)    = 0.58 
De novo EIAH definition  
(>4% fall in SpO2 on exercise  
and lowpoint of SpO2 <93%)    = 0.51   142
3.7.1.3 EIAH, Sleep Hypoxia and white cell counts 
ROC statistics were used to compare the sensitivity  and specificity for measures of 
sleep and exercise hypoxia in the detection of abnormal white cell counts - Figure 3.17. 
 
Figure 3.17 
ROC curve of performance of sleep hypoxia and EIAH definitions in the identification 
of childhood CF subjects with white cell counts >11x10
9.mL
-1 
 
 
The area under the curve is greatest for the definition of hypoxia as SpO2 <93% for 
>10% study, suggesting that this is a more sensitive and specific definition than either 
of  the  EIAH  definitions  in  identifying  childhood  CF  subjects  abnormal  white  cell 
counts. This is further illustrated in Table 3.15. 
 
Table 3.15 
Summary of identification of abnormal white cell counts using sleep and exercise 
hypoxia definitions  
 
  De novo SLEEP 
SpO2 <93% for 
>10% study 
EIAH 
>4% fall in SpO2 
on exercise  
EIAH 
>4% fall in SpO2 on exercise 
and lowest exercise 
SpO2<93%  
White cell count  
> 11x10
9.mL
-1 
6/2  2/6  2/6 
White cell count  
< 11x10
9.mL
-1 
3/29  6/25  2/29 
Chi-square statistic 
p-value 
(Fisher’s exact test) 
15.8 
p=0.001 
0.1 
p=0.53 
2.4 
p=0.18 
Kappa score 
p-value 
0.63 
p<0.001 
0.06 
p=0.72 
0.23 
p=0.12 
* 39/41 subjects had exercise data and a measured white cell count 
Area under curve: 
SpO2 <93% for >10% study    = 0.83 
Existing EIAH definition  
(>4% fall in SpO2 on exercise)    = 0.53 
De novo EIAH definition  
(>4% fall in SpO2 on exercise  
and lowpoint of SpO2 <93%)    = 0.59 
  
3.7.1.4 EIAH, Sleep Hypoxia and peripheral blood neutrophil counts
ROC statistics were used to compare the sensitivity  and specificity for measures of 
sleep and exercise hypoxia in the detection of abnorma
counts (>8 x 10
9.mL
-1
 
Figure 3.18 
ROC curve of performance of sleep hypoxia and EIAH definitions in the identification 
of childhood CF subjects with neutrophils>8 x10
The area under the curve is greatest for the definition of hypoxia as SpO
>10% study, suggesting that this is a more sensitive and specific definition than either 
of the EIAH definitions in identifying childhood CF subjects with elevated peripheral 
blood neutrophil counts.  This is borne out by the associated statistics 
 
Table 3.16 
Summary of identification of abnormal peripheral blood neutrophil counts (>8x10
1) using sleep and exercise hypoxia definitions 
 
 
Neutrophils  
> 8x10
9.mL
-1 
Neutrophils  
< 8x10
9.mL
-1 
Chi-square statistic 
p-value 
(Fisher’s exact test) 
Kappa score 
p-value 
* 39/41 subjects had exercise data and a measured neutrophil count
 
3.7.1.4 EIAH, Sleep Hypoxia and peripheral blood neutrophil counts
ROC statistics were used to compare the sensitivity  and specificity for measures of 
sleep and exercise hypoxia in the detection of abnormal peripheral blood neutrophil 
1) - Figure 3.18. 
ROC curve of performance of sleep hypoxia and EIAH definitions in the identification 
of childhood CF subjects with neutrophils>8 x10
9.mL
-1 
 
The area under the curve is greatest for the definition of hypoxia as SpO
>10% study, suggesting that this is a more sensitive and specific definition than either 
of the EIAH definitions in identifying childhood CF subjects with elevated peripheral 
blood neutrophil counts.  This is borne out by the associated statistics 
Summary of identification of abnormal peripheral blood neutrophil counts (>8x10
) using sleep and exercise hypoxia definitions  
De novo SLEEP 
SpO2 <93% for 
>10% study 
EIAH 
>4% fall in SpO2 
on exercise  
>4% fall in SpO
5 hypoxic / 
1 normoxic  
2/4 
4 /30  6/27 
15 
p=0.001 
0.72 
p=0.58 
0.59 
p<0.001 
0.13 
p=0.40 
* 39/41 subjects had exercise data and a measured neutrophil count
Area under curve: 
SpO2 <93% for >10% study
Existing EIAH definition 
(>4% fall in SpO2 on exercise)
De novo EIAH definition 
(>4% fall in SpO2 on exercise 
and lowpoint of SpO2 <93%)
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3.7.1.4 EIAH, Sleep Hypoxia and peripheral blood neutrophil counts 
ROC statistics were used to compare the sensitivity  and specificity for measures of 
l peripheral blood neutrophil 
ROC curve of performance of sleep hypoxia and EIAH definitions in the identification 
The area under the curve is greatest for the definition of hypoxia as SpO2 <93% for 
>10% study, suggesting that this is a more sensitive and specific definition than either 
of the EIAH definitions in identifying childhood CF subjects with elevated peripheral 
blood neutrophil counts.  This is borne out by the associated statistics (Table 3.16). 
Summary of identification of abnormal peripheral blood neutrophil counts (>8x10
9.mL
-
EIAH 
>4% fall in SpO2 on exercise 
and lowest exercise 
SpO2<93%  
2/4 
2/31 
4.1 
p=0.10 
0.32 
p=0.04 
* 39/41 subjects had exercise data and a measured neutrophil count 
10% study  = 0.86 
Existing EIAH definition  
on exercise)  = 0.58 
EIAH definition  
on exercise  
<93%)  = 0.64   144
3.7.1.4 EIAH, Sleep Hypoxia and serum IL-8 levels 
ROC statistics were used to compare the sensitivity  and specificity for measures of 
sleep and exercise hypoxia in the detection of abnormal serum IL-8 (>10pg.mL
-1) levels 
- Figure 3.19. 
 
Figure 3.19 
ROC curve of performance of sleep hypoxia and EIAH definitions in the identification 
of childhood CF subjects with serum IL-8 levels >10pg.mL
-1 
 
 
The area under the curve is greatest for the definition of hypoxia as SpO2 <93% for 
>10% study, suggesting that this is a more sensitive and specific definition than either 
of the EIAH definitions in identifying childhood CF subjects with elevated serum IL-8 
levels.  This is reiterated in Table 3.17. 
 
Table 3.17 
Summary of identification of abnormal serum IL-8 (>10pg.mL
-1) using sleep and 
exercise hypoxia definitions  
 
  De novo SLEEP 
SpO2 <93% for 
>10% study 
EIAH 
>4% fall in SpO2 
on exercise  
EIAH 
>4% fall in SpO2 on exercise 
and lowest exercise 
SpO2<93%  
Interleukin-8 
> 10 pg.mL
-1 
6/6  3/9  3/9 
Interleukin-8  
< 10 pg.mL
-1 
3/25  5/23  1/27 
Chi-square statistic 
p-value 
(Fisher’s exact test) 
7.4 
p=0.01 
0.1 
p=0.53 
4.3 
p=0.08 
Kappa score 
p-value 
0.42 
p=0.01 
0.06 
p=0.72 
0.27 
p=0.04 
* 40/41 subjects had exercise data and a measured IL-8 
Area under curve: 
SpO2 <93% for >10% study    = 0.70 
Existing EIAH definition  
(>4% fall in SpO2 on exercise)    = 0.54 
De novo EIAH definition  
(>4% fall in SpO2 on exercise  
and lowpoint of SpO2 <93%)    = 0.61 
  
3.7.1.5 EIAH, Sleep Hypoxia and the need for intravenous antibiotics
ROC statistics were used to compare the sensitivity  and specificity for measures of 
sleep and exercise hypoxia in the detection of the need for intravenous antib
preceding 12 months 
 
Figure 3.20 
ROC curve of performance of sleep hypoxia and EIAH definitions in the identification 
of children with CF requiring intravenous antibiotics
 
The area under the curve is greatest for the definition of hypoxia as SpO
>10% study, suggesting that this is a more sensitive and specific definition than either 
of the EIAH definitions in identifying child
antibiotics in the preceding year. This is borne out by the statistics of Table 3.18.
 
Table 3.18 
Summary of identification of the need for intravenous antibiotics (
using sleep and exercise hypoxia definitions 
 
 
>1 IV antibiotic course in 
preceding year 
Zero IV antibiotic courses in 
preceding year 
Chi-square statistic
p-value 
(Fisher’s exact test)
Kappa score 
p-value 
* 40/41 subjects had exercise data. Data on antibiotic usage were available for all.
3.7.1.5 EIAH, Sleep Hypoxia and the need for intravenous antibiotics
ROC statistics were used to compare the sensitivity  and specificity for measures of 
sleep and exercise hypoxia in the detection of the need for intravenous antib
preceding 12 months - Figure 3.20. 
ROC curve of performance of sleep hypoxia and EIAH definitions in the identification 
of children with CF requiring intravenous antibiotics 
 
The area under the curve is greatest for the definition of hypoxia as SpO
esting that this is a more sensitive and specific definition than either 
of the EIAH definitions in identifying children with CF who had required intravenous 
antibiotics in the preceding year. This is borne out by the statistics of Table 3.18.
Summary of identification of the need for intravenous antibiotics (
using sleep and exercise hypoxia definitions  
De novo SLEEP 
SpO2 <93% for 
>10% study 
EIAH 
>4% fall in SpO2 
on exercise  
1 IV antibiotic course in  8 hypoxic / 
12 normoxic  
6/14 
Zero IV antibiotic courses in  1/20  2/18 
square statistic 
(Fisher’s exact test) 
7.4 
p=0.009 
2.5 
p=0.24 
0.36 
p=0.006 
0.20 
p=0.11 
* 40/41 subjects had exercise data. Data on antibiotic usage were available for all.
Area under curve: 
SpO2 <93% for >10% study
Existing EIAH definition 
(>4% fall in SpO2 on exercise)
De novo EIAH definition 
(>4% fall in SpO2 on exercise 
and lowpoint of SpO2 <93%)
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3.7.1.5 EIAH, Sleep Hypoxia and the need for intravenous antibiotics 
ROC statistics were used to compare the sensitivity  and specificity for measures of 
sleep and exercise hypoxia in the detection of the need for intravenous antibiotics in the 
ROC curve of performance of sleep hypoxia and EIAH definitions in the identification 
The area under the curve is greatest for the definition of hypoxia as SpO2 <93% for 
esting that this is a more sensitive and specific definition than either 
who had required intravenous 
antibiotics in the preceding year. This is borne out by the statistics of Table 3.18. 
Summary of identification of the need for intravenous antibiotics (> 1 course per year) 
EIAH 
>4% fall in SpO2 on 
exercise and lowest 
exercise SpO2<93%  
3/17 
1/19 
1.1 
p=0.61 
0.10 
p=0.29 
* 40/41 subjects had exercise data. Data on antibiotic usage were available for all. 
<93% for >10% study  = 0.68 
Existing EIAH definition  
on exercise)  = 0.6 
EIAH definition  
on exercise  
<93%)  = 0.55   146
3.8 Discussion  
3.8.1 SpO2 in our CF study population compared with healthy controls 
SpO2 during sleep in our CF study population were lower than that reported in a non-CF 
population. A home oximetry study of 100 school-age children (Urschitz et al 2003), 
reported a median SpO2 of 97%, and stated that desaturations below 92% were unusual. 
 
3.8.2 Summary of performance of tested definitions of hypoxia in the detection of 
measures of inflammation 
From the analyses presented, a de novo definition of sleep hypoxia (SpO2 <93% for> 
10%  study  time)  appears  to  perform  best  in  the  detection  of  all  measures  of 
inflammation that were considered in this study, as assessed by comparison of ROC 
characteristics for a variety of measures of sleep hypoxia and EIAH.  
 
The  definition  of  SpO2  <93%  for>  10%  study  time  appears  to  show  the  best  ROC 
characteristics for detecting abnormal CRP and IL-8 levels, as well as elevated ESR, 
white cell and neutrophil counts, and also the need for intravenous antibiotics.  
 
The  high  sensitivity  and  specificity  of  this  hypoxia  definition  in  the  detection  of 
elevations in CRP [for which IL-6 is a precursor (Heikkila et al. 2007)], as well as IL-8 
and neutrophil counts would support the hypothesis that hypoxia is closely associated to 
NFκB-mediated inflammation. 
 
 
 
3.8.3 Study Limitations 
 
3.8.3.1 Study numbers 
The study numbers are small (n=41), and frequencies of some adverse clinical outcomes 
within this study sample are too small to allow meaningful analysis. To confirm these 
observations  in  our  study  group  and  to  further  validate  the  adopted  sleep  hypoxia 
definition, the study should be repeated in a second population using similar outcome 
measures. However, while this is planned, it is beyond the scope of this MD thesis.   
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3.8.3.2 Lack of control subjects 
A number of tests were undertaken on each of the study subjects that took a full day’s 
testing protocol to achieve. Time constraints and the availability of historical control 
data for outcomes including spirometry, respiratory and skeletal muscle strength, and 
bone mineral density acted as justification for the absence of a healthy control group. 
The reliance on epidemiological control data is, however, an acknowledged limitation 
of this study. 
 
3.8.3.3 Method of assessment of sleep hypoxia 
By  relying  on  time  increments  with  low  arterial  oxygen  saturations  from  oximetry 
measures alone as our gold standard, an assumption is made that the desaturation in CF 
is not due to obstruction. This assumption appears a reasonable one to make. Baseline 
SpO2 are low, with little heart rate variability or obstructive (>4% fall in SpO2) dips 
seen on analyses of the full studies of each of the hypoxic individuals; suggesting that 
hypoventilation  is  occurring  throughout  sleep  (both  REM  and  non-REM),  although 
without EEG monitoring, the sleep phases are unknown. Indeed sleep state is unknown, 
and it is possible that the children were not asleep at all and that no desaturations were 
seen due to the subject being awake all night. A verbal report from parents suggests that 
all children were studied during sleep, although it is known that inaccuracies may exist 
in parental reporting of their children’s sleep patterns (Minde et al. 1993). 
 
The software package enabled calculation of the majority of desired study parameters, 
but the inability to calculate hourly mean SpO2 measures was a potential limitation as 
this prevented us applying the existing nocturnal hypoxia criteria of Versteegh et al. 
(1990)  to  our  study  population.  Oximetry-only  studies  can  be  associated  with  false 
negative results, for example oximetry alone may miss arousals related to obstruction.  
 
Significant hypoxia is, however, either present or absent on the study, and oximetry 
appears  both  sensitive  and  specific  in  the  detection  of  hypoxia.  Indeed  continuous 
documentation  of  SpO2  over  a  minimum  of  8  hours  is  the  recommended  first-line 
investigation  of  hypoxaemia  in  CF  in  the  American  Thoracic  Society  (ATS) 
recommendations for cardiopulmonary sleep studies in children (Am J Respir Crit Care 
Med 1996; 153: 866-878), with full polysomonography (PSG) reserved for those CF 
patients in whom snoring or sleep disturbance is present.   148
A strength of the study however, is that oximetry was done in the patient's own home 
and they did not have to come into hospital and sleep in an artificial environment to 
undertake full polysomnography. 
 
A further strength was the timing of the sleep study. All patients were studied at a time 
of clinical stability, and in each case the sleep study preceded the measurement of 
clinical and inflammatory outcomes. 
 
3.8.4 Adoption of a new sleep hypoxia definition 
Based on the ROC characteristics, and ability to detect measures of inflammation in a 
childhood CF population, SpO2 <93% for> 10% study time is the definition of hypoxia 
to  be  used  for  assessing  the  inter-relationship  of  hypoxia  and  measured  clinical 
outcomes. These inter-relationships will be explored in detail in Chapters 4 and 5. Study 
demographics using this new definition are displayed below (Table 3.19). 
 
Table 3.19 
Nocturnal hypoxia in our study population using new hypoxia definition 
 
 
  Median 
(IQR)  Age 
Sex   Mean (sd) 
Sleep SpO2 
Median (IQR) 
time spent 
with SpO2 
<93% 
Hypoxic Group 
[SpO2 <93% for >10% sleep time] 
(n=9) 
14.9  
(12.3-14.9) 
3M:6F  92.6 
(1.1) 
49.8 
(19.6-79.7) 
Normoxic Group 
(n=32) 
12.2  
(10-13.7) 
17M:15F  96.1  
(1.1) 
0.1 
(0.1-1.8) 
 
 
Validation of this definition in a second population using similar outcome measures is 
planned.  
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Hypoxia, defined as SpO2 <93% for >10% sleep time –the most sensitive and specific 
definition in the detection of measures of inflammation was noted in nine of 41 children 
studied. Given that only 1-2% UK children with CF receive oxygen therapy (Balfour-
Lynn et al. 2005, Douglass et al. 2008), the proportion of children (22%) identified as 
hypoxic suggests that a proportion of children with CF may be being under-treated for 
potentially clinically significant nocturnal hypoxia. 
 
In 1990, a study of daytime SpO2 in 100 children with CF aged 5-16 years, was carried 
out at Great Ormond Street (GOS) Hospital (Betancourt et al. 1991). The median SpO2 
of the CF population was 94% (range 75%-99%), compared with 97% in a group of 50 
age-matched controls.  
 
In the 2005/06 GOS cohort studied for this thesis, median daytime SpO2 were 99% 
(range  95-100%).  Although  the  study  exclusion  criteria  included  children  already 
receiving oxygen therapy, only 2 children were excluded for this reason, and this would 
not skew the median resting SpO2 data.  A clear difference in median daytime SpO2 in 
the GOS CF population is evident, with marked improvement noted over a 15-year 
period. It is, therefore, suggested that the prevalence of hypoxia in children with CF has 
been falling over the past two decades. This fall is likely to be due to the current cohort 
of CF patients having less severe lung disease than their predecessors, as reflected in the 
ongoing continued improvement in survival in UK CF patients (Dodge et al. 2007).  
 
3.8.5 Implications of measures of exercise induced arterial hypoxia 
Hypoxia  in  CF  is  reported  to  occur  more  frequently  during  sleep  than  on  exercise 
(Bradley et al 1999, Coffey et al 1991). Our results (Figures 3.12 and 3.14) bear out this 
finding,  regardless  of  how  EIAH  is  quantified.  The  implications  of  this  include  the 
recommendation that a sleep study may be indicated for those with exercise-induced 
arterial hypoxaemia.  
 
The mechanisms for sleep hypoxia and EIAH are thought to differ, and this is borne out 
by  the  identification  of  different  individuals  with  sleep  hypoxia  when  compared  to 
EIAH.  Exploration  of  mechanisms  by  which  differences  occur  will  be  attempted  in 
chapter  4.  Further  research  directions  may  seek  to  better  understand  the  effects  of 
EIAH, and help to develop a clinically-relevant definition of EIAH that can be used in 
the CF population.   150
3.8.6 Consideration of a new EIAH definition 
The definition of EIAH in CF appears flawed, as a 4% dip in SpO2 from baseline on 
exercise may not result in exercise-induced hypoxia at all i.e. a dip from 100% to 96% 
would be encompassed by this definition, although clearly a SpO2 of 96% (equating to a 
PaO2 of 12kPa) would not be considered hypoxic. Such falls in SpO2 are known in elite 
athletes, and postulated to be due to intrapulmonary shunting, diffusion limitation, and 
ventilation-perfusion mismatching (Prefaut et al. 2000).  
 
It was therefore proposed that a more robust definition of EIAH may be that of a fall in 
SpO2  during  exercise  of  >4%  and  nadir  of  SpO2  below  93%.    However,  the  ROC 
characteristics of  either  existing or de novo definitions of EIAH in the  detection of 
adverse clinical outcomes (Figures 3.15 to 3.20) appear inferior to the de novo sleep 
hypoxia definition.  
 
This suggests that the most clinically useful measure of hypoxia in children with CF is 
SpO2 <93% for >10% sleep time, and groups will be dichotomised on this basis for 
chapters 4 and 5. 
 
 
 
 
3.9 Definition of clinically important hypoxia in childhood CF 
The definition to be used for assessing the inter-relationship of hypoxia in CF and a 
variety of study outcomes in Chapters 4 and 5 is SpO2 <93% for >10% sleep time.  
 
Chapter 4 will explore the association between hypoxia in children with CF (as defined 
by SpO2 <93% for >10% sleep time) and various clinical, radiological, physiological 
and  psychological  outcome  measures,  whilst  Chapter  5  will  explore  the  association 
between hypoxia and surrogate measures of inflammation. 
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CHAPTER 4: Association of hypoxia and clinical outcomes in 
children with cystic fibrosis 
 
4.1 Introduction 
Following on from Chapter 3, where a de novo definitions of hypoxia in CF has been 
proposed, we now seek to apply the suggested definition of hypoxia (SpO2 <93% for 
10% sleep time) to our study population.  
 
By  dichotomising  on  the  basis  of  hypoxia,  we  are  able  to  explore  the  relationship 
between hypoxia in children with CF and various clinical, radiological, physiological 
and psychological outcome measures as outlined below. It is hypothesised that hypoxia 
may  be  associated  with  deleterious  clinical  outcomes,  in  particular  a  reduction  in 
exercise capacity (Figure 1.5).   
 
4.2 Aims 
The aim of this chapter was to investigate the relationship between measures of hypoxia 
and clinical parameters, namely: 
-  Anthropometric data 
-  Spirometry and lung function data 
-  Radiological data (Chrispin-Norman X-ray scores) 
-  Respiratory muscle pressure measurements (SnIP, MIP and MEP) 
-  Cardiopulmonary exercise testing (CPET) data 
-  Quality of life (CFQ) data 
-  Echocardiographic data 
 
The relationship between measures of hypoxia and ACE genotype, bone densitometry, 
skeletal  muscle  strength,  and  surrogate  measures  of  inflammation  including  exhaled 
breath condensate measures will be investigated in Chapter 5. 
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4.3 Methods 
Application  of  a  definition  of  hypoxia  in  CF  as  declared  in  section  3.9  allows 
dichotomisation  of  our  population  into  hypoxic  and  normoxic  groups  for  statistical 
analyses. 
 
4.3.1 Definition of Hypoxia 
Following  the  use  of  ROC  statistics  to  consider  a  number  of  definitions  of  both 
nocturnal hypoxia and EIAH, a single definition (SpO2 <93% for 10% sleep time) was 
chosen as the most clinically useful definition of hypoxia in our study population. This 
definition was used to dichotomise the study population and allows comparison between 
hypoxic and normoxic groups, in order to investigate the relationship between hypoxia 
and  the  various  study  outcome  measures  described  above,  and  to  validate  this  as  a 
clinically useful definition. 
 
4.3.2 Anthropometric data and demographics 
Briefly, anthropometric measures of height were made using a stadiometer, and body 
mass  measurements  were  undertaken  on  electronic  scales  in  accordance  with  the 
methodology of section 2.2.2.1.  
 
4.3.3 Spirometry 
Briefly, incentive spirometry was performed (Jaeger Masterscreen 4.65) in accordance 
with  the  ATS/ERS  recommendations  (Miller  et  al.  2005),  as  described  in  section 
2.2.2.3.   
 
4.3.4 Plethysmographic data 
Plethysmography (see section 2.2.2.3.3) had been undertaken as part of each CF 
patient’s annual assessment in the 12 months preceding the study. Measures of both 
residual volume (RV) and total lung capacity (TLC) were estimated, and from these 
measures, an estimate of gas trapping can be made from the RV to TLC ratio. 
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4.3.5 Chrispin-Norman chest radiograph score  
Chrispin-Norman scoring (CNS) of a chest radiograph had been undertaken as part of 
each  CF  patient’s  annual  assessment  in  the  12  months  preceding  the  study.  The 
modified CNS scoring system (Benden et al. 2005) was used (section 2.2.2.3.4). The 
proforma used for CNS scoring is included in Appendix 2. 
 
4.3.6 Respiratory muscle pressure measurements 
Measures of respiratory muscle pressure were undertaken in accordance with the 
methods described in section 2.2.2.4. Briefly these were: 
a) Sniff Inspiratory Pressure (SnIP) – A maximal sniff obtained from FRC with the 
contralateral nostril occluded. 
b) Mouth Inspiratory Pressure (MIP)  
– A maximal inspiratory effort from FRC whilst wearing a noseclip. 
c) Mouth Expiratory Pressure (MEP)  
– A maximal expiratory effort from TLC whilst wearing a noseclip. 
 
An accompanying software package (PUMA software - Micro Medical Ltd., Chatham, 
Kent, UK) allowed real-time quality control assessment for each manoeuvre, as well as 
analysis of pressure-time plots. 
 
4.3.7 Cardiopulmonary exercise testing (CPET) 
Incremental  cycle  ergometer  exercise  testing  with  breath  by  breath  ventilatory  gas 
analysis  using  a  metabolic  cart  (MedGraphics,  St  Paul,  Minnesota,  USA)  was 
undertaken using the methodology of section 2.2.2.8.  
 
Briefly, the subject exercises on an investigator-determined ramp protocol that is geared 
to the size, age and fitness level of the child. Resting data is collected followed by a 
period of unloaded cycling. The incremental exercise test then takes place, and the 
subject is subsequently monitored during their recovery.  
 
Information is collected on heart rate , oxygen uptake (VO2), carbon dioxide elimination 
(VCO2), work rate, respiratory rate and tidal volume, as well as the monitoring of end-
tidal CO2 (etCO2), and arterial oxygen saturations (SpO2) throughout exercise.   154
4.3.8  Quality  of  life  assessment  using  the  United  Kingdom  Cystic  Fibrosis 
Questionnaire [CFQ-UK] 
Quality of life was assessed using the CFQ-UK. A CD-ROM package that accompanies 
the questionnaire enables various quality of life dimensions to be assessed. The methods 
are described in full in section 2.2.2.10.  
Briefly, there are several versions of the questionnaire: 
 -  The  CFQ-14+  was  used  for  children  aged  over  14  years,  and  is  a  self-assessed 
questionnaire that takes around 10 minutes to complete.  
- A self-reporting format was used for 12 and 13 year-olds.  
- The CFQ child P is a parent-proxy evaluation used for children aged 6 - 13.  
Copies of the various CFQ questionnaires used are attached in Appendix 3. 
 
4.3.9 Echocardiographic measures  
Trans-thoracic echocardiography was undertaken on all study patients, in accordance 
with the methods described in section 2.2.2.7. Cardiac structure and morphology were 
first assessed.  
 
Measures  of  left  ventricle  (LV)  wall  thickness  at  both  interventricular  septum  and 
posterior wall (IVSd and LVPWd), and right ventricle wall thickness (RVWd) were 
made.  LV  fractional  shortening  (%)  was  assessed,  and  LV  ejection  fraction  (%) 
estimated using the methodology of section 2.2.2.7. 
 
Systolic pulmonary artery pressure (sPAP) was estimated from the Doppler signal of 
tricuspid regurgitation (TR) gradient (if any TR present) using the modified Bernoulli 
equation, described in section 2.2.2.7. 
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4.4 Results 
Nine out of 41 subjects were classified as hypoxic using the definition SpO2 <93% for 
>10%  sleep  time.  Thus  the  study  was  adequately  powered  to  detect  differences  in 
primary outcome – exercise capacity (section 4.4.6) in accordance with the a priori 
power calculation outlined in section 2.1.3. 
4.4.1 Anthropometric data and demographics 
4.4.1.1 Anthropometric and demographic data for study population 
Table  4.1  displays  the  age,  sex  and  physical  characteristics  of  the  study  population 
including  average  z  scores  for  height,  weight  and  BMI.  Also  displayed  are  CFTR 
genotypes, pancreatic status and Pseudomonas aeruginosa and Staphylococcus aureus 
infection status. 
 
Table 4.1 
Demographic data for the study population (n=41) 
 
Variable  Study population (n=41) 
  Range  Median (IQR) 
Age  8 to 16.2  12.7 (10.4 to 14.6) 
Sex  20M:21F  - 
Height (cm)  123 to 184  147 (136 to 160) 
Weight (kg)  22 to 64  40 (30 to 47) 
BMI (kg.m
-2)  14 to 23  18 (15.7 to 19) 
Height SDS  -2.1 to +1.8  -0.5 (-1.1 to 0.2) 
Weight SDS  -2.2 to +1.7  -0.7 (-1.4 to 0.1) 
BMI SDS  -2.2 to +2  -0.4 to (-1.1 to 0.2) 
 
CFTR genotype 
•  ∆F508/∆F508 
•  ∆F508/Other 
•  Other/Other 
 
 
25 
13 
3 
 
 
- 
- 
- 
 
Pancreatic status 
Pancreatic-insufficient (PI)  
Pancreatic-sufficient (PS) 
 
 
PI (n=39) 
PS (n=2) 
 
 
- 
- 
 
Lung function 
FEV1 SDS 
FVC SDS 
 
 
-5 to +2 
-4 to +1.6 
 
 
-1.9 (-3.2, -0.9) 
-1 (-2.3, 0) 
 
Pseudomonas aeruginosa infection 
 
•  Ever (n=37)  
•  Never (n=4) 
 
- 
- 
Staphylococcus aureus infection 
 
•  Ever (n=33)  
•  Never (n=8) 
- 
-  
4.4.1.2 Anthropometric and demographic data and
Using  the  definition  of  nocturnal  hypoxia  in  CF  (
suggested in section 3.
taller (Figure 4.1) but with body mass indices that are significantly lower (Figure 4.2) 
than their normoxic peers (Table 4.2).
 
Table 4.2 
Comparison of demographic and anthropometric data between hypoxic (
>10% sleep time) and normoxic groups 
 
Variable 
 
(SpO
Age (years) 
Height SDS 
Weight SDS 
BMI SDS 
All values quoted are median (+/
 
Figure 4.1 
Distribution of height
(SpO2<93% for >10% sleep time
 
 
 
Although statistical significance is achieved, 
heights of hypoxic and normoxic subjects. This may suggest an artefactual difference 
pertaining to small study numbers.
 
NORMOXIA 
p<0.05, Mann
Anthropometric and demographic data and hypoxia 
Using  the  definition  of  nocturnal  hypoxia  in  CF  (SpO2<93%  for  >10%  sleep  time
suggested in section 3.9, it is apparent that the hypoxic group are older and relatively 
taller (Figure 4.1) but with body mass indices that are significantly lower (Figure 4.2) 
than their normoxic peers (Table 4.2). 
son of demographic and anthropometric data between hypoxic (
) and normoxic groups  
Study population (n=41) 
 
Hypoxic (n=9) 
(SpO2<93% for >10% sleep time) 
Normoxic (n=32)
14.9 (12.4, 15.6)  12.2 (10, 13.7)
0 (-0.5, +0.2)  -0.8 (-1.2, 0.1)
-0.8 (-1.4, -0.2)  -0.6 (-1.3, 0.1)
-1.1 (-2, -0.6)  -0.2 (-0.7, +0.3)
All values quoted are median (+/- IQR), *Mann-Whitney U-test 
Distribution of height z scores in normoxic CF patients and those with hypoxia 
<93% for >10% sleep time) 
 
Although statistical significance is achieved, there is considerable overlap between the 
heights of hypoxic and normoxic subjects. This may suggest an artefactual difference 
pertaining to small study numbers. 
HYPOXIA 
(SpO2<93% for >10%) 
Medians shown 
p<0.05, Mann-Whitney U-test 
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for  >10%  sleep  time) 
, it is apparent that the hypoxic group are older and relatively 
taller (Figure 4.1) but with body mass indices that are significantly lower (Figure 4.2) 
son of demographic and anthropometric data between hypoxic (SpO2<93% for 
 
Normoxic (n=32)  p-value 
(10, 13.7)  <0.05* 
1.2, 0.1)  0.05* 
1.3, 0.1)  0.38* 
0.7, +0.3)  <0.01* 
scores in normoxic CF patients and those with hypoxia 
there is considerable overlap between the 
heights of hypoxic and normoxic subjects. This may suggest an artefactual difference   157
NORMOXIA  HYPOXIA 
(SaO2<93% for >10%)  Medians shown 
p=0.01, Mann-Whitney U-test 
Figure 4.2 
Distribution of BMI z scores in normoxic CF patients and those with hypoxia 
(SpO2<93% for >10% sleep time) 
 
 
 
 
 
 
 
 
 
BMI z scores appear to be significantly lower in the hypoxic group, although once again 
a degree of overlap exists. The catabolic effects of being in a pro-inflammatory state 
may impact negatively on nutritional status (Gan et al. 2004), providing a potential 
explanation for these observed differences. 
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4.4.2 Spirometry 
4.4.2.1 Demographic data of study population 
Spirometry was successfully undertaken in all 41 study subjects. Subjects ranged from 8 
to 16.2 years of age, with a mean (sd) age of 12.5 (2.4) years, and a median age of 12.7 
years. Twenty-one subjects were female, and 20 male. The distribution of spirometry 
measures is illustrated in Table 4.3. 
 
Table 4.3 
Spirometry of the study population 
 
Variable  Subjects (n=41) 
  Range  
 
Median (IQR)  
FEV1  -5.0 to +2.0  
[35 to 128%] 
-1.9 (-3.2 to -0.9) 
[74 (57 to 88)%] 
FVC  -4.0 to +1.6  
[51 to 123%] 
-1.0 (-2.3 to 0) 
[88 (71 to100)%] 
FEF50 
 
-3.8 to 2.5  
[9 to 159%] 
-2.4 (-2.9 to -1.3) 
[51 (30-74)%] 
FEF75  -3.5 to 1.8  
[7 to 156%] 
-1.9 (-2.7 to -1.2) 
[33 (19 to 42)%] 
     
All values are standard deviation score for lung function parameters. 
(%predicted values are given in parentheses [] thereafter). 
 
 
4.4.2.2 Spirometric parameters and hypoxia 
The relationship between FEV1 and mean overnight SpO2 was explored (Figure 4.3). 
Using z scores based on validated reference ranges (Rosenthal et al. 1993) Spearman 
rank correlation coefficient was r
2=0.38, p<0.001.  
  
Figure 4.3 
Correlation of FEV1 SDS and mean overnight SpO
 
  Subject meeting criteria for hypoxia (SpO2<93% for >10% sleep time)
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This graph illustrates that all of the hypoxic subjects had abnormal FEV
 
Similar correlations were observed for comparison of mean sleep 
mid-expiratory flow measures (Table 4.4).
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Correlation coefficients for mean sleep SpO
 
 
Mean sleep 
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Comparison  of  spirometric  measures  of  lung  function  between  those  with  nocturnal 
hypoxia and normoxic controls was carried out, using the 
for >10% sleep time) definition of hypoxia (Table 4.5). 
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z score 
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2 = 0.25 **  r
2 = 0.24 **
* p<0.001; ** p=0.001 (Spearman test) 
Comparison  of  spirometric  measures  of  lung  function  between  those  with  nocturnal 
hypoxia and normoxic controls was carried out, using the newly proposed
) definition of hypoxia (Table 4.5).  
 
r
2 =0.38, p<0.001 
Spearman rank test 
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Table 4.5 
Comparison of spirometry data between hypoxic (SpO2<93% for >10% sleep time) and 
normoxic groups 
   
Variable  Study population (n=41) 
 
  Hypoxic (n=9) 
(SpO2<93% for >10% sleep time) 
Normoxic (n=32)  p-value 
FEV1 SDS  -3.9 (-3.3, -4.7)  -1.7 (-2.5, -0.4)  <0.001* 
FVC SDS  -2.6 (-3.8, -1.8)  -0.6 (-1.8, +0.1)  <0.001* 
FEF50 SDS  -3.3 (-3.6, -2.8)  -1.8 (-2.5, -0.8)  <0.001* 
FEF75 SDS  -2.9 (-3.2, -2.3)  -1.9 (-2.2, -1.0)  0.002* 
Values are median (IQR) of lung function z scores, * Mann-Whitney U test. 
 
All of the above spirometric indices were lower in the hypoxic group when compared to 
the remainder of the study population. Figure 4.4 illustrates the distribution of FEV1 
SDS values across hypoxic and normoxic groups. 
 
Figure 4.4 
Distribution of FEV1 z scores in normoxic CF patients and those with hypoxia 
(SpO2<93% for >10% sleep time) 
 
 
It can be seen that if FEV1 z score is within normal range (>-2 z scores), then no subject 
meets the criteria for hypoxia. Work to delineate the optimal level of lung function at 
which to consider a sleep study will be defined in section 4.5.3. 
NORMOXIA  HYPOXIA 
(SpO2<93% for >10%) 
p<0.001, Mann-Whitney U-test 
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4.4.3 Plethysmographic data 
Plethysmography was successfully undertaken in all 41 study subjects. Subjects ranged 
from 8 to 16.2 years of age, with a mean (sd) age of 12.5 (2.4) years, and a median age 
of 12.7 years. Twenty-one subjects were female, and 20 male. The measure considered 
to be most representative of gas trapping was RV/TLC Ratio. Across the entire study 
population, RV/TLC ratio had a median (IQR) value of 0.36 (0.27, 0.5). 
 
4.4.3.1 Hypoxia and RV/TLC ratio 
Hypoxic subjects (SpO2<93% for >10% sleep time) had a median (IQR) ratio of 
RV/TLC of 0.5 (0.45, 0.64), compared with 0.32 (0.24, 0.45) in normoxic subjects 
(p<0.001, Mann-Whitney U-test). 
 
Therefore it is suggested that hypoxic CF subjects have a greater degree of gas-trapping 
than do their normoxic counterparts. 
 
4.4.4 Radiographic data: Chrispin-Norman chest radiograph score (CNS) 
CNS  was  successfully  undertaken  in  all  41  study  subjects.  Across  the  entire  study 
population, median (IQR) CNS was 11 (7, 14). Given that baseline age differences exist 
between the groups when classified for nocturnal hypoxia (Tables 4.2 and 4.3), age-
corrected CNS was also considered (CNS/Age). The CNS/age measure had a median 
value of 0.81 (0.65, 1.19). 
  
4.4.4.1 Hypoxia and 
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negative correlation (r
Figure 4.5 
Relationship of mean sleep 
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Comparison of Chrispin
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Variable 
 
(SpO
CNS 
CNS/Age 
All values quoted are median (+/
 
r
2= 0.38, p<0.001, Spearman Rank test
4.4.4.1 Hypoxia and radiographic data 
A relationship is observed between CNS and mean sleep SpO2 (Figure 4.5), 
r
2=0.38, Spearman). 
Relationship of mean sleep SpO2 and Chrispin-Norman X-ray score
Statistically higher CNS were observed in the hypoxic (SpO2<93% for >10% sleep 
) group. These differences were maintained when the CNS were corrected for age 
(Table 4.6). These findings are of importance as they suggest that lung structure (as well 
as function) may be worse in the hypoxic group. 
Comparison of Chrispin-Norman chest radiograph scores between hypoxic (
) and normoxic groups  
Study population (n=41) 
 
Hypoxic (n=9) 
(SpO2<93% for >10% sleep time) 
Normoxic (n=32)
16 (12,19)  10 (7,13)
1.1 (0.8,1.3)  0.8 (0.6,1)
All values quoted are median (+/- IQR), *Mann-Whitney U-test 
= 0.38, p<0.001, Spearman Rank test 
Hypoxic subject
 
Normoxic subject
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(Figure 4.5), showing 
ray score 
 
SpO2<93% for >10% sleep 
) group. These differences were maintained when the CNS were corrected for age 
hey suggest that lung structure (as well 
between hypoxic (SpO2<93% 
 
Normoxic (n=32)  p-value 
10 (7,13)  0.002* 
0.8 (0.6,1)  0.04* 
Hypoxic subject 
Normoxic subject   163
4.4.5 Respiratory muscle pressure measurements 
 
4.4.5.1 Demographic data of study population 
SnIP and MEP measurements were successfully undertaken in all 41 study subjects. 
Subjects ranged from 8 to 16.2 years of age, with a median age of 12.7 years. Twenty-
one  subjects  were  female,  and  20  male.  MIP  measurements  were  successfully 
undertaken in forty of the 41 study subjects. One male subject was unable to perform 
MIP due to poor technique. He was at the lower end of the age range studied, at 9.02 
years.  Respiratory  muscle  pressure  data  for  the  entire  study  population  is  displayed 
below (Table 4.7) 
 
Table 4.7 
Demographics for SnIP/MIP and MEP 
 
Variable  Study population (n=41) 
  Median (IQR) 
Pressure 
(cm H20) 
Range  
(cm H20) 
Median (IQR) SDS 
SniP 
(n=41) 
89 (79-108)  29-207  -0.35 (-0.8 to 0) 
MIP 
(n=40) 
81 (65-104)  40-131  -0.12 (-0.7 to +1) 
MEP 
(n=41) 
90 (69-109)  38-149  -0.32 (-1.2 to +0.5) 
 
4.4.5.1.1 Relationship of SnIP and MIP in CF 
Limits of agreement for SnIP and MIP were assessed using a Bland-Altman plot (Bland 
and Altman 1986). SnIP was, on average, higher than MIP with a mean (sd) difference 
of 10.4 (24.4) cm H2O (Figure 4.6). 
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Figure 4.6 
Limits of agreement for two methods of inspiratory pressure measurement (SnIP and 
MIP) using a Bland and Altman plot 
 
 
These  mean  (sd)  differences  are  similar  to  those  reported  in  healthy  children  [13.5 
(21.4) cm H20] (Rafferty et al. 2000). 
 
4.4.5.2 Hypoxia and respiratory muscle pressure  
Data were considered as absolute measures of muscle strength (cm H2O), and also as z 
scores using age and sex-specific reference ranges (Stefanutti and Fitting 1999). Inter-
group  comparisons  were  carried  out  (Table  4.8),  and  no  statistically  significant 
differences  were  noted  between  hypoxic  (SpO2<93%  for  >10%  sleep  time)  and 
normoxic subject groups.   165
Table 4.8 
Effects of hypoxia (SpO2<93% for >10% sleep time) on respiratory muscle strength in 
children with CF 
 
a)  Absolute values 
Variable  Study population (n=41) 
 
  Hypoxic (n=9) 
(SpO2<93% for >10% sleep time) 
Normoxic (n=32)  p-value 
SnIP  92 (66,103)  89 (81,113)  0.57* 
MIP  85 (54,103)  78 (66,109)
 #  0.55* 
MEP  91 (83,120)  85 (67,109)  0.41* 
 
b)  z scores 
Variable  Study population (n=41) 
 
  Hypoxic (n=9) 
(SpO2<93% for >10% sleep time) 
Normoxic (n=32)  p-value 
SnIP  -0.2 (-1.3,-0.1)  -0.4 (-0.8, 0.2)  0.61* 
MIP  -0.7 (-1.2, 1.2)  0.1 (-0.5, 1) 
#  0.41* 
MEP  0.4 (-0.9,0.9)  -0.6 (-1.3,0.5)  0.47* 
All values are median (IQR) *Mann-Whitney U-test, 
# n=31  
 
 
A potential explanation for such a lack of effect may be that children with CF have a 
relative training effect on their respiratory muscles due to increased work of breathing, 
which allows preservation of muscle strength. This is supported by Figure 4.12 which 
illustrates similar minute ventilation at maximal exercise in both hypoxic and normoxic 
subjects, despite reduced lung volumes on forced expiratory manoeuvres in the hypoxic 
group.   166
4.4.6 Cardiopulmonary exercise testing (CPET) parameters 
40 individuals successfully undertook CPET testing. A single individual was unable to 
undergo CPET testing, as he was too small for the exercise bike. 
 
4.4.6.1 Demographic data of study population 
Displayed below (Table 4.9) are the spread of selected CPET measures recorded in the 
study population across the phases of exercise.  
 
Table 4.9 
CPET data for the study population (n=40) 
 
Variable  Study population (n=40) 
  Range  Median (IQR) 
Age  8 to 16.2  12.9 (10.7, 14.7) 
Sex  19M:21F  - 
 
Resting: 
HR 
RR 
etCO2 (mm Hg) 
SpO2 
VO2 at rest (mls.m
-2.min
-1) 
 
 
66-127 
11-45 
24-42 
95-100 
111-269 
 
 
92 (82, 108) 
23 (19, 27) 
34 (31, 36) 
99 (97, 100) 
184 (168, 216) 
 
AT: 
VO2 at Anaerobic Threshold 
mls.kg
-1.min
-1 
mls.m
-2.min
-1 
 
 
 
11.3-37.3 
357-978 
 
 
 
19.6 (16.6,23) 
606 (516, 696) 
 
Peak: 
Peak VO2 
mls.kg
-1.min
-1 
mls.m
-2.min
-1 
 
 
 
21-55 
589-1685 
 
 
 
35 (30, 42) 
1074 (917, 1277) 
 
HR 
RR 
etCO2 (mm Hg) 
VE (L) 
Workload (Watts.m
-2) 
 
144-208 
26-86 
23-47 
22-96 
50-184 
 
180 (170, 191) 
58 (47, 63) 
35 (31, 38) 
56 (41, 66) 
83 (68, 103) 
Lowest exercise SpO2  85-100  98 (96, 99) 
Change in SpO2 on exercise  -13 to +4  -1 (-2, 0) 
 
 
4.4.6.2 Hypoxia and CPET testing 
Dichotomisation by a definition of SpO2<93% for >10% sleep time was used to 
investigate the effects of hypoxia on cardiopulmonary exercise (Table 4.10).    167
Table 4.10 
Effects of hypoxia (SpO2<93% for >10% sleep time) on CPET in CF  
 
Variable  Study population (n=40) 
 
  Hypoxic (n=9) 
(SpO2<93% for >10% 
sleep time) 
Normoxic (n=31)  p-value 
Resting: 
HR 
RR 
etCO2 (mm Hg) 
SpO2 
VO2 at rest (mls.m
-2.min
-1) 
 
99 (93, 118) 
24 (20, 38) 
29 (28, 33) 
98 (97, 98) 
193 (175, 214 
 
89 (81, 101) 
23 (19, 27) 
35 (32, 36) 
99 (98, 100) 
184 (146, 216) 
 
0.09* 
0.22* 
0.003* 
0.01* 
0.73* 
VO2 at AT 
mls.kg
-1.min
-1 
mls.m
-2.min
-1 
 
16.6 (15.4, 18.4) 
503 (431, 587) 
 
20.6 (17.9, 23.8) 
640 (559, 700) 
 
0.01* 
0.01* 
Peak: 
Peak VO2 
mls.kg
-1.min
-1 
mls.m
-2.min
-1 
 
 
28.8 (24, 34.2) 
1138 (906, 1750) 
 
 
35.3 (33.3, 43.2) 
1353 (1126, 1637) 
 
 
0.01* 
0.04* 
HR 
RR 
etCO2 (mm Hg) 
VE (L) 
(VE – predicted MVV) (L) 
Workload (Watts m
-2) 
170 (164, 178) 
61 (52, 69) 
36 (31, 38) 
57 (32, 73) 
8.8 (-8.4, 15.3) 
64 (57, 89) 
182 (174, 192) 
55 (47, 61) 
34 (31, 38) 
56 (41, 64) 
-10.2 (-26, -0.2) 
86 (74, 106) 
0.02* 
0.11* 
0.92* 
1.0* 
<0.001* 
0.02* 
Lowest exercise SpO2  97 (93, 98)  98 (97, 99)  0.06* 
Change in SpO2 on 
exercise 
-1 (-6, 1)  -1 (-2, 0)  0.75* 
All values are median (IQR) *Mann-Whitney U-test 
 
Resting end-tidal CO2 measures were lower in the hypoxic group. The implication of 
this might be that hypoxic subjects were hyperventilating at rest relative to normoxic 
controls. Although no differences in median resting respiratory rates were noted, this 
hypothesis may be supported by the fact that the IQR for respiratory rate varied from 
20-38 in hypoxic subjects compared with 19-28 in controls. Early work in exercise and 
CF (Godfrey and Mearns 1971) recognised the necessity for increased VE in children 
with CF to maintain alveolar ventilation in the face of an increased physiological dead 
space. 
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4.4.6.2.1 Hypoxia and VO2 
It is noted that hypoxic subjects had reduced exercise capacity as measured by oxygen 
uptake (VO2), at both anaerobic threshold (AT) (Figure 4.7) and peak exercise (Figure 
4.8), as well as achieving a lower workload (Figure 4.9). A lower peak heart rate was 
reached in the hypoxic group, indicative of the fact that exercise was limited by 
ventilation with the presence of some cardiac reserve at the end of exercise. 
 
Figure 4.7 
Effects of hypoxia (SpO2<93% for >10% sleep time) on oxygen uptake at anaerobic 
threshold in children with CF  
 
 
 
A greater than 10% reduction in VO2 at AT was seen in hypoxic subjects – the primary 
study outcome. VO2 at AT is a more reproducible measure than peak oxygen uptake, for 
it is less likely to be influenced by the volitional aspect of exercise i.e. AT comes on 
considerably before peak exercise, and almost all if not every subject will reach AT 
with encouragement. This was the case in our study population where AT was attained 
in all. 
 
The effect of the suggested increased height in the hypoxic group (Table 4.2) is 
controlled for by correcting the units for analysis of oxygen uptake for body surface 
area (mls.m
-2.min
-1) rather than weight (mls.kg
-1.min
-1) which is most commonly used 
for analysis. 
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) on peak oxygen uptake in children 
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Workload (Watts.m
-2) achieved by hypoxic (SpO2<93% for >10% sleep time) subjects 
was statistically lower in hypoxic subjects compared with normoxic controls (Figure 
4.9).  
 
Subjects with nocturnal hypoxia had a trend towards a lower SpO2 on exercise (p=0.06), 
and  also  reached  a  lower  peak  heart  rate  (p=0.02,  Mann-Whitney  U  test).  Potential 
explanations for this may be that there is respiratory limitation to maximal exercise with 
cardiac reserve, or that adaptation has occurred in response to nocturnal hypoxia leading 
to a reduced peak heart rate on exercise. Analogous to athletes who are exposed to 
repeated periods of hypoxia whilst training, the hypoxic stimulus in our hypoxic CF 
cohort  is  repeated  every  evening  whilst  asleep.  Improved  cardiovascular  efficiency 
following a period of  mountaineering training has been reported (Purkayastha et al. 
2000), although more recent work found no difference in heart rate changes between 
groups of healthy athletes (n=23) randomised to hypoxic or sea-level training (Truijens 
et al. 2008). 
 
4.4.6.2.2 Hypoxia and maximal exercise ventilation 
No statistically significant differences in minute ventilation (VE) were seen between 
hypoxic and normoxic groups (Figure 4.10), despite differences in lung volumes as 
assessed by spirometry (section 4.4.2).  
 
Figure 4.10 
Effects of hypoxia (SpO2<93% for >10% sleep time) on minute ventilation in children 
with CF  
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The implication of this finding is that increases in minute ventilation in children with 
CF and hypoxia are similar to those of their normoxic counterparts. The reasons for this 
remain  unclear,  but  some  possible  explanations  are  discussed  below.  First,  hypoxic 
subjects have statistically lower vital capacity measured on forced manoeuvres (section 
4.4.2),  and  one  might  expect  greater  incremental  increases  in  respiratory  rate  on 
exercise  in  the  hypoxic  subjects,  to  account  for  the  similarities  observed  in  minute 
ventilation.  Previous  work  (Godfrey  and  Mearns  1971)  has  shown  that  increasing 
disease severity in CF leads to increases in physiological dead space and limitation of 
tidal volumes that are accompanied by markedly increased respiratory rate on exercise 
to  maintain  VE.  However,  no  differences  in  respiratory  rate  at  baseline  (p=0.22), 
anaerobic threshold (p=0.5), or peak exercise (p=0.11) were noted (Mann-Whitney U-
test).  
 
Secondly, an alternative explanation could be that improved airway clearance occurs on 
exercise leading to an ability to increase tidal volumes and maintain rate of increase in 
minute ventilation. Similar median (IQR) tidal volumes were noted between hypoxic 
and  normoxic  subjects  at  peak  exercise  [0.85(0.6,  1.25)  L  versus  1.0(0.84,  1.3)  L] 
(p=0.32, Mann-Whitney U-test), as well as at  AT [0.66(0.52, 0.83) versus 0.6(0.52, 
0.78), p=0.92; Mann-Whitney U-test]). This suggests that tidal volumes can increase on 
near-maximal  exercise  in  both  hypoxic  and  normoxic  CF  subjects.  However,  the 
percentage increase in tidal volumes between rest and peak exercise showed a trend 
(p=0.06, Mann-Whitney U-test) towards a smaller median (IQR) % increase in VT in 
hypoxic  [144(78,189)]  subjects  compared  with  normoxic  [179(133,232)]  controls 
(Figure 4.11). 
  
Figure 4.11 
Percentage change in tidal volumes from rest to peak exercise in hypoxic (
for >10%) and normoxic children with CF
 
 
 
Finally,  it  could  be  argued  that,  as  the  hypoxic  group  are  taller,  this  may  result  in 
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Percentage change in tidal volumes from rest to peak exercise in hypoxic (SpO2<93% 
 
Finally,  it  could  be  argued  that,  as  the  hypoxic  group  are  taller,  this  may  result  in 
elevated minute ventilation as a result of higher tidal volumes at baseline. However, 
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are,  on  average,  are  able  to  exceed  their 
ercise when comparing 
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In  the  hypoxic  (SpO2<93%  for  >10%  sleep  time)  group,  maximal  VE  measured  on 
exercise is a median (IQR) of 8.8 (0, 14.6) litres higher than the predicted (35xFEV1) 
MVV. In the normoxic group, predicted MVV was 10.2 (-25.9,-0.2) litres higher than 
measured maximal VE on exercise. A statistically significant difference is seen between 
hypoxic and normoxic subjects (p<0.001, Mann-Whitney U test). 
 
This concurs with early work on exercise and CF (Godfrey and Mearns 1971) which 
showed that exercise ventilation exceeded MVV in all those with more severe disease 
(MVV<50L.min
-1). 
 
4.4.7 Quality of life measures 
The cystic fibrosis questionnaire (CFQ) was successfully completed for 37 of the 41 
subjects.  In  three  cases  the  questionnaire  was  incorrectly  completed,  or  incomplete 
making scoring impossible. On one occasion, the questionnaire was not carried out. 
 
4.4.7.1 Demographic data for CFQ  
Twenty-three caregiver (6-13 years) CFQ questionnaires were completed, along with 13 
self-assessment  questionnaires  (14+  years),  13  self-assessment  questionnaires  (12-13 
years), and 2 Interviewer format (6-11 year olds) questionnaires.  
 
For purposes of standardisation, either caregiver (children aged 13 or under) or aged 
14+ questionnaires (children aged 14 or over) were entered into the study database for 
analysis. However, for two patients, 12/13 year old self-assessment questionnaires were 
analysed in the absence of a parental report. 
 
CFQ score (both average and for individual modalities) is expressed as a percentage, 
whereby a score of 100 represents perfect quality of life and a score of zero, abject 
misery. The average CFQ score varied between 39.1 and 94.4% with a median (IQR) 
quality of life score of 71.4% (58.3 to 86). Furthermore, the CFQ is divided into number 
of individual modalities. Median (IQR) scores and ranges of scores for each modality 
are shown below (Table 4.11).   175
Table 4.11 
CFQ data demographics for the study population (n=37) 
 
CFQ variable  Number of subjects  Median (IQR)  Range  
Age  37  13.1 (10.7, 14.8)  7.98-16.22 
Sex  19 Male/ 
18 Female 
-  - 
CFQ Average  37  71.4 (58.3, 86)  39.1-94.4 
CFQ Physical  37  83.3 (53.8, 96.3)  25-100 
CFQ School  23  88.9 (55.6, 77.8)  11.1-100 
CFQ Role  12  75 (66.7, 97.9)  25-100 
CFQ Vitality  35  60 (53.3, 80)  33.3-100 
CFQ Emotional  37  86.7 (73.3, 93.3)  53.3-100 
CFQ Social  14  75 (70.2, 83.3)  61.1-88.9 
CFQ Body  37  66.7 (44.4, 94.5)  11.1-100 
CFQ Eating  37  100 (50, 100)  0-100 
CFQ Treatment  37  55.6 (33.3, 77.8)  11.1-100 
CFQ Health  35  77.8 (66.7, 88.9)  33.3-100 
CFQ Weight  35  66.7 (33.3, 100)  0-100 
CFQ Respiratory  37  72.2 (50, 88.9)  22.2-100 
CFQ Digestion  37  88.9 (55.6, 100)  11.1-100 
Maximum score for each modality = 100 (CFQ score is a percentage) 
 
Because different scoring components are included in the CFQ 14+ and parent/caregiver 
(6 to 13 year olds) questionnaire, some modalities (school, role, social) are collated on 
small numbers of individuals. 
 
 
4.4.7.2 Hypoxia and quality of life as assessed by CFQ  
Data for both sleep studies and CFQ scores were obtained on 37 subjects.  
Dichotomisation into hypoxic and normoxic groups gave the following results (Table 
4.12).  
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Table 4.12 
Effects of hypoxia (SpO2<93% for >10% sleep time) on CFQ modalities in children 
with CF  
 
Variable  Study population (n=37) 
 
  Hypoxic (n=8) 
(SpO2<93% for >10% time) 
Normoxic (n=29)  p-value 
CFQ Average  62 (45, 70)  74 (66, 88)  p=0.03* 
CFQ Physical  50 (30, 86)  89 (70, 96)  p<0.05* 
CFQ Emotional  80 (68, 93)  87 (77, 93)  p=0.46* 
CFQ Eating  56 (37, 67)  100 (53, 100)  p=0.06* 
CFQ Weight  33 (0, 92)  100 (33, 100)  p=0.17* 
CFQ Treatment  44 (14, 78)  56 (44, 83)  p=0.35* 
CFQ Respiratory  58 (44, 85)  78 (61, 89)  p=0.19* 
CFQ Digestion  94 (67, 100)  89 (56, 100)  p=0.53* 
All values are median (IQR) *Mann-Whitney U-test 
 
CF  children  with  sleep  hypoxia  were  noted  to  have  statistically  significantly  lower 
average CFQ scores (Figure 4.14) than normoxic individuals. 
 
Figure 4.14 
Effects of hypoxia (SpO2<93% for >10% sleep time) on quality of life (as assessed by 
the average CFQ-UK score)  
 
Additionally, a weak relationship between mean sleep SpO2 and CFQ (r= 0.4, p=0.02 
Spearman Rank test) was observed (Figure 4.15).  
 
NORMOXIA  HYPOXIA 
(SpO2<93% for >10%) 
p=0.03, Mann-Whitney U-test 
Medians shown  
Figure 4.15 
Relationship between average CFQ score and mean sleep 
 
 
Significant (but weak) relationships were also noted between mean sleep 
health (r
2 =0.24, p=0.003), body (r
respiratory (r
2 =0.17, p=0.01) components of the CFQ score. 
 
Relationship between average CFQ score and mean sleep SpO2 
Significant (but weak) relationships were also noted between mean sleep 
=0.24, p=0.003), body (r
2 =0.12, p=0.04), physical (r
2 =0.15, p=0.02), and 
=0.17, p=0.01) components of the CFQ score.  
Normoxic sub
Hypoxic subject
r
2= 0.16, p=0.02,  
Spearman Rank test 
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Significant (but weak) relationships were also noted between mean sleep SpO2 and the 
=0.15, p=0.02), and 
Normoxic subject 
Hypoxic subject 
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4.4.7.3 Effects of exercise on quality of life as assessed by CFQ  
CPET  testing  and  satisfactory  completion  of  the  CFQ-UK  questionnaire  was 
successfully undertaken in 37 subjects.  
 
Firstly, aerobic fitness as assessed by peak oxygen uptake (VO2 peak) in mls.m-
2.min
-1 
shows  a  significant  relationship  with  average  CFQ  quality  of  life  score  (r
2  =0.37, 
p<0.001, Spearman rank test), as illustrated below (Figure 4.16). 
 
Figure 4.16 
Relationship between average CFQ score and VO2 peak 
 
Similar associations were seen between VO2 peak and individual CFQ modalities for 
physical (r
2= 0.42, p<0.001) and emotional (r
2= 0.34, p<0.001) well-being, as well as 
health (r
2= 0.46, p<0.001), vitality (r
2= 0.37, p<0.001), respiratory (r
2= 0.29, p=0.001), 
eating (r
2= 0.18, p<0.01), and body (r
2= 0.19, p<0.01) scores (Spearman rank test).  
 
The associations between VO2 at AT in mls.m
-2.min
-1 and quality of life scores are less 
strong than those seen at peak exercise. However, statistically significant associations 
were seen between VO2 at AT and the average CFQ score (r
2= 0.13, p=0.03), as well as 
physical (r
2 = 0.19, p<0.01) and emotional (r
2= 0.16, p=0.01) well-being modalities, and 
health (r
2= 0.26, p<0.01), vitality (r
2= 0.17, p=0.02) and respiratory (r
2= 0.14, p=0.02) 
scores (Spearman rank test). 
r
2
 = 0.37, 
Spearman rank test   179
4.4.8 Echocardiographic measures  
Echocardiography was undertaken in 40/41 of the study population. 
 
4.4.8.1 Demographic data for the study population 
Displayed below (Table 4.13) are the spread of echocardiographic measures recorded in 
the study population. It should be noted that 12 subjects had no detectable TR. 
 
Table 4.13 
Demography of echocardiogram data for the study population 
 
Variable  Study population (n=40) 
  Range  Median (IQR) 
Age  8 to 16.2  12.9 (10.7, 14.7) 
Sex  19M:21F  - 
LV wall thickness (in diastole) 
Interventricular septum - IVSd (mm) 
Posterior wall - PWd (mm) 
 
3.9 – 9 
4 - 10 
 
6.4 (5, 7) 
6 (5.5, 6.7) 
LV dimension # 
LVD (mm) 
 
30 - 56.2 
 
43.4 (40.5, 47) 
LV fractional shortening  
LVFS (%) 
 
28 - 46 
 
33 (30, 36) 
LV ejection fraction  
LVEF (%) 
 
42 - 78 
 
62 (58, 66) 
RV wall thickness (mm)  2 – 6.1  4 (3.2, 5) 
Tricuspid Regurgitation 
TRmax (m.s
-1) 
 
0 – 2.8 
 
1.9 (0, 2.2) 
Systolic pulmonary artery pressure 
sPAP (mmHg) 
 
5 - 37 
 
19.2 (5, 24.3) 
# n=27 
 
 
4.4.8.2 Hypoxia and echocardiographic measures 
Dichotomisation using the definition SpO2<93% for >10% sleep time as denoting 
hypoxia in CF, was undertaken and the echocardiogram data obtained from our study 
population was analysed thus (Table 4.14). 
  
Table 4.14 
Effects of hypoxia (SpO
 
Variable 
 
LV wall thickness 
(in diastole) 
IVSd (mm) 
PWd (mm) 
LV dimension # 
LVD (mm) 
LVFS (%) 
LVEF (%) 
RV wall thickness 
(mm) 
TRmax m.s
-1 
sPAP mmHg 
All values are median (IQR) *Mann
#  Only 23 normoxic and 4 hypoxic patients had LV dimension measured
 
Statistically greater right ventricle thickness was seen in hypoxic subjects (Figure 4.1
Additionally, increased LV posterior wall diameter was noted (Figure 4.
 
Figure 4.17 
Effects of hypoxia (SpO
  NORMOXIA 
p=0.04, Mann
SpO2<93% for >10% sleep time) on the heart in children with CF 
Study population (n=40)
 
Hypoxic (n=9) 
(SpO2<93% for >10% time) 
Normoxic (n=31)
LV wall thickness    
 
6.5 (5.5, 7.1) 
6.5 (6.1, 7.6) 
 
 
6.4 (5, 7)
6 (5.3, 6.4)
 
46 (42.3, 46.9) 
 
42.6 (40.2, 47)
35 (30, 38)  32 (29, 36)
65 (59, 71)  62 (57, 66)
RV wall thickness  4.3 (4.1, 5.1)  4 (3, 4.4)
1.8 (0.5, 2.6)  1.9 (0, 2.6)
18 (7, 31)  19 (5, 24)
All values are median (IQR) *Mann-Whitney U-test 
normoxic and 4 hypoxic patients had LV dimension measured
Statistically greater right ventricle thickness was seen in hypoxic subjects (Figure 4.1
Additionally, increased LV posterior wall diameter was noted (Figure 4.
SpO2<93% for >10% sleep time) on RV wall thickness 
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p=0.04, Mann-Whitney U-test 
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) on the heart in children with CF  
Study population (n=40) 
Normoxic (n=31)  p-value 
 
 
6.4 (5, 7) 
6 (5.3, 6.4) 
 
 
0.68* 
0.04* 
 
42.6 (40.2, 47) 
 
0.48* 
32 (29, 36)  0.44* 
62 (57, 66)  0.35* 
4 (3, 4.4)  0.04* 
1.9 (0, 2.6)  0.50* 
19 (5, 24)  0.55* 
normoxic and 4 hypoxic patients had LV dimension measured 
Statistically greater right ventricle thickness was seen in hypoxic subjects (Figure 4.17). 
Additionally, increased LV posterior wall diameter was noted (Figure 4.18). 
) on RV wall thickness   
The finding of increased
of pulmonary hypertension, 
the groups. Indeed no TR whatsoever was recordable in over ¼ of patients studied.
 
Figure 4.18 
Effects of hypoxia (SpO
 
 
 
The finding of increased LV geometry is not previously reported in CF, but has been 
reported in obstructive sleep apnoea, another paediatric disorder causing intermittent, 
repeated hypoxic episodes (Amin 
 
Amin and colleagues (Amin 
(Devereux et al. 1986). This formula allows calculation of LV mass as: 
dimension + IVSd + PWd]
septal and posterior wall thickness in cm. measured in diastole, and LV dimension to 
the  end-diastolic  dimension  (in  cm.)  of  the  LV.  Division  by  (height)
construct  the  LV  mass  index  (de  Simone 
subjects in our study population had a measure of LV dimension made, including only 
4/9 of the hypoxic group. This makes statistical comparison between the two groups 
impossible. No trends were seen, and the 23 normoxic subject
mass index of 29.6 (23.9, 32.3) g m
hypoxic subjects on whom LV dimension were measured (p=0.58, Mann
test). 
p=0.04, Mann
NORMOXIA 
The finding of increased RV wall thickness may suggest that this measure is a precursor 
of pulmonary hypertension, at a time when no differences in sPAP were noted between 
the groups. Indeed no TR whatsoever was recordable in over ¼ of patients studied.
SpO2<93% for >10% sleep time) on LV posterior wall thickness 
The finding of increased LV geometry is not previously reported in CF, but has been 
reported in obstructive sleep apnoea, another paediatric disorder causing intermittent, 
peated hypoxic episodes (Amin et al. 2002).  
Amin and colleagues (Amin et al. 2002) calculated LV mass using a published formula 
1986). This formula allows calculation of LV mass as: 
dimension + IVSd + PWd]
3 − LV dimension
3)]} + 0.6 where IVSd and PWd refer to 
septal and posterior wall thickness in cm. measured in diastole, and LV dimension to 
diastolic  dimension  (in  cm.)  of  the  LV.  Division  by  (height)
construct  the  LV  mass  index  (de  Simone  et  al.  1992).  Unfortunately,  only  27/41 
subjects in our study population had a measure of LV dimension made, including only 
4/9 of the hypoxic group. This makes statistical comparison between the two groups 
impossible. No trends were seen, and the 23 normoxic subjects had a median (IQR) LV 
mass index of 29.6 (23.9, 32.3) g m
-2.7 compared with values of 26.2 (18, 30.9) in the 4 
hypoxic subjects on whom LV dimension were measured (p=0.58, Mann
p=0.04, Mann-Whitney U-test 
Medians shown 
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RV wall thickness may suggest that this measure is a precursor 
at a time when no differences in sPAP were noted between 
the groups. Indeed no TR whatsoever was recordable in over ¼ of patients studied. 
) on LV posterior wall thickness  
 
The finding of increased LV geometry is not previously reported in CF, but has been 
reported in obstructive sleep apnoea, another paediatric disorder causing intermittent, 
2002) calculated LV mass using a published formula 
1986). This formula allows calculation of LV mass as: 0.8 {1.04[([LV 
where IVSd and PWd refer to 
septal and posterior wall thickness in cm. measured in diastole, and LV dimension to 
diastolic  dimension  (in  cm.)  of  the  LV.  Division  by  (height)
2.7  is  used  to 
Unfortunately,  only  27/41 
subjects in our study population had a measure of LV dimension made, including only 
4/9 of the hypoxic group. This makes statistical comparison between the two groups 
s had a median (IQR) LV 
compared with values of 26.2 (18, 30.9) in the 4 
hypoxic subjects on whom LV dimension were measured (p=0.58, Mann-Whitney U-
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4.5 Discussion 
4.5.1 Which is more important – sleep hypoxia or exercise hypoxia? 
Sleep and exercise hypoxia may represent different pathophysiological defects. At the 
outset of this work it was unknown which is the more relevant assessment with the 
greatest clinical impact (section 3.2).  
 
Following  the  analysis  of  the  above  results,  clear  differences  can  be  seen  between 
children with CF and nocturnal hypoxia and their normoxic counterparts. Subjects with 
sleep hypoxia (SpO2<93% for >10% sleep time) in CF have, when compared to their 
normoxic counterparts: 
•  Reduced exercise capacity 
•  Lower Body Mass Index 
•  Lower FEV1 
•  Lower FVC 
•  Lower mid-expiratory flows 
•  Worse gas-trapping as measured by elevation of RV/TLC ratio 
•  Higher Chrispin-Norman chest radiograph scores 
•  Greater number of intravenous antibiotic courses 
•  Worse quality of life as assessed by the CFQ-UK 
•  Increased right ventricle thickness 
•  Increased left ventricle (posterior wall) diameter 
 
Such  differences  were  not  observed  when  subjects  with  exercise-induced  arterial 
hypoxia were compared with controls (data not shown). Previous papers suggest the 
pathophysiological  mechanisms  for  sleep  and  exercise  hypoxia  in  CF  are  different. 
Airflow limitation related to increase in physiological dead space is reported to be the 
mechanism by which exercise hypoxia ensues (Godfrey and Mearns 1971), although no 
evidence for this was found in our study population, with no differences in resting mid-
expiratory flows between EIAH and normoxic groups. Flow-volume loops associated 
with exercise were not analysed, however. Alternatively, dynamic hyperinflation during 
exercise has been put forward as a potential mechanism for causation of EIAH, but 
again, no differences in RV/TLC ratios between those with EIAH and the normoxic 
group were noted. 
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It appears that hypoxia during sleep, a frequently-repeated (daily) and more prolonged 
hypoxic insult than EIAH, is associated with greatest clinical impact in CF.  The effect 
of sample size cannot however be discounted, and subject numbers with EIAH were 
smaller. 
 
4.5.2 Sleep Hypoxia – definitions and outcomes 
Previous authors (Bradley et al. 1999, Coffey et al. 1991) have noted that hypoxia in CF 
is more likely to occur in sleep than on exercise, because of changes in muscle tone and 
relative  hypoventilation,  suggesting  that  assessment  during  sleep  may  be  the  most 
relevant assessment of hypoxia in CF.  
 
Various definitions have been used to define hypoxia in CF based on its relationship to 
inflammation, as outlined in Chapter 3 and led us to propose a new definition of sleep 
hypoxia (SpO2<93% for >10% sleep time).  
 
4.5.3 Who needs a sleep study? - Prediction of nocturnal hypoxia in CF 
The  American  Thoracic  Society  (ATS)  recommendations  published  in  1996  (Am  J 
Respir  Crit  Care  Med  1996;  153:  866-878)  suggest  that  sleep  studies  should  be 
performed in CF as follows: 
 
1.  CF subjects with awake PaO2 <70mmHg (or SpO2 <95%) should have an 
overnight oximetry during a period of disease stability. 
 
2.  Patients with polycythaemia or cor pulmonale, and those who complain of 
headache on wakening, daytime sleepiness, or disturbed sleep patterns should 
have an overnight oximetry. 
 
3.  Patients with CF receiving supplemental oxygen may require a full 
polysomnography (PSG) to rule out OSA in those with snoring and sleep 
disturbance. 
 
4.  PSG may also help assess potential adverse effects of oxygen in CF i.e. 
promotion of hypercapnia in those with advanced lung disease. 
 
 
Whilst recommendations 3 and 4 are self-evident, recommendations 1 and 2 require 
closer scrutiny.    184
Recommendation 1: Comment 
Firstly, daytime SpO2 are a poor predictor of sleep desaturation in CF. Versteegh and 
colleagues  reported  SpO2<94%  as  the  best  independent  predictor  of  nocturnal 
hypoxaemia (Versteegh et al. 1990) in patients with CF. The other reference alluded to 
in the ATS statement studied daytime blood gas recordings in 14 CF patients aged 9-34 
years  (Montgomery  et  al.  1989),  and  compared  these  to  overnight  oximetry  data. 
However, blood gases are not routinely done in children with CF. 
 
Frangolias’ group studied 70 adults with CF in whom 40% had significant nocturnal 
hypoxaemia  (Frangolias  et  al.  2001).  Using  resting  SpO2  of  93%  as  a  cut-off  for 
predicting nocturnal hypoxaemia they found that 3/3 patients with a resting SpO2<93% 
were hypoxemic at night, but 24/67 with resting SpO2>93% had nocturnal hypoxaemia 
also.  These  data  can  be  used  to  construct  sensitivity  (11%)  and  specificity  (100%) 
values  for  SpO2  of  <93%  as  a  predictor  of  nocturnal  hypoxaemia  in  CF.  One  can 
construct  Likelihood  Ratios  (LR+  infinite,  LR-  0.89),  and  using  a  prevalence  of 
nocturnal hypoxaemia of 40%, post-test probabilities can be calculated. One starts with 
a pre-test probability of nocturnal hypoxaemia of 40% in an adult CF patient group. If 
resting SpO2 is below 93%, then the probability of nocturnal hypoxaemia rises to 100%, 
whereas if resting SpO2 is above 93%, the probability of nocturnal hypoxaemia falls to 
37%. Therefore, resting SpO2 when less than 93% (and it rarely is) is a useful predictor 
of nocturnal hypoxaemia, but a sleep study is needed to confidently rule in/rule out 
hypoxaemia in the remainder.  
 
Similarly,  an  Australian  study  reported  that  in  children  with  significant  nocturnal 
hypoxaemia  (average  SpO2  during  sleep  <90%),  19%  had  resting  SpO2>94%  and 
therefore 1 in 5 would have been missed without a sleep study (Milross et al. 2001). 
 
Recommendation 2: Comment 
For  subjects  with  polycythaemia  or  cor  pulmonale,  and  those  who  complain  of 
headache  on  wakening,  daytime  sleepiness,  or  with  disturbed  sleep  patterns,  an 
overnight oximetry alone is an inappropriate and incomplete investigation. Monitoring 
of  CO2  is  required,  be  it  transcutaneous  pCO2  recording,  early-morning  arterial  or 
capillary blood gas analysis, or end-tidal measures as part of a full PSG. Clearly full 
PSG may not be available in all centres, but would provide the gold standard in such 
scenarios, as sleep disturbance can be directly correlated with stage of sleep.   185
4.5.3.1 Who needs a sleep study? – The role of lung function in the prediction of 
nocturnal hypoxia in CF  
Lung  function  did  not  feature  in  the  1996  ATS  recommendations,  although  an 
association between sleep SpO2 and FEV1 has been reported (Pond and Conway 1995). 
Our work supports the notion that FEV1 may be a potentially important predictive index 
for  nocturnal  desaturation.  Using  the  de  novo  paediatric  definition  of  sleep  hypoxia 
(SpO2  <93%  for  >10%  sleep  time),  the  utility  value  of  lung  function  cut-offs  were 
assessed using ROC statistics (Figure 4.19). Lung function cut-offs [Rosenthal] were 
considered thus: 
 
i)   FEV1 <80% predicted  
ii)   FEV1 <70% predicted  
iii)   FEV1 <65% predicted  
iv)   FEV1 <60% predicted  
v)   FEV1 <55% predicted  
 
Figure 4.19 
ROC  curve  of  performance  of  various  cut-offs  of  FEV1  in  the  identification  of 
childhood CF subjects with hypoxia (SpO2<93% for >10% sleep time) 
 
Area under curve: 
FEV1 <80% predicted = 0.73 
FEV1 <70% predicted = 0.84 
FEV1 <65% predicted = 0.89 
FEV1 <60% predicted = 0.92 
FEV1 <55% predicted = 0.84 
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Previous  authors  have  suggested  a  cut  off  of  FEV1  <65%  predicted  to  be  the  most 
sensitive  and  specific  predictor  of  hypoxia  (section  1.3.5.2.3.2).  Versteegh  and 
colleagues  established  that  an  FEV1  <65%  predicted  was  88%  sensitive  and  50% 
specific (positive predictive value [PPV] 47%)  in detecting hypoxia measured as a 
lowest hourly mean SpO2 below 90% (Versteegh et al. 1990). Frangolias’ group report 
93% sensitivity and 44% specificity (PPV 51%) for FEV1 <65% predicted in detecting 
SpO2<90% for >5% sleep time (Frangolias et al. 2001).  
 
If a cut off of FEV1 <65% predicted were used to detect hypoxia defined as SpO2<93% 
for >10% sleep time in our study population, this would be 100% sensitive and 78% 
specific in the detection of hypoxia with a positive predictive value of 56%. 
 
The greatest area under the curve is, however, seen for FEV1 <60% predicted, and this 
is the predictive measure with the best sensitivity/specificity trade-off (Table 4.15). 
 
Table 4.15 
2x2 table on use of FEV1 <60% predicted in the detection of hypoxia (SpO2 <93% for 
>10% sleep time) in children with CF 
 
  Hypoxia: 
SpO2 <93% for >10% sleep time 
Normoxia: 
 
FEV1 <60% predicted  9  5 
FEV1 >60% predicted  0  27 
 
FEV1 <60% predicted 
Sensitivity for detection of sleep hypoxia: 100% 
Specificity for detection of sleep hypoxia: 84% 
Positive predictive value for detection of sleep hypoxia: 64% 
   
It therefore appears that lung function assessment may be useful in the detection of 
hypoxia in CF. For example, if we were to study all CF children with FEV1 <60% 
predicted, two hypoxic (SpO2<93% for >10% sleep time) children would be detected 
for every 3 sleep studies performed. 
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4.5.4 Limitations of study 
As discussed in section 3.8.2.3, the use of oximetry alone as our sleep study method has 
some disadvantages namely: 
 
a)  False negative results 
Oximetry-only studies may be associated with false negative results, i.e. subclinical 
obstructive events or arousals may be missed. However, hypoxia is either present or 
absent on the study, and oximetry appears both sensitive and specific in the detection of 
hypoxia.  
 
b)  Lack of information on sleep state 
Sleep state is unknown, to the point that subjects could have been awake all night, 
although verbal reports from parents confirmed all were sleeping. Baseline SpO2 were 
low, with little heart rate variability or SpO2 dips seen on analyses of oximetry studies 
of each of the hypoxic individuals; suggesting hypoventilation is occurring throughout 
sleep  (both  REM  and  non-REM).  Without  EEG  monitoring  the  sleep  phases  are 
unknown, however.  
 
c)  Cause of hypoxia on study remains speculative 
Furthermore, an assumption is made that desaturations seen in our study population 
were not due to obstruction. This appears a reasonable assumption to make, given the 
rationale of point b) above, and non-obstructive hypoventilation seems most likely to 
explain the study findings. A limitation of the study is that data on snoring were not 
collected. 
 
The strengths of oximetry were the performance of the study at home, and at a time of 
clinical  stability.  Each  case  was  standardised  so  that  oximetry  preceded  the 
measurement  of  clinical  and  inflammatory  outcomes.  A  number  of  the  previously 
published studies alluded to in this thesis used oximetry alone to assess hypoxia during 
sleep (Coffey et al. 1991, Versteegh et al. 1990, Frangolias et al. 2001) whilst others 
(Milross  et  al.  2001)  performed  full  PSG.  Furthermore,  oximetry  alone  is  the 
recommended  first-line  investigation  of  hypoxaemia  in  CF  in  the  ATS 
recommendations for cardiopulmonary sleep studies in children as discussed in section 
4.5.3. 
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d)  Study numbers 
Further  limitations  lie  in  the  study  numbers  and  the  inability  to  perform  multiple 
regression analyses to assess for potential confounding factors that might have an effect 
on outcome measures. For example, the relationship between hypoxia, lung function 
and Pseudomonas aeruginosa (PA) may be important. However, the fact that only 4/41 
subjects had never grown PA, and these were all in the normoxic group made such a 
relationship impossible to ascertain. Larger numbers would have allowed identification 
of, and correction for, other factors/confounders. 
 
4.5.5 Adaptation to hypoxia in CF 
Our data concur with previous work (Stein et al. 2003), that use of 35 x FEV1 as a 
predictor of MVV (Fulton et al. 1995; Sexauer et al. 2003) will underestimate the MVV 
in CF. Furthermore, earlier work (Godfrey and Mearns 1971) showed that VE max on 
exercise was increasingly likely to exceed MVV in CF subjects as lung disease severity 
worsened.  
 
Fourteen of our subject group had VE max on exercise which exceeded their predicted 
MVV (Figure 4.13). The degree of underestimation has been reported to be proportional 
to the degree of airflow limitation (Stein et al. 2003). Our data do not directly support 
these findings, with no significant associations seen between VE max and z scores for 
FEV1, FVC or mid-expiratory flows. However, the hypoxic group had a VE max on 
exercise  that  was,  on  average  higher  than  predicted  MVV,  as  well  as  statistically 
significantly lower lung volumes and airflows (Table 4.5).  
 
Hypoxic and airflow-limited CF patients have an innate capacity to increase VE, which 
is rate-dependent in the absence of ability to further increase VT. Mechanisms for this 
may include changes in chemoreceptor sensitivity, central effects on respiratory drive, 
as  well  as  the  effects  of  preservation  of  respiratory  muscle  strength  (Aldrich  et  al. 
1982), a phenomenon seen in the hypoxic subjects studied. A study of healthy adult 
volunteers showed that increases in VE on exercise under hypoxic conditions exceeded 
the  VE  dynamics  of  exercise  in  air  (Fukoaka  et  al.  2003).  Altered  carotid  body 
chemoreceptor  sensitivity,  as  well  as  the  effect  of  muscle  chemoreceptors  on  the 
respiratory centre were considered most likely explanations for this phenomenon.  
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Genetic  influences  such  as  the  known  effect  of  the  ACE  genotype  on  hypoxic 
ventilatory responses (HVR) also are worthy of consideration. Previous work has shown 
that increases in VE on exercise under hypoxic condition were significantly greater in 
those with an II genotype (Patel et al. 2003). The effects of ACE polymorphism on VE 
in our study population will be considered in Chapter 5. There are more questions than 
answers, and there is scope for future studies to further our knowledge of HVR in the 
childhood CF population. 
 
4.6 Conclusions 
CF subjects with sleep hypoxia were noted to have, when compared to normoxic 
controls: 
•  Reduced exercise capacity 
•  Lower Body Mass Index 
•  Lower FEV1 
•  Lower FVC 
•  Lower mid-expiratory flows 
•  Worse gas-trapping as measured by elevation of RV/TLC ratio 
•  Higher Chrispin-Norman chest X-ray scores 
•  Greater number of intravenous antibiotic courses 
•  Worse quality of life as assessed by the CFQ-UK 
•  Increased left and right ventricle thickness 
 
Such findings serve to verify that an association between hypoxia and adverse clinical 
status exists.  
 
The  question  of  hypoxia  being  cause  or  effect  in  theses  associations  remains 
unanswered. Clearly hypoxia may arise as an end result of severe CF lung disease, but 
the evidence reviewed in the introductory chapter suggest also that hypoxia could be an 
effector  mechanism  for  perpetual  neutrophilic  inflammation,  leading  to  a  pro-
inflammatory state and deleterious clinical sequelae. Chapter 6 describes a set of in vitro 
experiments designed to assess the effects of hypoxia on IL-8 mediated inflammation in 
CF bronchial epithelial cells, in an attempt to delineate whether hypoxia can be a direct 
cause of inflammation in the CF airway. 
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If it is true that hypoxia can be both cause and effect of lung inflammation in children 
with CF, then trials of mechanisms of restoration of normoxia (oxygen therapy and/or 
non-invasive ventilation) and their effects on amelioration of inflammation and clinical 
status appear worthy of consideration.  
 
The role of exercise as an anti-inflammatory therapy in CF is also an area of interest. 
Long-term  oxygen  therapy  during  exercise  in  hypoxic  CF  subjects  has  potential 
cumulative benefits (Elphick and Mallory Jr. 2009).  
 
Exercise  capacity  was  chosen  as  a  primary  outcome  of  our  study  because  of  the 
purported  relationship  that  exercise  and  hypoxia  may  exert  on  lung  disease  in  CF 
(Figure  1.5).  It  is  known  that  exercise  improves  airway  clearance,  and  this  may  be 
beneficial in minimising bacterial load and prevention of worsening lung inflammation. 
In  addition,  an  immunological  mechanism  for  exercise  exerting  anti-inflammatory 
benefit has been reported (Petersen and Pedersen 2006) and the CF patient group would 
potentially benefit from this. 
 
Hypoxic subjects achieved lower work rates and have diminished exercise capacity at 
both peak exercise capacity and AT. Quality of life scores are also lower in the hypoxic 
group (Table 4.12, Figures 4.14 and 4.15), and our data also show that quality of life is 
related  to  exercise  capacity  (Figure  4.16),  with  a  VO2  –  CFQ  association  (r=0.61, 
p<0.001,  Spearman)  seen.  Therefore,  exercise  may  help  to  bring  about  beneficial 
psychological as well as physiological effects. These data suggest exercise prescription 
may be a beneficial therapeutic intervention in hypoxic CF subjects. 
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CHAPTER 5:  
Relationship  between  hypoxia  and  surrogate  measures  of 
inflammation in children with cystic fibrosis 
 
5.1 Introduction 
In Chapter 4, the suggested definition of hypoxia (SpO2 <93% for 10% sleep time) was 
used to dichotomise the study population and assess the association of hypoxia with 
clinical,  radiological,  physiological  and  psychological  outcome  measures  in  children 
with CF. Chapter 5 seeks to apply this definition of hypoxia to surrogate measures of 
inflammation in CF. 
 
5.2 Aims 
The aim of this chapter is to investigate the relationship between measures of hypoxia 
and inflammatory parameters, namely: 
-  ACE genotype 
-  Exhaled breath condensate inflammatory markers 
-  Skeletal muscle (Quadriceps and hand-grip) strength measures  
-  Bone densitometry data 
The  rationale  for  measuring  each  of  the  above  as  a  surrogate  marker  of  lung 
inflammation is outlined below: 
 
5.2.1 ACE genotype 
The  ACE  I/D  polymorphism  described  previously  codes  for  an  insertion/deletion 
polymorphism within the ACE gene. Those with DD genotype have increased serum 
and tissue ACE activity (Danser et al. 1995) and are thought to be at increased risk of 
lung inflammation. 
 
5.2.2 Exhaled breath condensate inflammatory markers 
A full raft of pro- and anti-inflammatory cytokines were measured including IL-8 which 
for reasons above may be central to the process of ongoing airway inflammation in CF. 
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5.2.3 Skeletal muscle (Quadriceps and hand-grip) strength measures  
AND 
5.2.4 Bone densitometry data 
These measures may be indirect markers of the consequences of inflammation in CF. 
Putative deleterious effects that may arise from being in a pro-inflammatory state in CF 
include muscle-wasting (Gan et al. 2003), and CF bone disease (Haworth et al. 2004). 
The mechanism by which these effects occur is thought to be due to up-regulation of 
catabolic cytokines including TNF-α and IL-6. 
 
5.3 Methods 
Measures of inflammation (inflammatory markers in exhaled breath), the predisposition 
to  inflammation  (ACE  genotype)  and  the  end  results  of  inflammation  (wasting  of 
muscle and bone) were made. These are each described below. 
 
5.3.1 ACE genotype 
Briefly, ACE genotype for the I/D polymorphism was established using a three-primer 
PCR set up with MADGE gel electrophoresis used to visualise the DNA amplification 
products (Section 2.2.2.6.7). This work was carried out in conjunction with Dr Christina 
Hubbart, Rayne Institute, University College London. 
 
5.3.2 Exhaled breath condensate (EBC) 
Samples were collected as per the methods of section 2.2.2.5.1. Oral inhalation-
exhalation for 20 minutes of tidal breathing was undertaken, using a commercially 
available system (ECoScreen, Jaeger, Hoechberg, Germany). A nose-clip was worn in 
accordance with the ATS/ERS recommendations (Horvath et al. 2005).  
EBC was immediately frozen at –80
oC and used for later cytokine analyses.  A human 
10-plex kit (BioSource International Inc., Camarillo, California) was used to assay EBC 
levels of IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IFN-γ, GM-CSF and TNF-α,  using 
Luminex technology (section 2.2.2.5.2.2). The methodology is identical to that used for 
the analysis of serum by this method. Furthermore, an ultrasensitive ELISA assay for 
quantification of interleukin-8 (IL-8) levels in EBC (section 2.2.2.5.2.1). 
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5.3.3 Skeletal muscle strength measurement 
Measures of proximal (quadriceps isometric voluntary contraction), and distal (handgrip 
strength dynamometry) musculature were undertaken: 
 
5.3.3.1 Quadriceps isometric voluntary contraction 
Maximal  voluntary  isometric  contractions  were  measured  using  a  custom-built 
isometric  dynamometer  (University  College  [Royal  Free  Campus]  Medical  School 
Physiology Department), as per the methodology of section 2.2.2.9.1.  
 
Briefly, with the subject sat upright with knee flexed to 90
O, a clamp placed above the 
ankle transmitted knee extensor force via an inextensible chain to a strain gauge bar. 
Subjects maintained maximal contraction for 2-3 seconds and then relaxed. Forces from 
the strain gauge bar were amplified and displayed on a chart recorder. Maximal forces 
achieved by voluntary quadriceps contraction in our study subjects were converted to 
standard deviation scores (SDS) using validated reference data (Backman et al. 1989). 
 
5.3.3.2 Handgrip strength dynamometry 
Distal skeletal muscle strength was assessed by peak force measurements made using a 
Jamar  hydraulic  hand  dynamometer  (Sammons  Preston,  Bolingbrook,  IL,  USA),  in 
accordance with the methods of section 2.2.2.9.2.  
 
Briefly, alternate dominant and non-dominant hand grip strength measures were made 
one minute apart (3 measures per side). The maximal force generated was recorded. 
Maximal handgrip strength values from our study subjects were converted to standard 
deviation scores (SDS) using this validated reference data (Mathiowetz et al. 1986). 
 
5.3.4 Bone densitometry 
Briefly,  children  underwent  dual  energy  X-ray  absorptiometry  (DXA)  scans  (Lunar 
Prodigy, GE Medical Systems). Bone mineral density (BMD) measures were calculated 
from  measures  of  bone  mineral  content  and  bone  area  and  converted  to  z  scores. 
However, it is known that BMD is underestimated in small subjects, and overestimated 
in tall subjects (Fewtrell et al. 2003). Therefore, a volumetric assessment – the bone 
mineral apparent density (BMAD) was undertaken to adjust for calculated bone volume 
rather than bone area, and again values were converted to BMAD z scores.    194
5.4 Results 
First, anthropometric and demographic data for the study population has already been 
displayed (section 4.4.1), as well as a breakdown for groups when dichotomised for 
sleep and exercise hypoxia. 
 
5.4.1 ACE genotype 
ACE genotyping was successfully undertaken in forty of the 41 subjects. 
 
5.4.1.1 Distribution of ACE genotype across study population 
Subjects ranged from 7.98 to 16.22 years of age, with a mean (sd) age of 12.6 (2.4) 
years, and a median age of 12.9 years. Twenty-one subjects analysed were female, and 
19 male. The reason that no ACE genotype was established in 1 subject was due to 
insufficient  blood  being  obtained.  The  distribution  of  ACE  genotype  in  our  study 
population  was  as  follows  (Table  5.1).  The  observed  gene  frequency  in  our  study 
population - D allele frequency 56%, I allele 44% is similar to that reported in the 
literature for a UK-based sample population - 49% D allele and 51% I allele (Nagi et al. 
1995). 
 
Table 5.1 
Gene frequencies for ACE polymorphism 
ACE genotype  Study population (n=40) 
 
  OBSERVED  EXPECTED 
ID  19  19.7 
DD  8  7.6 
II  13  12.7 
χ
2 =0.048, p>0.50 
The ACE polymorphism obeys Hardy-Weinberg equilibrium in our study population. 
The full Hardy-Weinberg equilibrium calculation is provided in Appendix 5. 
 
5.4.1.2 Hypoxia and ACE genotype  
Similar distribution for ACE genotype was seen for both hypoxic and normoxic groups 
when  existing  definitions  of  sleep  hypoxia  were  applied  (Table  5.2),  with  Hardy-
Weinberg equilibrium preserved.  
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Table 5.2 
ACE genotype and hypoxia defined as SpO2 <93% for 10% sleep time 
 
  Study population (n=40) 
 
  ID  II  DD 
Hypoxia (n=9)  4  1  4 
Normoxia (n=31)  15  12  4 
 
 
5.4.2 Exhaled breath condensate (EBC) cytokine analyses  
 
5.4.2.1 EBC cytokine levels by Luminex analyses 
The human 10-plex cytokine assay utilised (BioSource International Inc., Camarillo, 
California) uses Luminex technology to assay levels of 10 different cytokines – IL-1β, 
IL-2,  IL-4,  IL-5,  IL-6,  IL-8,  IL-10,  Interferon  gamma  (IFN-γ ,  granulocyte  and 
macrophage colony stimulating factor (GM-CSF) and TNF-α. Using this kit to assay 
raw EBC samples (neither concentrated or diluted), no cytokines were detected. For 
interleukin-8, the range in which IL-8 can be detected is from 16.5 to 4000 pg.mL
-1. 
 
5.4.2.2 EBC interleukin-8 [IL-8] levels 
An ultrasensitive IL-8 assay was also used to detect lower concentrations of IL-8 
(Biosource ultrasensitive IL-8 [KHC0084] ELISA assay). This assay will detect IL-8 
levels in the range of 0.39pg.mL
-1 to 25pg.mL
-1. 
 
In  our  hands  the  KHC0084  ELISA  kit  detected  only  1  positive  EBC  sample  at  a 
concentration of 0.4pg.mL
-1.The kit did however correctly pick up a sample spiked with 
a  known  concentration  of  IL-8  and  variability  between  this  sample  and  standard  of 
similar  concentration  was  <10%.  The  subject  identified  was  markedly  hypoxic  with 
78.9% of the night spent with SpO2 <93%, and a lowest exercise saturation of 85%. 
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5.4.3 Skeletal muscle strength 
Measures  of  proximal  muscle  strength  (quadriceps  maximal  isometric  voluntary 
contraction) and distal muscle strength (handgrip) are presented. 
 
 
5.4.3.1 Quadriceps maximal isometric voluntary contraction (MIVC) 
Quadriceps force was successfully measured in all forty-one subjects (Table 5.3).  
 
Table 5.3 
Quadriceps MIVC for the study population as a whole 
 
Variable  Study population (n=41) 
  Range  Median (IQR) 
Dominant Leg     
Quadriceps MIVC (N)  82 to 498  172 (136, 239) 
Quadriceps MIVC (N.m
-2)  63 to 295  144 (112, 173) 
Quadriceps MVC SDS  -3.6 to 4.4  -0.7 (-1.5, 0.1) 
Non-dominant Leg     
Quadriceps MIVC (N)  70 to 447  154 (126, 216) 
Quadriceps MIVC (N.m
-2)  61 to 274  128 (103, 165) 
Quadriceps MVC SDS  -3.7 to 4.1  -1.3 (-2, -0.5) 
 
 
As  a  group,  our  study  population  had  median  quadriceps  strength  values  that  are 
approximately 0.7 to 1.3 standard deviations below that of the reference population. 
However, there were children within our study population with stronger than muscles 
than healthy subjects.  
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5.4.3.1.1 Hypoxia and quadriceps MIVC 
No differences in quadriceps strength were observed when either existing or de novo 
definitions of nocturnal hypoxia were used to dichotomise the study population (Table 
5.4). 
 
Table 5.4 
Quadriceps MIVC and hypoxia defined as SpO2<93% for >10% sleep time 
 
Variable  Study population (n=41) 
 
  Hypoxic (n=9) 
 
Normoxic (n=32)  p-value 
Dominant Leg       
Quadriceps MIVC (N)  185 (129, 280)  166 (138, 232)  0.59* 
Quadriceps MIVC (N.m
-2)  146 (109, 170)  143 (110, 178)  0.89* 
Quadriceps MIVC SDS  -0.6 (-2, -0.1)  -0.8 (-1.6, 0.5)  0.99* 
Non-dominant Leg       
Quadriceps MIVC (N)  175 (119, 232)  151 (126, 208)  0.61* 
Quadriceps MIVC (N.m
-2)  122 (98, 162)  129 (103, 166)  0.63* 
Quadriceps MIVC SDS  -1.3 (-1.9, -0.9)  -1.3 (-2, 0)  0.63* 
Figures given are median (IQR) * Mann-Whitney U-test     
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5.4.3.2 Handgrip strength dynamometry 
Handgrip strength of the dominant hand was successfully measured in all forty-one 
subjects (Table 5.5), but that of the non-dominant hand was only measured in 40 
subjects as one child had a fracture of the non-dominant wrist. 
 
Table 5.5 
Handgrip strength for the study population as a whole 
 
Variable  Study population (n=41) 
  Range  Median (IQR) 
Dominant Hand     
Handgrip force (N)  8 to 41  17 (14, 23) 
Handgrip force SDS  -5.1 to 0.7  -1.2 (-1.9, 0.5) 
Non-dominant Hand     
Handgrip force (N)  7 to 37  17 (12, 21) 
Handgrip force SDS  -4.9 to 0.4  -1.0 (-1.7, -0.5) 
 
5.4.3.2.1 Hypoxia and handgrip strength 
No differences in handgrip strength were observed when the de novo definition of 
nocturnal hypoxia was used to dichotomise the study population (Table 5.6). 
 
Table 5.6 
Handgrip strength and hypoxia defined as SpO2<93% for >10% sleep time 
   
Variable  Study population (n=40) 
 
  Hypoxic (n=9)  Normoxic (n=31)  p-value 
Dominant Hand       
Handgrip force (N)  20 (17, 27)  16 (14, 22)  0.15* 
Handgrip force SDS  -1.1 (-1.3, -0.4)  -1.2 (-2.2, -0.5)  0.17* 
Non-dominant Hand       
Handgrip force (N)  18 (16, 23)  14 (12, 19)  0.18* 
Handgrip force SDS  -0.9 (-1.8, -0.6)  -0.9 (-1.2, -0.3)  0.26* 
Figures given are median (IQR) * Mann-Whitney U-test     
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5.4.4 Bone densitometry 
Thirty subjects out of the total study population underwent bone densitometry within a 
year of the date of their exercise test, either for clinical reasons or as part of a separate 
research study. 
5.4.4.1 Bone densitometry data for study population 
The baseline characteristics of the 30 subjects who underwent bone densitometry are 
displayed  below  (Table  5.7).  The  baseline  characteristics  are  similar  to  that  for  the 
whole study population (Table 4.1). Bone densitometry data, in the form of raw (BMD) 
and adjusted (BMAD) bone mineral density z scores are displayed also. 
 
Table 5.7 
Demographic data for the 30 subjects that underwent bone densitometry 
Variable  Study population (n=30) 
  Range  Median (IQR) 
Age  8 to 15.7  12.4 (10.7, 13.9) 
Sex  15M:15F  - 
 
Height SDS 
 
-2.1 to +1.8 
 
-0.4 (-1.1, +0.2) 
Weight SDS  -2 to 1.7  -0.6 (-1.2, +0.4) 
BMI SDS  -1.9 to +2  -0.3 (-0.8, +0.3) 
 
CFTR genotype 
•  ∆F508/∆F508 
•  ∆F508/Other 
•  Other/Other 
 
 
18 
10 
2 
 
 
- 
- 
- 
 
Lung function 
FEV1 SDS 
FVC SDS 
 
 
-5 to 1.2 
-4 to 1.3 
 
 
-1.7 (-3, -0.9) 
-0.7 (-2, 0) 
 
Pseudomonas aeruginosa 
infection 
(Ever versus never) 
 
Ever (n=26)  
versus  
Never (n=4) 
 
- 
 
- 
 
Staphylococcus aureus infection 
(Ever versus never) 
 
Ever (n=24)  
versus  
Never (n=6) 
 
- 
 
- 
 
BMD z score 
 
-4.2 to +0.7 
 
-0.8 (-1.4, -0.3) 
BMAD z score  -2.8 to +2.2  -0.4 (-1.2, +0.3) 
  
5.4.4.1.1 Bone densitometry
Hypoxic subjects (SpO
lower size corrected bone density (BMAD), when compared with normoxic controls 
(Table 5.8, Figure 5.1).
 
Table 5.8 
Bone mineral density and hypoxia
 
Variable 
 
(SpO
BMD z score 
BMAD z score 
Figures given are median 
 
Figure 5.1 
Distribution of BMAD z 
as SpO2<93% for >10% sleep time
 
 
p=0.03, Mann
NORMOXIA 
Medians shown 
Bone densitometry data and hypoxia 
(SpO2<93% for >10% sleep time) were noted to have statistically 
lower size corrected bone density (BMAD), when compared with normoxic controls 
(Table 5.8, Figure 5.1). 
Bone mineral density and hypoxia defined as SpO2<93% for >10% sleep time
Study population (n=33) 
 
Hypoxic (n=6) 
(SpO2<93% for >10% sleep time) 
Normoxic (n=24)
-1.1 (-2.3, -0.7)  -0.6 (-1.4, 
-1.4 (-1.8, -0.4)  -0.3 (-1, +0.7)
Figures given are median (IQR) * Mann-Whitney U-test     
BMAD z scores in normoxic CF patients and those with hypoxia 
<93% for >10% sleep time  
p=0.03, Mann-Whitney U-test 
HYPOXIA
(SpO2<93% for >10%)
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were noted to have statistically 
lower size corrected bone density (BMAD), when compared with normoxic controls 
% sleep time 
 
Normoxic (n=24)  p-value 
1.4, -0.1))  0.16* 
1, +0.7)  0.03* 
scores in normoxic CF patients and those with hypoxia defined 
 
HYPOXIA 
(SpO2<93% for >10%)   201
5.5 Discussion 
The  results  presented  suggest  that  hypoxia  in  children  with  CF  is  associated  with 
reduced bone density, a potential end result of increased inflammation. No differences 
in skeletal muscle strength were noted between hypoxic and normoxic groups; although 
when compared with historical controls, muscle strength was lower in children with CF. 
 
The results would also question the potential usefulness of exhaled breath condensate as 
a clinical tool. 
 
5.5.1 ACE genotype 
The numbers in our study were too small to assess the effect of genotypic differences in 
ACE genotype and effects on clinical parameters. It is known from published data that 
subjects possessing II genotype have improved hypoxic ventilatory responses (Patel et 
al. 2003), with larger potential increases in minute ventilation (VE). A phenomenon of 
higher VE to MVV ratio was seen in the subjects with sleep hypoxia (Figure 4.13), and 
indeed despite differences in lung volumes as assessed by spirometry, no statistically 
significant  differences  in  minute  ventilation  (VE)  were  seen  between  hypoxic  and 
normoxic groups (Figure 4.11). It is possible that modification of hypoxic ventilatory 
responses may be a potential explanation for this phenomenon. From our small numbers 
however, it is impossible to assess whether this associated with any effects of the effects 
of ACE genotype.  
 
Genetic modifier studies in CF are hampered by small numbers and inadequate power to 
demonstrate outcome differences, as well as differences in phenotypic classification of 
disease  severity  (Accurso  and  Sontag  2003,  Davies  2004).  However,  inclusion  of  a 
modifier  gene  as  a  study  outcome  can  be  justified,  for  if  large  differences  between 
groups exist then these might be detected despite relatively small study numbers. An 
example  of  this  lies  in  the  association  reported  between  reduced  lung  function  and 
mannose binding lectin (MBL) polymorphism in 11 subjects with MBL polymorphism, 
matched with 11 controls from a study total of 164 subjects (Gabolde et al. 1999). 
 
A note of caution is that a positive association between a polymorphism and clinical 
phenotype does not prove that the gene studied is the cause for phenotypic differences. 
For  example  other  genes  may  travel  with  the  candidate  gene  and  account  for  such 
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5.5.2 Exhaled breath condensate 
It was not possible to detect markers of inflammation in EBC in our study population, 
apart from in a single child who was severely hypoxic. Reasons for this could be that 
there is no inflammation present, or that the levels of inflammatory markers in EBC are 
below the limits of detection for the assays used. It is implausible that inflammation is 
absent  in  EBC,  for  CF  lung  disease  is  characterised  by  persistent  neutrophilic 
inflammation.  Large  amounts  of  circulating  interleukin-8  (IL-8)  are  present  in  the 
inflamed CF lung, leading to neutrophil chemoattraction, release of neutrophil enzymes 
such  as  elastase,  and  resultant  parenchymal  lung  damage.  Bronchoalveolar  lavage 
(BAL) fluid taken from CF subjects contains elevated levels of IL-8, IL-6, IL-1β and 
TNF-α (Bonfield et al. 1995). BAL is an invasive procedure, and a bedside test such as 
EBC, would therefore be beneficial in evaluating lung inflammation.  
 
The  ATS/ERS  task  force  reported  that  IL-8  and  IL-6  have  been  detected  in  EBC 
(Horvath et al. 2005), although a note of caution was added that unconcentrated EBC 
samples may have cytokine levels below the lower limits of detection for conventional 
ELISA kits. IL-8 was detectable in only 33% of EBC samples (Cunningham et al. 2000) 
in a group of children with CF. However, more recent work (Bodini et al. 2005) has 
suggested that IL-8 can be detected in 90% EBC samples in CF. A wide discrepancy in 
EBC IL-8 levels detected in CF was noted between these studies. Cunningham et al. 
detected IL-8 in seven of 21 CF patients studied with median (range) concentration of 
49 (8 to 90) pg.mL
-1. Bodini’s group studied thirty CF patients and 10 controls. IL-8 
was undetectable in only 4 patients due to insufficient EBC volume. The mean (range) 
IL-8 level detected in CF patients with Pseudomonas aeruginosa infection was 0.73 
(0.58-0.87) pg.mL
-1 compared to 0.34 (0.29-0.43) pg.mL
-1 in healthy controls.  
 
There  are  methodological  differences  between  the  two.  Firstly,  the  mechanism  of 
collection  for  Cunningham  and  colleagues  was  to  collect  EBC  using  Teflon  tubing 
immersed in ice, whereas Bodini’s group used a condensing device made of 2 glass 
chambers. Secondly, the assays were different with Cunningham using an in-house IL-8 
ELISA that had a lower limit of detection of 0.5pg.mL
-1 , and Bodini using the same 
ultrasensitive IL-8 ELISA kit as ourselves (Biosource ultrasensitive IL-8 [KHC0084] 
ELISA assay), but presumably with an extra standard dilution to achieve a standard 
curve running from 0.18-25 pg.mL
-1 .  
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In  our  hands,  the  Biosource  ultrasensitive  IL-8  [KHC0084]  ELISA  assay  yielded  a 
solitary positive EBC sample at a concentration of 0.4pg.mL
-1. Reasons for failure to 
detect IL-8 in our EBC samples may include the following: 
-  a) Collection and storage problems 
-  b) Inhibition of cytokine detection due to salivary proteases 
-  c) True IL-8 concentration lay below detection limits of the assay 
 
a) Collection and storage 
The use of a commercially available device for collection of EBC (ECoScreen, Jaeger, 
Hoechberg, Germany) clearly differs from the two published papers on EBC in CF 
noted  above.  The  method  is,  however,  a  validated  method  for  EBC  collection.  In 
addition,  the  rapid  freezing  of  samples  (section  2.2.2.5.1)  is  in  accordance  with  the 
handling recommendations for EBC of the ATS and ERS (Horvath et al. 2005), and is 
unlikely to explain the negative findings in our study population. 
 
b) Cytokine inhibition due to salivary proteases 
This  appears  unlikely,  as  the  kit  correctly  detected  a  sample  spiked  with  a  known 
concentration  of  IL-8.  The  variability  between  this  sample  and  standard  of  similar 
concentration was less than 10%. 
 
c) True IL-8 concentration lying below the detection limits of the assay 
To summarise, Cunningham’s group detected IL-8 in EBC in 33% of the CF patients 
that they studied with median concentrations of 49 pg.mL
-1, whereas Bodini detected 
IL-8 in 90% CF patients and controls but with concentrations that were all below 1 
pg.mL
-1.  The  EBC  IL-8  concentrations  detected  by  Bodini  were  50-fold  lower  than 
those reported by Cunningham. The assay appears to function correctly, for a spiked 
sample was correctly identified. The only positive patient sample occurred in one of our 
most hypoxic patients, and one might surmise that he was in a pro-inflammatory state as 
a result of hypoxia, with up-regulated IL-8, the detection of which, at 0.4 pg.mL
-1 was 
only  just  possible  with  the  ultrasensitive  IL-8  assay.  The  remainder  of  the  study 
population may have varied levels of IL-8 expression, albeit below the lower limit (0.39 
pg.mL
-1) of detection of the assay.  
 
  
It is noted that the sole subject with elevated IL
IL-8 (   ) – Figure 5.2. 
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It is noted that the sole subject with elevated IL-8 in EBC, also had an elevated serum 
Figure 5.2.  
8 levels and hypoxia defined as SpO2<93% for >10% sleep time
 
Subject with elevated EBC IL-8,        Remaining subjects 
8  concentrations  lying  below  the  detection  limits  of  the  assay 
explanation for the lack of detection of IL-8 in our EBC samples. 
therefore,  measuring  IL-8  in  EBC  appears  fraught  with  difficulty  and  of  limited 
usefulness. Techniques such as lyophilisation to concentrate the EBC sam
improved the yield of cytokine detection (Wells et al. 2005).  
HYPOXIA 
(SpO2<93% for >10%) 
p<0.05, Mann-Whitney U-test 
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8 in EBC, also had an elevated serum 
<93% for >10% sleep time  
8  concentrations  lying  below  the  detection  limits  of  the  assay  seems  a  plausible 
8 in our EBC samples. As a clinical tool, 
8  in  EBC  appears  fraught  with  difficulty  and  of  limited 
usefulness. Techniques such as lyophilisation to concentrate the EBC sample may have   205
5.5.3 Skeletal muscle 
Median  quadriceps  strength  and  also  handgrip  strength  are  each  approximately  1 
standard deviation below the strength values of the reference population. The CF lung 
and its’ pro-inflammatory state and consequent cytokine up-regulation may provide an 
explanation for the observed reduction in skeletal muscle strength in CF. Alternative 
explanations could include the use of corticosteroids, although the pattern of wasting 
associated with steroid use would tend to be a disproportionate wasting of proximal 
muscle (quadriceps) compared with distal (handgrip), and this was not observed in our 
study population. 
 
However,  it  should  also  be  noted  that  within  our  study  population,  there  were 
individuals  with  stronger  quadriceps  than  reference  population  (one  child  had  a 
quadriceps  strength  that  was  4  standard  deviations  above  the  mean).  A  potential 
explanation for this may be that exercise promotion in CF has led these children to 
undertake more exercise than their peers, with published work suggesting that children 
with mild CF undertake greater exercise than healthy age-matched controls (Selvadurai 
et al. 2004).  
5.5.4 Bone mineral density
Subjects with nocturnal hypoxia were noted to have statistically lower size corrected 
bone  density  (BMAD),  than  normoxic  controls
multifactorial  (Figure  5.3),  and  the  various  potential  causes  of  CF 
considered. 
 
Figure 5.3 
Aetiological factors for CF bone disease 
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5.4 Bone mineral density 
Subjects with nocturnal hypoxia were noted to have statistically lower size corrected 
bone  density  (BMAD),  than  normoxic  controls  (Figure  5.1).  CF  bone  disease  is 
multifactorial  (Figure  5.3),  and  the  various  potential  causes  of  CF 
Aetiological factors for CF bone disease (adapted from Urquhart et al. 
BMAD observed in hypoxic subjects appears to be independent of 
vitamin D status. No differences in median (IQR) vitamin D levels recorded at annual 
assessment were observed between normoxic [47 (37, 62) nmol.L
subjects (p=0.35, Mann-Whitney U test).  
No correlation was seen between BMAD and vitamin D levels (Figure 5.4). 
note is that only 2/40 patients in whom Vitamin D levels were measured had levels 
above those recommended by the UK CF Trust guidelines (UK CF Trust 
Pro-inflammatory state
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Subjects with nocturnal hypoxia were noted to have statistically lower size corrected 
.  CF  bone  disease  is 
multifactorial  (Figure  5.3),  and  the  various  potential  causes  of  CF  bone  disease  are 
et al. 2007) 
 
BMAD observed in hypoxic subjects appears to be independent of 
vitamin D levels recorded at annual 
62) nmol.L
-1] and hypoxic [44 
No correlation was seen between BMAD and vitamin D levels (Figure 5.4). Also of 
note is that only 2/40 patients in whom Vitamin D levels were measured had levels 
above those recommended by the UK CF Trust guidelines (UK CF Trust 2007). 
inflammatory state 
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Figure 5.4 
Vitamin D levels and BMAD z scores
CFTR:  
No  differences  in  BMD  (p=0.66)  or  BMAD  (p=0.23)  between  CFTR  genotypes 
(considered as ∆F508/
Wallis test). 
 
Vitamin K status, Calcium intake, Steroid therapy: 
No data were collected.
 
Exercise:  
In  our  study  population,
subjects  with  reduced
exercise capacity below this level has been shown to relate to mortality in children with 
CF (Pianosi et al. 2005), echoing a previously reported association between VO
and BMD (Frangolias 
correction (BMAD) was carried out. It is known that subjects with nocturnal hypoxia 
had lower exercise capacity than normoxic controls (see section 4.4.6).
Vitamin D levels and BMAD z scores 
 
No  differences  in  BMD  (p=0.66)  or  BMAD  (p=0.23)  between  CFTR  genotypes 
F508/∆F508, ∆F508/Other and Other/Other) were observed (Kruskal
Vitamin K status, Calcium intake, Steroid therapy:  
No data were collected. 
In  our  study  population,  BMD  was  statistically  significantly  lower  (Table  5.9)  in 
subjects  with  reduced  exercise  capacity  denoted  by  VO2peak  <32  mls.kg
exercise capacity below this level has been shown to relate to mortality in children with 
2005), echoing a previously reported association between VO
and BMD (Frangolias et al. 2003). Statistical significance was however lost when size 
correction (BMAD) was carried out. It is known that subjects with nocturnal hypoxia 
had lower exercise capacity than normoxic controls (see section 4.4.6).
Recommended Vitamin 
D levels in CF
UK CF Trust Bone 
Mineralisation Working 
Group 2007
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No  differences  in  BMD  (p=0.66)  or  BMAD  (p=0.23)  between  CFTR  genotypes 
508/Other and Other/Other) were observed (Kruskal-
BMD  was  statistically  significantly  lower  (Table  5.9)  in 
peak  <32  mls.kg
-1.min
-1  as 
exercise capacity below this level has been shown to relate to mortality in children with 
2005), echoing a previously reported association between VO2max 
2003). Statistical significance was however lost when size 
correction (BMAD) was carried out. It is known that subjects with nocturnal hypoxia 
had lower exercise capacity than normoxic controls (see section 4.4.6). 
Recommended Vitamin 
D levels in CF 
UK CF Trust Bone 
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Table 5.9 
Exercise capacity and BMD 
 
  VO2peak  
<32 mls.kg
-1.min
-1 
VO2peak  
>32 mls.kg
-1.min
-1 
p-value 
BMD 
Z scores 
-1.2 (-1.5, -0.8)  -0.5 (-1.3, -0.1)  <0.05* 
BMAD 
z scores 
-0.8 (-1.5, -0.3)  -0.1 (-1.1, 0.1)  0.14* 
Figures given are median (IQR) * Mann-Whitney U-test     
 
 
CF lung disease:  
It  therefore  appears  plausible  that  the  pro-inflammatory  lung  status  associated  with 
hypoxia, and the consequent up-regulation of cytokines that promote wasting of bone 
may provide an explanation for the finding of reduced bone density in this hypoxic CF 
patient group. However, no differences in BMD or BMAD were observed when the 
groups was dichotomised on the basis of FEV1, FVC or MEF50 <-2 z scores; and no 
correlation between IL-8 levels and BMAD z scores (r
2=0.02, p=0.46, Spearman) were 
observed.  
 
Further work to evaluate the cause of reduced bone density in hypoxic CF subjects is 
required, and may include collection of longitudinal bone density data as well as more 
detailed profiling of pro-inflammatory cytokines. 
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5.6 Conclusions 
The results described in Chapter 5 suggest a possible association between hypoxia and 
bone mineral density.  Deleterious effects are reported to arise from being in  a pro-
inflammatory state in CF including muscle-wasting (Gan et al. 2003), and progression 
of CF bone disease (Haworth et al. 2004). 
 
Additionally, the data presented on exhaled breath condensate would suggest that this is 
not  a  useful  bedside  or  clinic  technique  for  assessing  fluctuations  in  the  levels  of 
inflammatory markers in children with CF. 
 
Similar to the associations described in chapter 4, it is unclear whether the observed 
relationship between hypoxia and bone density has occurred because hypoxia is simply 
a mere endpoint of severe CF lung disease and thus a state of increased inflammation, 
or whether hypoxia may be a contributor to a pro-inflammatory state and progression of 
bone disease. Chapter 6 describes a set of in vitro experiments designed to assess the 
effects of hypoxia on IL-8 mediated inflammation in CF bronchial epithelial cells, in an 
attempt to delineate whether hypoxia can be a direct cause of inflammation in the CF 
airway. 
 
Following on from the conclusions of chapter 4, trials of mechanisms of restoration of 
normoxia  (oxygen  therapy  and/or  non-invasive  ventilation)  and  their  effects  on 
amelioration  of  inflammation  and  clinical  status  appear  worthy  of  consideration. 
Furthermore  the  effects  of  exercise  as  a  therapy  also  may  be  beneficial  due  to  the 
promotion  of  new  bone  formation,  as  well  as  the  preservation  of  skeletal  muscle 
strength.   210
CHAPTER 6:  
Effects of hypoxia on inflammation in CF airway epithelial 
cells  
 
6.1 Introduction 
The results of Chapters 4 and 5 suggest an association between hypoxia and adverse 
clinical status in hypoxic CF subjects. The effects of hypoxia on adverse clinical status 
in  CF  may  be  causal,  but  it  is  also  possible  that  hypoxia  is  consequent  to  disease 
severity. 
 
There  is  in  vitro  evidence  that  hypoxia  may  exert  a  direct  pro-inflammatory  effect 
(Koong et al. 1994, Leeper-Woodford and Detmer 1999, Taylor and Cummins 2009) in 
non-CF  disease  states,  and  in  this  chapter  a  set  of  experiments  were  undertaken  to 
directly  investigate  the  effects  of  tissue  culture  in  an  hypoxic  environment  on 
inflammation, as assessed by interleukin-8 (IL-8) secretion in CF airway epithelial cells. 
 
6.1.1 Inflammation and the CF lung 
Briefly  (as  this  area  is  covered  in  detail  in  Chapter  1),  perpetual  neutrophilic 
inflammation is found in the CF airway which may contribute to parenchymal lung 
damage. Neutrophils are attracted to the airway by IL-8, a chemokine released as part of 
the  innate  immune  response  to  infection.  IL-8  levels  are  regulated  by  transcription 
factors of the NFκB family.  
 
The NFκB signalling pathway may be key to inflammation in the CF airway, and is 
activated by a number of factors including bacterial lipopolysaccharide from organisms 
such as Pseudomonas aeruginosa (Hajjar et al. 2002), cytokines, endoplasmic reticulum 
(ER) stress (Hershenson 2004) and possibly directly by CFTR itself (Schroeder et al. 
2002). The potential effects of hypoxia as an activator of this cascade are of interest 
also.  The  activation  of  NFκB  results  in  increases  in  pro-inflammatory  cytokines 
including  IL-6  and  IL-8,  with  resultant  neutrophil  chemo-attraction,  as  well  as  the 
initiation and propagation of chronic airway inflammation (Figure 6.1).   211
Figure 6.1 
Simplified mechanisms for NFκB signalling and the CF airway 
(from Urquhart et al. 2005) 
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6.1.2  Hypoxia and CFTR 
Evidence exists that CF patients with the ∆F508 mutation (85%
 UK CF patients) have 
ongoing NFκB-driven inflammation,
 due to cell stress caused by overload of  F508 
CFTR in the endoplasmic
 reticulum (ER) (Bauerle and Baltimore 1995), implying that 
neutrophilic inflammation
 in the CF airway may be associated with CFTR dysfunction 
as
 well as infection - 38/41 (93%) of our study population carry the ∆F508 mutation. In 
vitro work
 has shown increased NFκB activation in ∆F508
 CF cell lines (Weber et al. 
2001); whilst in vivo studies
 report increased IL-8 levels in BAL fluid of young children 
(Balough et al. 1995, Noah et al. 1997) and infants (Khan et al. 1995) with
 CF in the 
absence of infection. Thus, if CFTR protein function could be improved (by improving 
trafficking to the cell surface), inflammation might be reduced.  
In vitro work suggested
 that cell surface CFTR protein expression in a canine kidney 
cell line
 is impaired by hypoxia (Bebok et al. 2001), and hypoxia is also reported to 
reduce CFTR mRNA, protein expression and function in human cell lines (Guimbellot 
et al. 2008). This is backed by animal work that has shown reduced CFTR mRNA 
expression in the airways, gut and liver of mice subjected to hypoxia when compared 
with normoxic control mice (Guimbellot et al. 2008). 
Furthermore,  in  vivo  human  data  exist  to  suggest  that  hypoxia  may  inhibit
  CFTR 
function. In mountaineers with high altitude pulmonary
 oedema (HAPE), CFTR mRNA 
levels fell by 60% at altitude, (Mairbaurl et al. 2003). It is possible that a trafficking 
deficit could account for such CFTR
 dysfunction due to hypoxia. Additionally, levels of 
CFTR mRNA expression were observed to be lower in the lung epithelia of hypoxaemic 
lung  transplant  recipients  at  the  time  of  transplantation,  when  compared  to  of  non-
hypoxaemic donors (Guimbellot et al. 2008). 
 
Thus in vitro, rodent and in vitro work support a role for hypoxia having deleterious 
action on CFTR function, and a novel therapeutic role for oxygen in CF is suggested: 
CF disease severity correlates with the amount of functional
 CFTR protein expression 
on  airway
  epithelial  cells,  and  research  into  molecular
  chaperoning  has  studied  the 
ability of a number of agents in facilitating CFTR trafficking – guiding ∆F508 CFTR 
protein from the endoplasmic reticulum to the
 cell surface. As yet, the trafficking
 effects 
of oxygen in a ∆F508 CF cell line remain undocumented.  
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6.1.3  Hypoxia and NFκ κ κ κB 
As previously discussed above, in vitro evidence suggests that hypoxia increases NFκB 
activation  (Koong  et  al.  1994,  Leeper-Woodford  and  Detmer  1999)  leading  to 
proinflammatory cytokine expression, neutrophil recruitment and consequent CF airway 
inflammation. The role of supplemental oxygen in modulating CF inflammation would 
be both of interest and also of great potential therapeutic benefit.  
 
Although addressing the interaction of hypoxia and NFκB, the above studies focused on 
acute hypoxia, over periods of 2 (Koong et al. 1994) to 48 hours (Leeper-Woodford and 
Detmer 1999). The work discussed in 6.1.1 regarding the potential inhibitory effects of 
hypoxia on CFTR trafficking, and the potential for mutant CFTR to activate NFκB, 
provide another potential mechanism by which hypoxia may propagate inflammation in 
the CF lung.  
 
As a counterbalance to the above evidence, there is also in vitro work reporting that 
hyperoxia too is an activator of NFκB (Horowitz 1999), along with in vivo work noting 
an  increase  in  NFκB-mediated  inflammatory  markers  in  exhaled  breath  condensate 
(EBC) of chronic obstructive pulmonary disease (COPD) patients treated with oxygen 
(Carpagno  et  al.  2004).  Of  note  however,  are  the  difficulties  and  inconsistencies 
reported when measuring inflammatory cytokines in EBC (section 5.5.2). 
 
6.2 Aims 
This aims of this chapter were to assess the effects of variable degrees of hypoxia upon 
NFκB-mediated inflammation (as assessed by cellular IL-8 production) in both CF and 
non-CF cell lines. Furthermore, the effects of hypoxia on inflammation in CF and non-
CF cell lines was compared and contrasted to the effects of a known stimulus of the 
NFκB  cascade,  namely  bacterial  lipopolysaccharide  (LPS)  from  Pseudomonas 
aeruginosa,  and  in  addition  variable  lengths  of  incubation  under  the  given 
environmental  conditions  were  studied  up  to  a  maximum  of  96  hours.  The  study 
hypothesis that hypoxia exerts an in vitro effect on NFκB-mediated inflammation in the 
CF airway was thus tested. 
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6.3 Methods 
The methodology is discussed in detail in section 2.3. A précis is given below.  
 
6.3.1 Tissue Culture  
Tissue  culture  was  undertaken  using  immortalised  CF  (CFBE41o
-)  and  non-CF 
(1HAEo
-) cell lines (courtesy of Dieter Gruenert, University of Vermont, USA). The 
cells were grown in a standard tissue culture incubator (Galaxy-R, Wolf Laboratories 
Limited, Pocklington, UK) maintained at constant temperature (37
OC), CO2 (5%) and 
humidity levels. Hypoxia was controlled by a Pro-Ox controller (Biospherix Limited, 
Redfield, NY13437, USA), regulating oxygen concentration within a two-shelf tissue 
culture chamber (Biospherix Limited), housed in the incubator as illustrated previously 
(Figure 2.15b). Carbon dioxide within the cell culture chamber was maintained at 5% 
using a Pro-CO2 controller (Biospherix Limited, Redfield, NY13437, USA).  
 
In  order  to  maintain  a  control  environment,  cells  were  incubated  simultaneously  in 
normoxic conditions (incubator) alongside hypoxic conditions (tissue culture chamber) 
– see Figure 2.16.  
 
Three  sets  of  experiments  were  carried  out.  Firstly,  CF  and  non-CF  cells  were 
simultaneously incubated in air and variable degrees of hypoxia (0.1%, 1%, 5%, 10%) 
over a 48 hour period. Counting of cells and sampling of cell supernatant was carried 
out at time zero, and then at 8, 24 and 48 hours thereafter, according to the methodology 
of sections 2.3.3 and 2.3.4.  
 
In order to compare hypoxia to LPS as a stimulus of inflammation, and to assess the 
potential augmentation of inflammation by LPS in the presence of hypoxia, the above 
experiments were repeated in the presence of high (50µg.mL
-1 media) or low (10µg.mL
-
1)  levels  of  LPS  derived  from  Pseudomonas  aeruginosa  (L9143  Sigma-Aldrich,  St 
Louis, MO, USA), and in the absence of LPS, for both cell lines and with simultaneous 
incubation in both air and at variable (0.1%,1% and 10%) levels of hypoxia.  
 
To assess the impact of time, a further set of experiments were carried out comparing 
extreme hypoxia (0.1%) with normoxia over a 4-day period. In this experiment, cells 
were incubated with either high-dose LPS (50 µg.mL
-1 media) added or no LPS at all, 
enabling comparison of cell lines with and without LPS under extreme hypoxic and 
normoxic conditions at each timepoint.    215
At each timepoint in each of the experiments, cell supernatant was sampled from the 
T25 flask, and stored in cryovials (Nalge-Nunc International, Roskilde, Denmark) at –
80
OC for later cytokine analyses. 
 
6.3.2 Interleukin-8 (IL-8) enzyme-linked immunosorbent assay (ELISA)  
Given the hypothesis that hypoxia will upregulate NFκB, and that NFκB activation in 
turn leads to IL-8 production, then direct measurement of IL-8 appears an appropriate 
surrogate measure by which to test this hypothesis. A human IL-8 ELISA kit (ELH-IL8-
001, RayBiotech Inc., Norcoss, GA, USA) was used to measure IL-8 concentration in 
tissue culture cell supernatant for both human airway epithelial cells and CF bronchial 
epithelial cells. The kit detects IL-8 levels in the range of 2.74 to 2000 pg.mL
-1.  
 
Prior  to  ELISA,  cell  supernatant  was  centrifuged  (Rotina  46-R,  Wolf  Laboratories 
Limited, Pocklington, UK) to allow debris to sink to the bottom of the tube, then diluted 
to 1 in 100 using assay diluent. The protocol was based on manufacturer’s instructions. 
A 96-well plate pre-coated with capture antibody was used with standards generated by 
1:3 serial dilutions from 2000 pg.mL
-1 down to 2.74 pg.mL
-1. The assay is summarised 
in Figure 2.17.  
 
Optical densities of each well were read using an ELISA plate reader (Revelation 4.02, 
Dynex Technology, Chantilly, VA, USA) at 450nm, and cytokine concentrations in the 
unknown samples were read from the standard curve.    216
6.4 Results 
Results  for  each  set  of  experiments  are  summarised  below.  The  three  groups  of 
experiments undertaken were as follows: 
 
1.  Effects of variable degrees of hypoxia on inflammation in CF and non-CF cell lines 
(Section 6.4.1). 
2. Effects of variable degrees of hypoxia with or without exposure to lipopolysaccharide 
on inflammation in CF and non-CF cell lines (Section 6.4.2). 
3.    Effects  of  prolonged  extreme  hypoxia  and  exposure  to  lipopolysaccharide  on 
inflammation in CF and non-CF cell lines (Section 6.4.3). 
 
6.4.1 Effects of hypoxia on inflammation in CF and non-CF cell lines 
The effects of varying degrees of hypoxia (10%, 5%, 1% and 0.1%) on cell growth and 
IL-8 production were considered. 
 
6.4.1.1 Cell Counts at experimental time-points 
These are displayed below in Table 6.1. 
 
It  should  be  noted  that  only  live  cells  were  counted,  using  the  Trypan  blue  dye 
exclusion method described in section 2.3.4.  
 
Growth  patterns  appeared  broadly  similar  for  each  cell  line  at  varying  degrees  of 
hypoxia.  This  is  demonstrated  in  Figure  6.2  (a  and  b).  There  is  a  suggestion  of  a 
reduction in CFBE cell growth at extreme (0.1%) hypoxia (Figure 6.2 b).   
 
However, when repeatability measures were applied to cell growth across the entire set 
of  experiments,  no  significant  differences  in  growth  patterns  within  cell-lines  and 
between cell-lines were seen (Section 6.4.4). 
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Figure 6.2 
Growth of cells at variable levels of hypoxia
 
a) HAE cells 
b) CFBE cells 
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6.4.1.2 IL-8 levels at 
Having  established  survival  of  cells  despite  extreme  hypoxia,  it  was  decided  not  to 
assay each sample for IL
as part of the next stage of work 
lipopolysaccharide  (LPS)  at  varying  degrees  of  hypoxia.  An  ELISA  was  however 
carried out to establish the optimum dilution to be used for subsequent assays. Figure 
6.3 shows the standard curve, and the optimum dilution is seen to
optical density within the limits of detection of the assay. Table 6.2 lists the optical 
densities for each dilution.
 
Figure 6.3 
Standard curve for IL
 
8 levels at experimental time-points 
Having  established  survival  of  cells  despite  extreme  hypoxia,  it  was  decided  not  to 
assay each sample for IL-8 levels, as the same experiments were in effect to be repeated 
as part of the next stage of work – namely, incubation in the presence or absence of 
lipopolysaccharide  (LPS)  at  varying  degrees  of  hypoxia.  An  ELISA  was  however 
carried out to establish the optimum dilution to be used for subsequent assays. Figure 
6.3 shows the standard curve, and the optimum dilution is seen to be that which gives an 
optical density within the limits of detection of the assay. Table 6.2 lists the optical 
densities for each dilution. 
Standard curve for IL-8 ELISA  
r
2=0.91 
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Table 6.2  
Establishing optimum dilution 
 
[Optical densities] 
  NORMOXIA  1% HYPOXIA 
  HAE  CFBE  HAE  CFBE 
  1:10  1:50  1:100  1:10  1:50  1:100  1:10  1:50  1:100  1:10  1:50  1:100 
0  0  0  0  0  0  0  0  0  0  0  0  0 
8  1  0.3  0.2  0.6  0.1  0.1  0.6  0.2  0.1  1.3  0.4  0.2 
24  1.2  0.3  0.1  1.6  0.4  0.2  1.4  0.3  0.1  1.4  0.5  0.3 
48  1.4  0.5  0.2  1.4  0.5  0.3  1.8  0.5  0.4  1.8  0.9  0.6 
 
 
Extrapolation of these optical densities to the standard curve suggests that an optical 
density below 1 might be desirable, so a dilution of 1:50 or 1:100 appears most likely to 
provide optical densities within this range (at least when unstimulated by LPS). 
 
Using the data available from the 1 in 50 dilutions, IL-8 levels for each time-point and 
for each condition could be plotted (Figure 6.4). Absolute concentrations in pg.mL
-1 (a) 
as well as concentrations corrected for cell counts in ng.10
-6 cells.mL
-1 (b), are shown.  
Figure 6.4 
IL-8 production by CF and non
and 1% hypoxic conditions
 
a)  IL-8 concentrations in pg.mL
b)  IL-8 concentrations in ng.10
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This  experiment  was  only  undertaken  on  one  occasion,  but  suggests  that  IL-8 
production increases with time in both normoxic and hypoxic environments, and in both 
cell lines. Hypoxia may augment such an inflammatory process, and this is particularly 
noted for the CFBE cell studies. It would be necessary to repeat this experiment on a 
number of occasions to assess the reproducibility of these results, and clearly this is a 
limitation in our study findings.  
 
Aspects of this initial experiment were, therefore, incorporated into the next stage of 
experiments, which was designed to compare variable degrees of hypoxia to a known 
stimulus  of  NFκB  activation  (and  hence  IL-8  production),  namely  exposure  to  LPS 
derived  from  Pseudomonas  aeruginosa.  The  LPS  preparation  used  was  the  L9143 
preparation  from  Sigma-Aldrich  (St  Louis,  MO,  USA)  which  is  phenol-extracted 
Pseudomonas aeruginosa serotype 10. 
 
 
6.4.2  Effects  of  variable  degrees  of  hypoxia  with  or  without  exposure  to 
lipopolysaccharide on inflammation in CF and non-CF cell lines 
 
6.4.2.1 Cell Counts at experimental time-points 
These are displayed below in Table 6.3. 
 
For this set of experiments, LPS was added to the media in high (50 µg.mL
-1) or low (10 
µg.mL
-1) concentrations, or standard media (no LPS added) was used. Sampling was 
carried out at time zero, 24 and 48 hours.  
 
Growth  patterns  appeared  broadly  similar  for  each  cell  line  at  varying  degrees  of 
hypoxia, with and with each concentration of LPS. This is demonstrated in Figure 6.5 (a 
and b). Of significance is that the best growing CFBE cell conditions were normoxia in 
the absence of LPS, and similar to Figure 6.2 (b), CFBE cells at 1% hypoxia appear to 
grow more slowly than do their normoxic counterparts.  
 
Again, however, when repeatability measures were applied to cell growth across the 
entire set of experiments, no significant differences in growth patterns within cell-lines 
and between cell-lines were seen (Section 6.4.4).  
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6.4.2.2 IL-8 levels at experimental time-points 
The first stage of this second round of experiments was to compare the effect of a 
known stimulus for IL-8 production (LPS) with the effect produced by hypoxia (1% 
hypoxia arbitrarily chosen), and to assess for any synergy between the two – section 
6.4.2.2.1. 
 
Secondly, the effects of variable degrees of hypoxia on this process were analysed – 
section 6.4.2.2.2. 
 
 
6.4.2.2.1  Comparison of IL-8 production in the presence or absence of LPS under 
normoxic and hypoxic (1%) conditions 
This work was undertaken at the same time as the ELISA study described in section 
6.4.1.2. The standard curve for this assay is shown in Figure 6.4. The conditions studied 
were the effects of high LPS concentrations (50 µg.mL
-1) versus no LPS, in HAE and 
CFBE  cells  under  both  normoxic  and  hypoxic  (1%)  conditions.  Both  absolute 
concentrations in pg.mL
-1 (a) and concentrations corrected for cell counts in ng.10
-6 
cells.mL
-1 (b) are shown (Figure 6.6). A dilution factor of 1:100 was needed for LPS 
stimulated samples to achieve optical densities within the desired range. 
 
  
Figure 6.6 
IL-8 production by CF and non
hypoxic conditions, and in the presence or absence of LPS (50µg.mL
 
a)  IL-8 concentrations in pg.mL
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b)  IL-8 concentrations in ng.10
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These data would appear to bear out the findings of experiment 1 (Figure 6.5), namely 
that  IL-8  production  is  increased  under  hypoxic  conditions  when  compared  to 
normoxia.  Furthermore,  the  effect  of  hypoxia  on  IL-8  production  appears  to  be 
considerably lower than that of stimulation with LPS. Finally a synergistic effect on IL-
8 production is suggested by hypoxia and LPS in combination.  
 
It should however also be noted that the IL-8 concentration seen in HAE cells when 
stimulated  with  LPS  is  greater  than  that  observed  in  the  CFBE  cell  population. 
Although there is evidence that baseline IL-8 secretion may be lower in CF cell lines 
when compared with wild-type (Massengale et al. 1999), reduced IL-8 secretion when 
stimulated with LPS is an unexpected finding, for it is known that the innate immune 
response  to  Pseudomonas  LPS  within  the  CF  airway  is  exaggerated  and  prolonged 
compared with normal individuals.  
 
It is reported that Pseudomonas aeruginosa changes its configuration within the CF 
airway from a penta-acylated to a hexa-acylated LPS form (Hajjar et al. 2002). Human 
TLR4 recognises this change in configuration, and activation of NFκB is 100 times 
greater with the hexa-acylated form of LPS than with the penta-acylated form (Hajjar et 
al. 2002).  It is postulated that it is this differential recognition of LPS in the CF airway 
which leads to massive activation of innate immune response. The above experiment 
was performed with penta-acylated Pseudomonas LPS (L9143 Sigma-Aldrich, St Louis, 
MO, USA), which may explain why levels of IL-8 production were similar for the two 
cell lines. This differs from the in vivo situation, where a change in LPS configuration 
would take place in the CF airway leading to differential cytokine activation. 
 
Having  shown  that  1%  hypoxia  in  combination  with  LPS  exerts  an  effect  on 
inflammation as measured by IL-8 production, the effects of varying degrees of hypoxia 
on this inflammatory process (in the presence and absence of LPS) were then studied. 
 
6.4.2.2.2 Effect of variable hypoxia (10% v 1% v 0.1%) on IL-8 production in the 
presence or absence of LPS  
The next stage of analysis was to compare the effects of varying degrees of hypoxia on 
IL-8 production in the presence or absence of LPS using ELISA. The effects of 10%, 
1% and 0.1% hypoxia were compared to time-matched normoxic control cells over a 
48-hour culture period. The findings are illustrated below in Figure 6.7. 
  
Figure 6.7 
IL-8  production  by  CF  and  non
incubated in the presence or absence of LPS  
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Although the data are less clean than the results of the previous set of experiments, the 
following trends are seen: 
 
•  Lipopolysaccharide  (LPS)  appears  to  act  as  a  greater  stimulus  of  IL-8 
production  than  does  hypoxia  with  a  dose  gradient  for  LPS  concentration 
being observed 
•  IL-8 production appears to still be rising at 48 hours i.e. a peak may not have 
yet been reached 
•  Some evidence to support the findings from the first set of experiments that 
hypoxia acts a stimulus for IL-8 production, and may exert a synergistic action 
with LPS. 
 
Bearing these findings in mind, the third set of experiments was devised. 
 
 
 
 
6.4.3 Effects of prolonged extreme hypoxia and exposure to lipopolysaccharide 
on inflammation in CF and non-CF cell lines 
 
The final experiments were designed to compare the effects of extreme hypoxia (0.1% 
hypoxia) on IL-8 production in the presence or absence of LPS over a prolonged (96-
hour)  time  course.  In  this  set  of  experiments  only  one  concentration  of  LPS  (50 
µg.mL
-1) was used. 
 
6.4.3.1 Cell Counts at experimental time-points 
These are displayed below in Table 6.4. 
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There is an observed reduction in growth of HAE cells under hypoxic conditions, which 
only becomes apparent at 96 hours (0.1%), as demonstrated in Figure 6.8 (a), although 
for the CFBE cells growth patterns appear unaffected by hypoxia 
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There is an observed reduction in growth of HAE cells under hypoxic conditions, which 
only becomes apparent at 96 hours (0.1%), as demonstrated in Figure 6.8 (a), although 
- Figure 6.8 (b). 
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Both CFBE41o- and 1HAEo
- cells appear to adapt to prolonged periods of extreme 
hypoxia and survive. Previous work has shown that airway cells (human epithelial-like 
cell line A549) can survive extreme hypoxia, and even anoxia (0%) for up to 24 hours 
(Ahmad et al. 2003); whilst exposure of the CF cell line used in the above experiment 
(CFBE41o-) to hypoxia (1% O2) over a 48 hour time-course experiment (Guillembellot 
et  al.  2004)  resulted  in  a  reduction  in  CFTR  mRNA  levels  when  compared  with 
normoxic CFBE41o- cells although no report on growth kinetics was however, made. 
 
 
 
6.4.3.2 IL-8 levels at experimental time-points 
The next stage of analysis was to study the effects of a prolonged period of extreme 
hypoxia on IL-8 production in the presence or absence of LPS using ELISA.  
 
The effects of 0.1% hypoxia with and without LPS were compared to time-matched 
normoxic  control  cells  over  a  96-hour  culture  period.  The  findings  are  illustrated 
overleaf in Figure 6.9. 
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To summarise the effects of prolonged hypoxic cell culture of CF and non-CF airway 
epithelial cells, the following trends were noted: 
 
•  The largest stimulus for IL-8 production in both HAE and CFBE cells was 
incubation in the presence of both hypoxia and also LPS. 
•  The stimulus from LPS alone is much higher than that seen with hypoxia alone. 
 
A potential erroneous IL-8 level was noted at 96 hours for HAE cells incubated at 0.1% 
hypoxia in the absence of LPS, as this appears much higher than would be expected 
from the value obtained at 72 hours, and from previous experiments. The sample was 
run in duplicate and co-efficient of variation was 3.4% only. Adjacent wells were from 
96 hour samples exposed to LPS under normoxic conditions which had very similar IL-
8 concentrations making contamination in the form of overspill from adjacent wells a 
possibility.   238
6.4.4 Experimental repeatability 
The sample size was small and therefore limited these analyses, with experiments under 
the same conditions being replicated on two to four occasions. 
 
6.4.4.1 Cell counts 
The repeatability of cell counts was assessed using a repeated measures ANOVA test. 
As expected, cell counts significantly increased with time over the 48 hour incubation 
period (Wilks’ Lambda, p<0.001). No evidence of difference in cell counts were seen 
within cell lines exposed to the same environmental conditions on repeated occasions 
(Wilks’ Lambda, p=0.10). However, the sample size was small and these data could 
lack the power to detect a difference. 
 
After adjustment for repeated experiments, no statistical differences between cell lines 
and/or environmental conditions over time were observed (p=0.17). The small sample 
size precluded meaningful post hoc analysis (Bonferroni) to detect differences between 
the groups, although on visual assessment of these data, CFBE cells exposed to extreme 
(0.1%) hypoxia and coincubated with LPS had lower cell counts. 
 
6.4.4.2 IL-8 measures 
A significant increase in IL-8 levels with time over the 48 hour incubation period was 
noted (Wilk’s Lambda, p<0.001), as well as a trend towards a difference in IL-8 levels 
(Wilk’s Lambda, p=0.06) within the same environmental condition (cell line, FiO2, LPS 
concentration) on repeated occasions. The effects of successive passages of cells on IL-
8 production (i.e. cells with higher passage numbers may be more stressed) appears to 
be  the  most  likely  explanation  for  these  findings.  Although  affecting  the  ability  to 
compare IL-8 levels from separate experiments to one another, in each experiment the 
test  conditions  (variable  hypoxia  +/-  LPS  co-incubation)  were  matched  with  a 
contemporaneous  normoxic  control  of  the  same  passage  number  allowing  direct 
comparison of each test condition with a normoxic control. 
 
After adjustment for repeated experiments on the same cell line, there was a difference 
observed for  IL-8 production between environmental combinations - cell line,  FiO2, 
LPS  concentration  (p=0.05).  However,  once  again  the  small  sample  size  precluded 
meaningful post hoc analysis (Bonferroni) to detect differences between the groups.   239
When IL-8 levels were adjusted for cell count, differences were again noted over time 
(Wilk’s Lambda, p<0.001), and similar within-group trends were noted for tests under 
the  same  environmental  conditions  (Wilk’s  Lambda,  p=0.05).  After  adjustment  for 
repeated experiments on the same cell line, there was also a difference in observed IL-8 
production per cell (p=0.007). Post hoc analyses suggested that the greatest differences 
were between extremely hypoxic (0.1%) HAE cells exposed to LPS which produced 
greater amounts of IL-8 per cell than normoxic HAE controls (p=0.02). 
 
Whilst  such  trends  are  interesting,  and  may  suggest  that  hypoxia  (especially  in 
conjunction with LPS) can exert an effect on inflammation, the work would need to be 
repeated on multiple occasions, ideally at the same time (same cell passage, atmospheric 
pressure,  etc.)  to  accurately  assess  the  biological  variability  and  repeatability  of  the 
experiments. 
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6.5 Discussion 
 
To summarise the overall results for this series of experiments, the following trends 
were apparent. 
￿
1.  Cell growth appears largely preserved, even on exposure to extreme hypoxic 
conditions. 
 
2.  Hypoxia alone may exert an effect on IL-8 production in both CF and non-CF 
airway epithelial cells. This finding was however, not consistent across the range 
of experiments undertaken. 
 
3.  Lipopolysaccharide (LPS) stimulation of airway epithelial cells exerts a several-
fold effect on IL-8 production in both CF and non-CF airway epithelial cells 
when compared to baseline levels of IL-8 production in the absence of LPS. 
 
4.  The highest levels of IL-8 production are noted in the presence of both hypoxic 
incubation conditions and LPS stimulation suggesting possible synergy between 
the two. 
 
These results would support the notion that hypoxia may exert a pro-inflammatory 
effect in CF, supporting the in vivo findings of Chapter 5, where elevated WBC, 
neutrophil counts, and IL-8 levels were seen in hypoxic CF subjects, along with a 
reduction in bone density that may be related to such a pro-inflammatory (and therefore 
catabolic) state.   
 
 
This experimental work has some limitations, and a number of potential sources of 
experimental error need to be acknowledged.    241
6.5.1 Methodology and data acquisition 
Firstly, pipetting error may have led to differences in seeding densities between each of 
the tissue culture flasks. Although attempting to seed at a given density (0.7 or 0.3 x10
6 
cells per flask) based on cells counted after a new passage from stock cell culture flasks, 
errors in seeding densities are perhaps less important, as cell counts were undertaken at 
each timepoint, enabling IL-8 levels to be expressed in ng per million cells per mL of 
culture media. 
 
Second, the use of a haemocytometer to undertake cell counts may be a source of error 
at two points in the experiment. Cell counts at the seeding stage may be inaccurate, 
leading  to  inaccurate  seeding  densities.  More  importantly,  however  is  the  potential 
source of inaccuracy at the counting stage at each experimental time point. Because the 
numbers of cells being counted within the haemocytometer field were small, then a 
clump of cells within the counting field could lead to an overestimation of cell numbers, 
and an underestimation of IL-8 production (ng.10
-6 cells.mL
-1). There was no readily 
available alternative to count cells however, and data have been expressed throughout as 
absolute IL-8 concentrations as well as those corrected for cell numbers.   
 
In experiments 1 and 2, an a priori assumption was made that time zero readings for IL-
8 production would be zero. This hypothesis was tested along with the ELISA that was 
run for experiment 3. Time zero readings for IL-8 in blank media were of the order of 
150pg mL
-1, and for HAE and CFBE cells placed in media, then removed and stored, 
the time zero readings were between 250 and 350 pg.mL
-1. The 24-hour readings for 
unstimulated (normoxia, no LPS) HAE and CFBE were 1926 and 1415 pg.mL
-1 
respectively.  
 
A further question to address may have been to study the implications of exposing a 
sample of blank media to both hypoxic and normoxic conditions for the 24/48/72/96 
hour time period, and carry out analysis of IL-8 production. This could be undertaken to 
assess  whether  cellular  contamination  of  the  media  may  be  exerting  a  role  in  IL-8 
production, and may be useful to be performed in future work. 
 
The effects of successive passages of cells on IL-8 production (i.e. cells with higher 
passage numbers may be more stressed) were hopefully eradicated by each experiment 
being done with a simultaneous normoxic control.   242
Additionally, a new batch of LPS was used in the third set of experiments, but running 
alongside cells simultaneously incubated in the absence of LPS should have ensured 
that any confounding effect of this new reagent was eradicated. 
 
Therefore, although the work has limitations - in particular, statistical analyses were 
hampered  by  the  lack  of  repeatability  for  each  experimental  stage,  the  work  was 
undertaken as a feasibility study for setting up a hypoxic tissue culture environment 
which was successful. Furthermore, the work shows some supporting evidence for the 
proof of the principle that direct activation of CF airway inflammation may occur in the 
presence  of  hypoxia.  The  in  vitro  work  was  not  the  main  aim  of  the  thesis,  but 
nonetheless has proved an interesting aside, placing the in vivo findings in context, and 
generating a number of future research directions. 
 
 
6.5.2 Interpretation of results 
The combination of both hypoxia and LPS was chosen because of the in vivo effects of 
Pseudomonas aeruginosa (PA) on the lungs of a child with CF, whereby bacterial LPS 
from PA coupled with hypoxia may cause damage to the lung of a CF child. 
 
The potential synergy of LPS and hypoxia is therefore of huge potential importance to 
the  care  of  patients  with  CF.  This  may  lead  to  the  development  of  future  research 
directions to examine this interaction.  
 
These should include: 
 
a)  Repeated experiments to examine the effects of extreme hypoxia in the presence 
or absence of LPS on production of IL-8 in CF and non-CF airway epithelial 
cells.  This  is  essential  to  assess  for  potential  biological  variability  in  the 
experiments described above, and also to verify their findings.  
 
It should, however, be noted that cells may differ in their morphology and behaviour 
with time and number of passages (divisions), as may environmental conditions.  
Therefore, whilst some repeatability data is presented, across the series of experiments; 
if designing the experiments again, it would be desirable to run each set in duplicate 
such that repeatability could be assessed without the potential confounding effects of 
time, environmental pressure and cell passage number.    243
b)  In an experimental model similar to that described in a) to analyse not just the 
effects on IL-8 production, but also on other aspects of the NFκB cascade. This 
may include work to study downstream signalling regulators within the NFkB 
family,  in  a  bid  to  tease  out  the  signalling  mechanism  that  is  activated  by 
hypoxia in the CF airway. 
 
c)  To  examine  the  effects  in  primary  cell  lines  from  CF  subjects  rather  than 
immortalised cell lines, and undertake translational research on the effects of 
hypoxia and LPS stimulation in animal models such as CF and non-CF mice. 
 
d)  To study the effects of extreme hypoxia on CFTR trafficking by estimation of 
CFTR  protein  reaching  the  cell  surface.  This  may  need  to  be  undertaken  in 
primary cells in order that the apical cell surface can be identified. This could 
hopefully  be  achieved  by  selecting  an  optimal  antibody  to  stain  for  CFTR 
protein (Mendes et al. 2004, Farinha et al. 2004) in conjunction with confocal 
microscopy to evaluate trafficking to the cell surface using similar techniques to 
those described previously by Dormer and colleagues (Dormer et al. 2005). This 
series  of  experiments  in  a  CF  cell  line  may  help  to  delineate  whether  up-
regulation  of  inflammation  in  CF  airway  cells  under  hypoxic  conditions  is 
mediated by CFTR dysfunction. 
 
e)  Finally,  the  effects  of  oxygen  therapy  with  and  without  aggressive  anti-
pseudomonal treatment, and their effects on lung inflammation appear worthy of 
evaluation in animal models, and perhaps later in human subjects. 
 
Although  preliminary,  these  research  findings  are  novel,  and  not  without  clinical 
application. Further research will hopefully confirm or refute their importance. 
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6.6 Conclusions 
The results discussed in Chapter 4 suggest that CF subjects with sleep hypoxia have a 
reduction in clinical well-being with reductions in exercise capacity, anthropometric 
measures (BMI), lung function (lower FEV1 and FVC), and quality of life, as well as 
increased gas trapping (elevated RV/TLC ratio), chest radiograph (Chrispin-Norman) 
scores, number of intravenous antibiotic courses and measures of ventricular wall (LV 
and RV) thickness. Chapter 5 proposes an association between hypoxia and reduced 
BMAD z scores.  
 
The  paradigm  exists  of  whether  hypoxia  is  simply  an  effect  of,  or  whether  also  a 
possible contributor to CF lung inflammation remains contentious. However, the results 
of  chapter  6  would  suggest  that  hypoxia  may  indeed  exert  a  direct  effect  on 
inflammation (as assessed by IL-8 production) in HAE and CFBE cells. Furthermore, 
the greatest levels of IL-8 production were seen when hypoxia was combined with a 
known  stimulus  of  IL-8  production  in  the  CF  airway,  namely  bacterial  LPS  from 
Pseudomonas aeruginosa. 
 
Therefore,  this  thesis  provides  some  supporting  evidence  that  hypoxia  may  directly 
contribute  to  a  pro-inflammatory  state  in  the  CF  airway.  Further  research  should, 
however, require to be undertaken to assess the repeatability of these findings. 
 
If hypoxia can be both a contributor to, and a consequence of, decline in clinical status 
and pro-inflammatory state in CF, then strategies to ameliorate hypoxia and its sequelae 
should be evaluated. Chapter 7 (Discussion) will consider this in detail. 
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Chapter  7:  Hypoxia  in  children  with  cystic  fibrosis  – 
Conclusions and future directions 
 
7.1 Definition of hypoxia in CF 
 
At the beginning of this thesis, no unifying definition of hypoxia in CF was available, 
and one of the principal study aims was to select a definition of hypoxia in CF that best 
correlates with measures of inflammation.  
 
The most sensitive and specific definition for detecting measures of inflammation in 
children  with  CF  was  that  of  nocturnal  SpO2  <93%  for  >10%  sleep  time.  This  is 
proposed as the optimal definition of hypoxia in children with CF. 
  
 
7.1.1 Predicting hypoxia in CF - Recommendations 
   
The work presented in this thesis concurs with the findings of previous authors (Coffey 
et al. 1991, Bradley et al. 1999), in suggesting that hypoxia during sleep occurs more 
commonly  than  exercise  hypoxia.  It  is  proposed  that  all  subjects  with  exercise-
associated desaturation should undergo overnight oximetry. 
 
A further recommendation from this thesis is that all CF subjects with FEV1 <60% 
predicted should undergo an overnight oximetry at a time of clinical stability (100% 
sensitive,  84%  specific  and  positive  predictive  value  of  64%)  in  the  detection  of 
nocturnal hypoxia using the above definition.  
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7.2 Future research directions for hypoxia and childhood CF 
Future research hypotheses can be generated in areas allied to both in vivo and in vitro 
aspects of the research presented in this thesis. A call for randomised, controlled trials 
of restoration of normoxia is made. 
 
7.2.1 Mechanisms of hypoxia - Human work 
Follow-up of the 41 subjects in the thesis cohort at intervals throughout later childhood 
and into adulthood would be of immense value. In particular, delineating the time of 
onset of measurable pulmonary hypertension, and its correlation with hypoxia would be 
important, as it would confirm whether the increased right ventricle wall thickness seen 
in  our  hypoxic  subjects  was  indeed  a  true  precursor  of  pulmonary  hypertension. 
Evaluation of the longer term effects of hypoxia on life expectancy, rate of decline in 
lung function, exercise capacity, bone density, and quality of life would also be both 
interesting and informative. 
 
Replication  of  the  study  findings  in  a  second  population  would  be  vital  to  future 
research into both the causal mechanisms of, adaptation to, and potential treatment of 
hypoxia in CF.  
 
 
7.2.2 Mechanisms of hypoxia - In vitro work  
The preliminary data in this thesis suggest that the initial hypothesis that hypoxia is 
associated with inflammatory changes was correct. The data were limited by the small 
numbers  of  experiments  but  demonstrated  ‘proof-of-principle’.  Some  strategies  for 
future in vitro research are outlined in section 6.5.2.    247
7.2.3 Therapeutic trials of restoration of normoxia in hypoxic CF children 
If,  as  suggested,  clinically  important  nocturnal  hypoxia  is  more  prevalent  than  is 
estimated  from  the  numbers  currently  receiving  oxygen,  this  may  act  as  a  call  for 
research into the effects of restoration of normoxia. The adverse effects observed in 
hypoxic CF subjects in this study, and the putative deleterious effects that may arise 
from  existing  in  a  pro-inflammatory  state  in  CF  (muscle-wasting,  CF  bone  disease, 
ongoing neutrophilic lung inflammation, etc.) support research into strategies to restore 
normoxia.  
 
The effects of restoration of normoxia on inflammation are important to measure not 
only because of the  associations seen between  hypoxic CF subjects and markers of 
inflammation in this study, but because in other childhood disease models of nocturnal 
hypoxia  (namely  OSA),  restoration  of  normoxia  is  reported  to  be  associated  with  a 
reduction in inflammation (Gozal et al. 2008). If hypoxia can be both contributor to, and 
consequence  of  decline  in  clinical  status  and  pro-inflammatory  state  in  CF,  then 
strategies to ameliorate hypoxia and its sequelae should be evaluated. 
 
7.2.3.1 Restoration of normoxia using oxygen therapy 
A randomised, controlled trial of oxygen therapy in CF with entry criteria including a 
definition of hypoxia as SpO2 <93% for >10% sleep time may be a reasonable starting 
point. It is essential that night-time oxygen is titrated to provide the amount required to 
restore normoxia at night – a major limitation of the study design of the randomised trial 
of  oxygen  in  CF  undertaken  by  Zinman  and  colleagues  was  that  nocturnal  oxygen 
therapy flows were decided by the  flow required to normalise daytime  PaO2. Since 
daytime measures are poorly sensitive indicators of sleep hypoxia (section 4.5.3), it is 
possible that patients in the oxygen arm of the study may have remained hypoxic and 
any treatment effect may have been underestimated (Zinman et al. 1989). 
 
Outcome measures should include exercise capacity, lung function and quality of life 
data, as well as markers of inflammation including neutrophil counts, CRP, measures of 
NFκB-mediated inflammation (IL-8, and possibly direct assay of NFκB). Monitoring 
for side-effects is important, and should include measurement of transcutaneous CO2 in 
view of the theoretical effects on blunting of respiratory drive.  
 
 
     248
7.2.3.2 Restoration of normoxia with non-invasive ventilation (NIV) 
An alternative strategy to restore normoxia would be to use non-invasive ventilatory 
pressure support driven with air. When compared with either oxygen or placebo, NIV 
alone  (without  supplemental  oxygen)  had  beneficial  effects  on  nocturnal 
hypoventilation and daytime functioning including exercise capacity in 8 CF subjects 
with both hypoxia and hypercapnia (Young et al. 2008). Additionally, NIV alone led to 
a change in mean (95% CI) SpO2 of +3% (+0.7, +6.7) from baseline. This was similar 
to the order of increase in SpO2 seen in the oxygen arm of this cross-over trial (Young 
et al. 2008). Although encouraging, these data act as a call for further research into the 
effects of NIV in CF, echoing the need for adequately powered randomised trials of 
NIV in CF highlighted in the 2007 Cochrane review (Moran et al. 2007). Larger studies 
with adequate power may also be useful to compare the effects of NIV with oxygen 
therapy utilising similar measures of clinical and inflammatory status to that described 
above (section 7.4.3.1). 
 
7.2.3.3 Restoration of normoxia using Heliox21™ 
A further approach to consider in the future is the use of Heliox™ - a mixture of helium 
and air. Use of heliox in CF is confined to two single case reports (Stucki et al. 2002, 
Henchey 2003). Heliox has a density that is one third of that of air, and the lower 
density  of  heliox,  when  compared  with  air  enhances  flow  in  obstructed  airways  by 
decreasing the pressure gradient across these airways, resulting in reductions in both 
dyspnoea and work of breathing (Levine 2008). Furthermore, heliox reduces turbulence 
in the airways, restores laminar flow and enhances the deposition of aerosolised agents 
to the distal lung spaces (Piva et al. 2002), which may be of benefit to those with CF 
who  receive  mucolytic,  antibiotic,  bronchodilator,  and  corticosteroid  therapy  via  a 
nebulised or inhaled route.  
 
Various  helium/oxygen  mixtures  are  available  including  Heliox  21™,  which  is  a 
mixture of 79% helium and 21% oxygen that provides the same FiO2 as air, which may 
offer the restoration of normoxia without hyperoxia.  
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7.3  Summary:  The  proposed  circular  relationship  of  hypoxia, 
inflammation and lung disease in CF 
An  association  between  hypoxia  in  CF  and  clinical,  radiological,  psychological  and 
immunological  outcome  measures  is  demonstrated.  The  adverse  clinical  outcomes 
associated with the hypoxia could be argued to reflect increased disease severity for 
lung  function,  radiological  evidence  of  lung  disease,  number  of  antibiotic  courses, 
exercise capacity, and measures of inflammation are all worse in the hypoxic subjects.  
 
Hypoxia may, however, be both ‘cause’ and ‘effect’ in this sequence. As discussed in 
section 1.5, there are in vitro, rodent and in vivo data which support a causative role for 
hypoxia as an effector mechanism of perpetual neutrophilic inflammation, leading to a 
pro-inflammatory  state  and  adverse  clinical  sequelae.  The  case  for  hypoxia  acting 
directly on lung inflammation in CF is strengthened by the in vitro work of Chapter 6 of 
this thesis, whereby hypoxia is a potential stimulus for NFκB mediated inflammation 
and IL-8 production in a CF airway epithelial cell model. 
 
Quality of life was lower in children with sleep hypoxia, which too may simply be 
because children felt bad as a result of severe CF lung disease. However, published  
evidence  suggests  that  hypoxia  may  have  an  independent,  negative  impact  on 
psychological well-being in CF, as, in the only long-term study of oxygen therapy in 
CF, it is reported that 83% of those in oxygen maintained school/work attendance at 12 
months compared with only 20% of the air group (p<0.01) (Zinman et al. 1989).  
 
Therefore, whilst advancing lung disease undeniably promotes hypoxia, it appears also 
to  be  the  case  that  hypoxia  exerts  an  effect  on  lung  disease  (via  upregulation  of 
inflammation),  thus  perpetuating  a  downward  pathophysiological  spiral.  Further 
research is needed to tease out the effector signalling mechanisms (including effects on 
the ΝFκΒ signalling cascade and CFTR trafficking) by which hypoxia may mediate CF 
lung inflammation, and also the extent to which restoration of normoxia may impact on 
inflammation in the CF lung. The proposed circular relationship is illustrated in Figure 
7.1. 
 
A uniform approach to defining hypoxia needs to be adopted by paediatric specialist CF 
centres, along with guidelines for utilising oxygen therapy in children with CF. Any 
change  in  practice  must  be  evidence-based  and  the  need  for  adequately-powered 
randomised,  controlled  trials  of  oxygen  therapy  and/or  NIV  in  CF  is  apparent. 
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Institute  of  Child  Health/Great  Ormond  Street  Hospital  Research  Ethics 
Committee 
The Institute of Child Health 
30 Guilford Street 
London 
WC1N 1EH 
 
15 March 2005 
 
 
Dr Donald S Urquhart 
Cystic Fibrosis Research Fellow 
Great Ormond Street Hospital for Children 
Cystic Fibrosis Office, Level 8 Nurses Home,  
Great Ormond Street Hospital, 
London 
WC1N 3JH 
 
 
Dear Dr Urquhart 
 
Full title of study:  Definition of hypoxic phenotype in childhood cystic fibrosis 
REC reference number:  05/Q0508/19 
Protocol number:  Research proposal, not dated 
   
     
Thank you for your folder of extra information in support of the above project, 
responding to the Committee’s request for further information on the above 
research and submitting revised documentation. 
 
The further information was considered at the meeting of the Sub-
Committee of the REC held on 15 March 2005.  A list of the members 
who were present at the meeting is attached. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical 
opinion for the above research on the basis described in the application form, 
protocol and supporting documentation as revised. 
 
 
Conditions of approval 
The favourable opinion is given provided that you comply with the conditions 
set out in the attached document.  You are advised to study the conditions 
carefully. 
 Dr Urquhart, R&D number 05AR03, 15 March 2005 
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Approved documents 
 
The final list of documents reviewed and approved by the Committee is as 
follows: 
 
Document Type:  Version:  Dated:  Date Received: 
Application     12/01/2005  12/01/2005 
Investigator CV   Dr Urquhart's 
CV 
  13/01/2005 
Protocol   Research 
Proposal - MD 
Research Project 
2004 - 5 
  12/01/2005 
Participant 
Information Sheet  
Parent 
Information 
Sheet 
  12/01/2005 
Participant 
Information Sheet  
Patient 
Information 
Sheet, 14+ 
  12/01/2005 
Participant 
Information Sheet  
Patient 
Information 
Sheet, 8-14 
  12/01/2005 
Response to 
Request for 
Further 
Information  
Answers to 
LREC questions 
  25/02/2005 
Response to 
Request for 
Further 
Information  
Information 
about peer 
review 
  14/01/2005 
Other  Minutes from a 
Statistics 
meeting 
  02/03/2005 
Other  Further 
information 
about application 
24/01/2005  24/01/2005 
 
Management approval 
 
The study should not commence at any NHS site until the local Principal 
Investigator has obtained final management approval from the R&D Department 
for the relevant NHS care organisation. 
 
Membership of the Committee 
 
The members of the Ethics Committee who were present at the meeting were: 
Dr V Larcher (Consultant Paediatrician) and Dr R Gilbert (Senior Lecturer, 
Paediatric Epidemiology and Biostatistics). 
 Dr Urquhart, R&D number 05AR03, 15 March 2005 
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Notification of other bodies 
 
The Committee Administrator will notify the research sponsor that the study has 
a favourable ethical opinion. 
 
Statement of compliance  
 
The  Committee  is  constituted  in  accordance  with  the  Governance 
Arrangements for Research Ethics Committees (July 2001) and complies 
fully  with  the  Standard  Operating  Procedures  for  Research  Ethics 
Committees in the UK.  
 
05/Q0508/19         
Please quote this number on all correspondence 
 
 
With the Committee’s best wishes for the success of this project, 
 
Yours sincerely, 
 
 
 
 
     Taki Austin (Mrs) 
     Research Ethics Coordinator 
E-mail: t.austin@ich.ucl.ac.uk 
 
Enclosures   Standard approval conditions  
Site approval form (SF1)  
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APPENDIX TWO 
 
 
MODIFIED CHRISPIN-NORMAN X-RAY SCORING SYSTEM  
  275
Patient’s name            Review date    /  / 
Hospital Number           Scoring date    /  / 
D.O.B.              Scored by     
 
Chrispin-Norman X-ray score 
Feature       Not present    Present but     Marked 
              not marked 
Overinflation 
Diaphragmatic depression   0      1      2   
Chest wall shape     0      1      2   
Lung fields      0      1      2   
Bronchial Line Shadows 
Right upper zone     0      1      2 
Left upper zone      0      1      2 
Right lower zone     0      1      2 
Left lower zone      0      1      2 
Ring Shadows 
Right upper zone     0      1      2 
Left upper zone      0      1      2 
Right lower zone     0      1      2 
Left lower zone      0      1      2 
 
Mottled Shadowing 
Right upper zone     0      1      2 
Left upper zone      0      1      2 
Right lower zone     0      1      2 
Left lower zone      0      1      2 
 
Large Soft Shadows 
Right upper zone     0      1      2 
Left upper zone      0      1      2 
Right lower zone     0      1      2 
Left lower zone      0      1      2 
                TOTAL 
Instructions 
The frontal and lateral x-rays are inspected for the typical abnormalities seen in CF. These include 
increases in lung volume – hyperinflation, which result in forward bowing of the sternum and spinal 
kyphosis (lateral film) and the degree of diaphragm depression (frontal and lateral films). Each individual 
item is given a score of: 0 - not present; 1 – present but not marked; 2 – marked; depending on the degree 
of change. The lung fields are then divided into four zones on the PA film; right upper, left upper, right 
lower, left lower. Each field is then reviewed for parenchymal lung changes which are a consequence of 
bronchial mucus plugging and infection. These are seen as bronchial wall thickening, ring shadows, 
mottled shadowing and areas of confluent consolidation – large soft shadows. A score of 0, 1 or 2 is given 
according to severity for each zone in relation to these changes. The increased bronchial line shadowing 
indicates thickening of the walls of the airways; these are usually seen as longitudinal shadows with a 
straight line branching pattern and also as end-on bronchi. Ring shadows are formed by a central area of 
increased radiolucency circumscribed by a discrete shadow of lesser radiancy. These shadows are about 
5mm in diameter and are predominantly seen in peripheral areas of the lung; they represent bronchiectasis 
at the lobular level. Mottled shadows indicate sputum collection at the microlobular level and show as 
small rounded opacities with ill-defined edges which are seen as confluent areas of increased 
radiolucency. Large  “soft”  shadows are areas of more generalised lung collapse and consolidation 
affecting a lobe or segment within a lobe. A score of  0, 1 or 2 is given for the presence and severity of 
each of these signs in the four quadrants. The radiograph is best reviewed by two observers 
simultaneously in order to reduce inter-individual error. In clinical practice a score of 20 or more 
indicates advanced disease.   
Ref.  Chrispin AR, Norman AP. The systematic evaluation of the chest radiograph in cystic 
fibrosis. Pediatr Radiol 1974; 2: 101-5.  
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APPENDIX THREE 
 
 
CYSTIC FIBROSIS QUESTIONNAIRES [CFQ-UK] 
             
              Pages 
-  Adolescents and adults [CFQ 14+]       279-282 
-  Parents and caregivers [CFQ-child P]      283-286 
-  Self-completion format for children aged 12-13 years  287-290 
 
NB: Interviewer format for children aged 6-11 yrs also available 
(not used in data analyses for this study) 
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CYSTIC FIBROSIS QUESTIONNAIRE - REVISED 
Understanding the impact of your illness and treatments on your everyday life can help your healthcare team 
keep track of your health and adjust your treatments.  For this reason, this questionnaire was specifically 
developed for people who have cystic fibrosis.  Thank you for your willingness to complete this form. 
 
Instructions:  The following questions are about the current state of your health, as you perceive it.  This 
information will allow us to better understand how you feel in your everyday life.     
  Please answer all the questions. There are no right or wrong answers! If you are not sure how to 
answer, choose the response that seems closest to your situation. 
 
A.  What is your date of birth? 
Date                 
  Day  Month  Year 
B.  What is your gender? 
  ￿ Male  ￿ Female 
C.   During the past two weeks, have you been on holiday or 
out of school or work for reasons NOT related to your 
health? 
    ￿ Yes  ￿ No 
D.  What is your current marital status? 
  ￿  Single/never married 
  ￿  Married 
  ￿  Widowed 
  ￿  Divorced 
  ￿  Separated 
  ￿  Remarried  
  ￿  With a partner 
E.  Which of the following best describes your racial 
background? 
       ￿ White - UK 
       ￿ White - other 
       ￿  Indian/ Pakistani 
        ￿ Chinese/ Asian 
       ￿   African 
       ￿  Caribbean 
         ￿  Other [not represented above or people whose 
predominant origin cannot be determined/ mixed 
race] 
          ￿  Prefer not to answer this question 
 
 
 
F.  What is the highest level of education you have        
completed? 
  ￿  Some secondary school or less 
  ￿  GCSEs/ O-levels 
  ￿  A/AS-levels 
  ￿  Other higher education 
  ￿  University degree 
  ￿  Professional qualification or post-graduate study  
 
 
G.   Which of the following best describes your current work 
or school status? 
  ￿  Attending school outside the home 
  ￿  Taking educational courses at home 
  ￿  Seeking work  
  ￿  Working full or part time (either outside the 
         home or at a home-based business) 
  ￿  Full time homemaker 
  ￿  Not attending school or working due to my health  
  ￿  Not working for other reasons 
Please fill-in the information or tick the box indicating your answer.  Section I. Demographics  
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CYSTIC FIBROSIS QUESTIONNAIRE - REVISED 
 
 
 
 
During the past two weeks, to what extent have you had difficulty: 
A lot of 
difficulty 
Some 
difficulty 
A little 
difficulty 
No 
 difficulty 
  1. Performing vigorous activities such as running or playing 
sports.........................  ￿  ￿  ￿  ￿ 
  2.  Walking as fast as others  ...................................................................................   ￿  ￿  ￿  ￿ 
  3.  Carrying or lifting heavy things such as books, shopping, or school bags .........   ￿  ￿  ￿  ￿ 
  4.  Climbing one flight of stairs  ...............................................................................   ￿  ￿  ￿  ￿ 
  5.  Climbing stairs as fast as others .........................................................................  
   
￿  ￿  ￿  ￿ 
 
During the past two weeks, indicate how often: 
Always  Often 
Sometime
s  Never 
  6.  You felt well ........................................................................................................    ￿  ￿  ￿  ￿ 
  7.  You felt worried ..................................................................................................    ￿  ￿  ￿  ￿ 
  8.  You felt useless....................................................................................................    ￿  ￿  ￿  ￿ 
  9.  You felt tired .......................................................................................................    ￿  ￿  ￿  ￿ 
10.  You felt full of energy .........................................................................................    ￿  ￿  ￿  ￿ 
11.  You felt exhausted ...............................................................................................    ￿  ￿  ￿  ￿ 
12.  You felt sad .........................................................................................................    ￿  ￿  ￿  ￿ 
Please circle the number indicating your answer.  Please choose only one answer for each question. 
Thinking about the state of your health over the last two weeks:   
13.   To what extent do you have difficulty walking? 
1.  You can walk a long time without getting tired 
2.  You can walk a long time but you get tired 
3.  You cannot walk a long time because you get tired quickly 
4.  You avoid walking whenever possible because it’s too tiring for you 
14.  How do you feel about eating? 
1.  Just thinking about food makes you feel sick 
2.  You never enjoy eating 
3.  You are sometimes able to enjoy eating 
4.  You are always able to enjoy eating 
15.  To what extent do your treatments make your daily life more difficult?   
1.  Not at all 
2.  A little 
3.  Moderately 
4.  A lot 
Section II. Quality of Life 
Please tick the box indicating your answer.  
 
 
 
 
    2000, Quittner, Buu, Watrous and Davis.  Revised 2002.  CFQ Teen/Adult, English Version 1.0 
                           2005, Bryon and Stramik. CFQ-UK Teen/Adult, UK-English Language Version 1.0         Page 279                                                                                                                       
Adolescents and Adults (Patients 14 Years Old and Older)   
CYSTIC FIBROSIS QUESTIONNAIRE - REVISED 
16.  How much time do you currently spend each day on your treatments? 
1.  A lot 
2.  Some 
3.  A little 
4.  Not very much 
17.  How difficult is it for you to do your treatments (including medications) each day? 
1.  Not at all 
2.  A little 
3.  Moderately 
4.  Very 
18.  How do you think your health is now? 
1.  Excellent 
2.  Good 
3.  Fair 
4.  Poor 
 
Please select a box indicating your answer. 
Thinking about your health during the past two weeks, indicate the extent to which 
each sentence is true or false for you. 
Very 
true 
Somewhat 
true 
Somewhat 
false 
Very 
false 
19.  I have trouble recovering after physical effort ......................................................    ￿  ￿  ￿  ￿ 
20.  I have to limit vigorous activities such as running or playing sports.....................    ￿  ￿  ￿  ￿ 
21.  I have to force myself to eat ..................................................................................    ￿  ￿  ￿  ￿ 
22. I have to stay at home more than I want to  .............................................................    ￿  ￿  ￿  ￿ 
23. I feel comfortable discussing my illness with others ..............................................    ￿  ￿  ￿  ￿ 
24.  I think I am too thin ...............................................................................................    ￿  ￿  ￿  ￿ 
25.  I think I look different from others my age ...........................................................    ￿  ￿  ￿  ￿ 
26.  I feel bad about my physical appearance ...............................................................    ￿  ￿  ￿  ￿ 
27.  People are afraid that I may be contagious ............................................................    ￿  ￿  ￿  ￿ 
28.  I get together with my friends a lot .......................................................................    ￿  ￿  ￿  ￿ 
29.  I think my coughing bothers others .......................................................................    ￿  ￿  ￿  ￿ 
30.  I feel comfortable going out at night .....................................................................    ￿  ￿  ￿  ￿ 
31.  I often feel lonely ..................................................................................................    ￿  ￿  ￿  ￿ 
32.  I feel healthy ..........................................................................................................    ￿  ￿  ￿  ￿ 
33.  It is difficult to make plans for the future (for example, going to college, getting 
married, getting promoted at work, etc.) ...............................................................    ￿  ￿  ￿  ￿ 
34.  I lead a normal life ................................................................................................    ￿  ￿  ￿  ￿ 
... 
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CYSTIC FIBROSIS QUESTIONNAIRE - REVISED 
 
 
Questions 35 to 38 are about school, work, or other daily tasks. 
35.  To what extent did you have trouble keeping up with your schoolwork, professional work, or other daily activities 
during the past two weeks?  
1.  You have had no trouble keeping up 
2.  You have managed to keep up but it’s been difficult 
3.  You have been behind 
4.  You have not been able to do these activities at all 
36.  How often were you absent from school, work, or unable to complete daily activities during the last two weeks because of 
your illness or treatments? 
           ￿  Always      ￿  Often                    ￿  Sometimes                 ￿  Never         
37. How often does CF get in the way of meeting your school, work, or personal goals? 
                ￿  Always             ￿  Often               ￿  Sometimes         ￿  Never       
38. How often does CF interfere with getting out of the house to run errands such as shopping or going to the bank? 
                       ￿  Always             ￿  Often               ￿  Sometimes         ￿  Never       
     
 
Indicate how you have been feeling during the past two weeks.   A great deal  Somewhat  A little  Not at all 
39.  Have you had trouble gaining weight? .......................................................   ￿  ￿  ￿  ￿ 
40.  Have you been congested? .........................................................................   ￿  ￿  ￿  ￿ 
41.  Have you been coughing during the day? ..................................................   ￿  ￿  ￿  ￿ 
42.  Have you had to cough up mucus?  .............................................................   ￿  ￿  ￿  ￿ 
        Go to 
Question 
44 
43.  Has your mucus been mostly:  ￿ Clear  ￿ Clear to yellow ￿ Yellowish-green ￿ Green with traces of blood  ￿ Don't 
know 
How often during the past two weeks:  Always  Often  Sometimes  Never 
44.  Have you been wheezing? .........................................................................   ￿  ￿  ￿  ￿ 
45.  Have you had trouble breathing?  ...............................................................   ￿  ￿  ￿  ￿ 
46.  Have you woken up during the night because you were coughing? ..........   ￿  ￿  ￿  ￿ 
47.  Have you had problems with wind? ..........................................................   ￿  ￿  ￿  ￿ 
48.  Have you had diarrhoea? ...........................................................................   ￿  ￿  ￿  ￿ 
49.  Have you had abdominal pain? .................................................................   ￿  ￿  ￿  ￿ 
50.  Have you had eating problems? ................................................................   ￿  ￿  ￿  ￿ 
 
Please make sure you have answered all the questions. 
Section III. School, Work, or Daily Activities 
Section IV. Symptom Difficulties 
Please select a box indicating your answer. 
THANK YOU FOR YOUR COOPERATION!  
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CYSTIC FIBROSIS QUESTIONNAIRE - REVISED 
 
Understanding the impact of your child’s illness and treatments on his or her everyday life can help your 
healthcare team keep track of your child’s health and adjust his or her treatments. For this reason, we have 
developed a quality of life questionnaire specifically for parents of children with cystic fibrosis.  We thank you 
for your willingness to complete this questionnaire. 
 
Instructions:  The following questions are about the current state of your child’s health, as he or she perceives 
it.  This information will allow us to better understand how he or she feels in everyday life. 
  Please answer all the questions. There are no right or wrong answers! If you are not sure how to 
answer, choose the response that seems closest to your child’s situation. 
 
A.  What is your child’s date of birth? 
Date                 
  Day  Month  Year 
       
B.  What is your relationship to the child?     
  ￿ Mother 
  ￿ Father 
  ￿ Grandmother 
  ￿ Grandfather 
  ￿ Other relative 
  ￿ Foster mother 
  ￿ Foster father 
  ￿ Other (please describe) 
       ___________________________ 
C.  Which of the following best describes your child's racial 
background?  
       ￿  White - UK 
       ￿  White - other 
       ￿   Indian/ Pakistani 
       ￿  Chinese/ Asian  
       ￿  African 
       ￿   Caribbean 
       ￿  Other [not represented above or people whose predominant                                                  
origin cannot be determined/ mixed race] 
       ￿  Prefer not to answer this question 
   
D.   During the past two weeks, has your child been on holiday or   
  out of school for reasons NOT related to his or her health? 
      ￿ Yes  ￿ No 
 
 
 
E.   What is your date of birth? 
Date                 
  Day  Month  Year 
 
F.  What is your current marital status? 
  ￿  Single/never married 
  ￿  Married 
  ￿  Widowed 
  ￿  Divorced 
  ￿  Separated 
  ￿  Remarried  
  ￿  With a partner 
 
G.  What is the highest level of education you have completed?   
  ￿  Some secondary school or less 
  ￿  GCSEs/O-levels 
  ￿  A/AS-levels  
  ￿  Other higher education 
  ￿  University degree 
  ￿  Professional qualification or post-graduate study 
 
 
H.  Which of the following best describes your current work status?    
        ￿  Seeking work 
        ￿  Working full or part time (either outside the home or at a  
          home-based business 
       ￿  Full time homemaker 
       ￿  Not working due to my health 
       ￿  Not working for other reasons
Please fill-in the information or tick the box indicating your answer.  Section I. Demographics  
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Parents/Caregivers (Children Ages 6 to 13)   
CYSTIC FIBROSIS QUESTIONNAIRE - REVISED 
   Please indicate how your child has been feeling during the past 
two weeks by ticking the box matching your response. 
 
To what extent has your child had difficulty: 
A lot of 
difficulty 
Some 
difficulty 
A little 
difficulty 
No 
 difficulty 
  1.  Performing vigorous activities such as running or playing sports  ........................   ￿  ￿  ￿  ￿ 
  2.  Walking as fast as others ......................................................................................   ￿  ￿  ￿  ￿ 
  3.  Climbing stairs as fast as others ...........................................................................   ￿  ￿  ￿  ￿ 
  4.  Carrying or lifting heavy objects such as books, a school bag, or rucksack ........   ￿  ￿  ￿  ￿ 
  5.  Climbing several flights of stairs  ..........................................................................   ￿  ￿  ￿  ￿ 
Please tick the box matching your response. 
During the past two weeks, indicate how often your child:     Always  Often 
 
Sometimes  Never 
  6.  Seemed happy .......................................................................................................    ￿  ￿  ￿  ￿ 
  7.  Seemed worried  .....................................................................................................    ￿  ￿  ￿  ￿ 
  8.  Seemed tired  ..........................................................................................................    ￿  ￿  ￿  ￿ 
  9. Seemed short-tempered ..........................................................................................    ￿  ￿  ￿  ￿ 
10.  Seemed well ..........................................................................................................    ￿  ￿  ￿  ￿ 
11.  Seemed grouchy ....................................................................................................    ￿  ￿  ￿  ￿ 
12.  Seemed full of energy ...........................................................................................    ￿  ￿  ￿  ￿ 
13.  Was absent or late for school or other activities because of his/her illness or          
treatments 
…………………………………………………………………………….. 
￿  ￿  ￿  ￿ 
 
Please circle the number indicating your answer.  Please choose only one answer for each question. 
Thinking about the state of your child’s health over the past two weeks, indicate:   
14.  The extent to which your child participated in sports and other physical activities, such as P.E. (physical education) 
1.  Has not participated in physical activities 
2.  Has participated less than usual in sports  
3.  Has participated as much as usual but with some difficulty 
4.  Has been able to participate in physical activities without any difficulty 
 
15.  The extent to which your child has difficulty walking 
1. He or she can walk a long time without getting tired 
2. He or she can walk a long time but gets tired 
3. He or she cannot walk a long time, because he or she gets tired quickly 
4. He or she avoids walking whenever possible, because it’s too tiring for him or her 
 
Section II. Quality of Life  
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Please tick the box that matches your response to these questions. 
Thinking about your child’s state of health during the past two weeks, indicate the extent to which each 
sentence is true or false for your child: 
  Very 
true 
Somewhat 
true 
Somewhat  
false 
Very 
false 
16.  My child has trouble recovering after physical effort ................................................   ￿  ￿  ￿  ￿ 
17.  Mealtimes are a struggle ............................................................................................   ￿  ￿  ￿  ￿ 
18.  My child’s treatments get in the way of his/her activities ..........................................   ￿  ￿  ￿  ￿ 
19.  My child feels small compared to other kids the same age ........................................   ￿  ￿  ￿  ￿ 
20.  My child feels physically different from other kids the same age  ..............................   ￿  ￿  ￿  ￿ 
21.  My child thinks that he/she is too thin .......................................................................   ￿  ￿  ￿  ￿ 
22.  My child feels healthy ................................................................................................   ￿  ￿  ￿  ￿ 
23.  My child tends to be withdrawn .................................................................................   ￿  ￿  ￿  ￿ 
24.  My child leads a normal life  .......................................................................................   ￿  ￿  ￿  ￿ 
25.  My child has less fun than usual ................................................................................   ￿  ￿  ￿  ￿ 
26.  My child has trouble getting along with others ..........................................................   ￿  ￿  ￿  ￿ 
27.  My child has trouble concentrating ............................................................................   ￿  ￿  ￿  ￿ 
28.  My child is able to keep up with his/her school work or holiday activities ...............   ￿  ￿  ￿  ￿ 
29.  My child is not doing as well as usual in school or holiday activities  ........................   ￿  ￿  ￿  ￿ 
30.  My child spends a lot of time on his/her treatments everyday ...................................   ￿  ￿  ￿  ￿ 
Please circle the number indicating your answer.  Please choose only one answer for each question. 
31.  How difficult is it for your child to do his/her treatments (including medications) each day?   
1. Not at all 
2. A little 
3. Moderately 
4. Very 
 
32.  How do you think your child’s health is now? 
1.Excellent 
2. Good 
3. Fair 
4. Poor 
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The next set of questions is designed to determine the frequency with which your child has certain respiratory. difficulties, 
such as coughing or shortness of breath.                                                                                                                                                                           
 
Please indicate how your child has been feeling during the past two weeks.  A great 
deal 
Somewhat  A little  Not at all 
33.  My child had trouble gaining weight ..............................................................  ￿  ￿  ￿  ￿ 
34.  My child was congested ..................................................................................  ￿  ￿  ￿  ￿ 
35.  My child coughed during the day  ....................................................................  ￿  ￿  ￿  ￿ 
36.  My child had to cough up mucus ....................................................................  ￿  ￿  ￿  ￿  
￿ ￿ ￿ ￿ 
Go to  
Question 38 
37.  My child’s mucus has been mostly:   ￿ Clear      ￿ Clear to yellow     ￿ Yellowish-green   
  ￿ Green with traces of blood       ￿ Don't know 
During the past two weeks:  Always  Often  Sometimes  Never 
38.  My child wheezed ...........................................................................................  ￿  ￿  ￿  ￿ 
39.  My child had trouble breathing .......................................................................  ￿  ￿  ￿  ￿ 
40.  My child woke up during the night because he/she was coughing..................  ￿  ￿  ￿  ￿ 
41.  My child had wind ..........................................................................................  ￿  ￿  ￿  ￿ 
42.  My child had diarrhoea ...................................................................................  ￿  ￿  ￿  ￿ 
43.  My child had abdominal pain ..........................................................................  ￿  ￿  ￿  ￿ 
44.  My child has had eating problems  ...................................................................  ￿  ￿  ￿  ￿ 
 
Please make sure you have answered all the questions.
       
Section III. Symptom Difficulties 
THANK YOU FOR YOUR COOPERATION!  
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These questions are for children like you who have cystic fibrosis. Your answers will help us understand what 
this disease is like and how your treatments help you. So, answering these questions will help you and others 
like you in the future. 
 
Please answer all the questions. There are no right or wrong answers! If you are not sure how to answer, choose 
the response that seems closest to your situation. 
  
Please fill in the answer or tick the box that matches your response to these questions.
A.  What is your date of birth? 
Date                 
  Day  Month  Year 
 
B.  Are you? 
   
      ￿ Male  ￿ Female 
 
C.  During the past two weeks, have you been on 
holiday  or  out  of  school  for  reasons  NOT 
related to your health? 
   
       ￿ Yes  ￿ No 
 
D.  Which of the following best describes your 
racial background?  
      ￿  White - UK 
      ￿  White - other 
      ￿   Indian/ Pakistani 
      ￿ Chinese/ Asian 
      ￿  African 
      ￿  Caribbean 
      ￿ Other [not represented above or people whose 
predominant origin cannot be determined/ mixed race] 
      ￿  Prefer not to answer this question 
 
E.  What year are you in now at school? 
     (If summer, year you just finished) 
  ￿  Year 6 
  ￿  Year 7 
  ￿  Year 8 
  ￿  Year 9 
  ￿  Year 10 
   ￿  Year 11 
  ￿  Not in school 
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Please tick the box matching your response. 
In the past two weeks: 
Very  
True 
Mostly 
True 
Somewhat 
True 
Not at 
all True 
  1.  You were able to walk as fast as others................................................................   ￿  ￿  ￿  ￿ 
  2.  You were able to climb stairs as fast as others .....................................................   ￿  ￿  ￿  ￿ 
  3.  You were able to run, jump, and climb as you wanted ........................................   ￿  ￿  ￿  ￿ 
  4.  You were able to run as quickly and for as long as others ...................................   ￿  ￿  ￿  ￿ 
  5.  You were able to participate in sports that you enjoy (e.g., swimming, football, 
dancing or others)  .................................................................................................   ￿  ￿  ￿  ￿ 
  6.  You had difficulty carrying or lifting heavy things such as books, your school 
bag, or a rucksack  .................................................................................................   ￿  ￿  ￿  ￿ 
Please tick the box matching your response. 
 And during these past two weeks, indicate how often:  Always  Often  Sometimes  Never 
  7. You felt tired .......................................................................................................   ￿  ￿  ￿  ￿ 
  8.  You felt mad.......................................................................................................   ￿  ￿  ￿  ￿ 
  9.  You felt grouchy ................................................................................................   ￿  ￿  ￿  ￿ 
10. You felt worried ..................................................................................................   ￿  ￿  ￿  ￿ 
11.  You felt sad ........................................................................................................   ￿  ￿  ￿  ￿ 
12.  You had trouble falling asleep ...........................................................................   ￿  ￿  ￿  ￿ 
13.  You had bad dreams or nightmares ....................................................................   ￿  ￿  ￿  ￿ 
14.  You felt good about yourself  ..............................................................................   ￿  ￿  ￿  ￿ 
15.  You had trouble eating .......................................................................................   ￿  ￿  ￿  ￿ 
 
Please tick the box matching your response. 
And during these past two weeks, indicate how often: 
  Always  Often  Sometimes  Never  
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16.  You had to stop fun activities to do your treatments ..........................................   ￿  ￿  ￿  ￿ 
17.  You were forced to eat .......................................................................................   ￿  ￿  ￿  ￿ 
Please tick the box matching your response. 
During the past two weeks: 
Very 
True 
Mostly 
True 
Somewhat 
True 
Not at 
all True 
18.  You were able to do all of your treatments ........................................................   ￿  ￿  ￿  ￿ 
19.  You enjoyed eating ............................................................................................   ￿  ￿  ￿  ￿ 
20.  You got together with friends a lot  .....................................................................   ￿  ￿  ￿  ￿ 
21.  You stayed at home more than you wanted to ...................................................   ￿  ￿  ￿  ￿ 
22.  You felt comfortable sleeping away from home (at a friend or family 
member’s house or elsewhere) ...........................................................................   ￿  ￿  ￿  ￿ 
23.  You felt left out ..................................................................................................   ￿  ￿  ￿  ￿ 
24.  You often invited friends to your house .............................................................   ￿  ￿  ￿  ￿ 
25.  You were teased by other children .....................................................................   ￿  ￿  ￿  ￿ 
26. You felt comfortable discussing your illness with others (friends, teachers)  ￿  ￿  ￿  ￿ 
27.  You thought you were too short .........................................................................   ￿  ￿  ￿  ￿ 
28.  You thought you were too thin  ...........................................................................   ￿  ￿  ￿  ￿ 
29.  You thought you were physically different from others your age ......................   ￿  ￿  ￿  ￿ 
30.  Doing your treatments bothered you ..................................................................   ￿  ￿  ￿  ￿ 
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Please tick the box matching your response. 
 
Let us know how often in the past two weeks: 
Always  Often  Sometimes  Never 
31.  You coughed during the day ........................................................................................   ￿  ￿  ￿  ￿ 
32.  You woke up during the night because you were coughing .........................................   ￿  ￿  ￿  ￿ 
33.  You had to cough up mucus .........................................................................................   ￿  ￿  ￿  ￿ 
34.  You had trouble breathing ............................................................................................   ￿  ￿  ￿  ￿ 
35.  Your stomach hurt ........................................................................................................   ￿  ￿  ￿  ￿ 
 
Please make sure all the questions have been answered. 
 
 
 
 
 
 
 
 
 
 
THANK YOU FOR YOUR COOPERATION!  
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  290
Cardiopulmonary Exercise Testing (CPET) Summary of Protocol 
Equipment 
Cycle ergometer          Stadiometer 
MedGraphics metabolic cart        Digital scales 
SpO2 ear probe/temporal probe      Breath by breath gas analyser 
Pneumotachograph          Sphygmomanometer  
Stethoscope 
 
General Instructions 
•  Subjects asked to refrain from eating at least two hours before test and avoid 
strenuous exercise for at least 24 hours before CPET. 
•  Subjects  asked  to  wear  comfortable  clothing  and  running  shoes  suitable  for 
exercise. 
•  It should be made clear to subjects that sensations such as shortness of breath, 
tiredness and muscle fatigue are ‘normal’.  
•  Subjects should be informed that the CPET will be terminated at any such time 
that they choose not to continue.  
•  However, it should be emphasised that data collected throughout the test will be 
of ‘most’ use if the participant works to near maximal capacity by the end of the 
CPET. 
•  The CPET should be terminated at the point of voluntary exhaustion, when the 
participant is unable to continue despite strong verbal encouragement. 
•  Experienced  technicians  should  monitor  the  subject  for  any  undue  signs  of 
distress including severe wheezing, chest pain, lack of coordination, and marked 
decrease in SpO2 throughout the CPET. 
 
Protocol 
•  Subjects  currently  taking  bronchodilators  should  be  administered  usual 
bronchodilator i.e. 200 µg Salbutamol or 500 µg Terbutaline at least 10 minutes 
prior to CPET.  
  [NB: Cold air may precipitate bronchospasm (Consideration at altitude)]. 
•  Spirometry and direct measurement of Maximal Voluntary Ventilation (MVV), 
i.e. 12 seconds of maximally deep and rapid breathing should be made prior to 
CPET 
•  Predicted peak workload (Watts) calculated as 3 x bodyweight (in kg) for girls, 
and  3.5  x  bodyweight  (in  kg)  for  boys.  This  may  need  to  be  adjusted  for 
subject’s fitness level, and if any reduction in predicted lung function. 
•  The target cadence should be approximately 60 - 80 rpm. 
    
  291
•  Ergometer ramp protocol adjusted to reach the predicted peak Watts within 8 - 
12 minutes of exercise. 
 
Example for a 50 kg girl. 3 x 50 =150 Watts.  
150/10 = 15 Watts/minute for an estimated 10-minute exercise test. 
Therefore,  a  15  W  workload  could  be  selected,  or  otherwise  the  closest 
appropriate option offered by the software.  
NB: The predicted workload should be lowered if a patient's diagnosis suggests 
impaired aerobic fitness. 
 
The exercise test should include: 
•  5 minutes at rest (while connected to the 12-lead ECG and breathing through the 
PNT or mass flow sensor) 
•  3 minutes of load-less cycling  
•  8 – 12 minutes of exercise, or until volitional exhaustion 
•  4 minutes active recovery (slow pedalling) 
 
Blood pressure measurements should be made every 1-2 minutes at rest, throughout the 
test and during active recovery. 
 
Analysis 
The fulfilment of at least three of the following four criteria should be required to meet 
the  definition  of  a  ‘maximal’  exercise  test:    1)  a  maximal  heart  rate  similar  to  the 
theoretically predicted maximal value i.e. >85% of the participant’s predicted maximal 
heart rate, where predicted maximal heart rate is calculated as 210 – (0.65*age) (Spiro 
1977); 2) a peak VE close to the predicted target; 3) a plateau in oxygen uptake despite 
an increasing workload (i.e. final increase in VO2 < 200 mls.min
-1 for an increase in 
work  of  5  to  10%);  4)  an  inability  of  the  participant  to  maintain  cadence  despite 
encouragement (Crapo et al., 2000, Wasserman et al., 2004). 
 
Key measurements 
  Heart Rate        Blood Pressure  
  Respiratory Rate      Tidal volumes 
  Oxygen utilisation (VO2)    Carbon dioxide elimination (VCO2) 
  End-tidal CO2 (etCO2)    Oxygen saturations (SpO2) 
  Work Rate (Watts) 
Outcomes 
  VO2max/ VO2peak      Anaerobic thresh-hold 
  Exercise desaturation     Maximal exercise ventilation VEmax 
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HARDY-WEINBERG CALCULATION FOR  
ACE POLYMORPHISM 
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The ACE polymorphism – Hardy Weinberg equilibrium calculation 
 
 
I  allele frequency= 0.5625 
D allele frequency = 0.4375 
 
p=0.5625, q=0.4375 
 
  II  ID  DD  Total 
Observed  13  19  8  40 
Expected  p
2  2pq  q
2   
  0.31  0.49  0.19  1 
Number expected  p
2N
  2pqN  q
2N   
  12.6562  19.6875  7.6562   
Deviation  0.3438  0.6875  0.3438   
Chi-Squared 
[Deviation squared 
divided by number 
expected] 
 
0.009  0.024  0.0154  0.0484 
 
 
χ
2 =0.0484 
 
With 1 degree of freedom, p>>0.50. 
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Appendix 6 
 
Publications arising from this thesis 
•  Review articles (3) 
•  Book Chapters (1) 
•  Abstracts (8) 
 
Review articles: 
1. Urquhart DS, Narang I, Jaffé A.  
Assessment and interpretation of arterial oxygen saturations in children with CF.  
CF Worldwide 2008; 10: Published online January 2008 
 
2. Prasad SA, Urquhart DS.  
Exercise and Cystic Fibrosis.  
HealthEx Specialist 2006; 10: 9-14. 
 
3. Urquhart DS, Montgomery H, Jaffé A.  
Assessment of hypoxia in childhood cystic fibrosis.  
Arch Dis Child 2005, 90: 1138-1143. 
 
Book Chapters: 
1. Urquhart DS, Montgomery H, Jaffé A.  
Assessment, definition and treatment of hypoxia in children with cystic fibrosis.  
In: 2008 Yearbook of respiratory care clinics and applied technologies. Eds: Esquinas  A, Volsko T. 
Tipografia San Francisco S.A., Murcia, Spain. ISBN: 978-84-612-5901-4.  ps. 769-774. 
 
Abstracts: 
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Narang I , Jaffé A. 
Association of nocturnal hypoxia and adverse clinical status in children with cystic fibrosis – cause or 
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 Jaffé A.  
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